[
    {
        "Patient Information": {
            "Name": "Liam Chen",
            "Age": "33",
            "Gender": "Male",
            "Medical History": "Recent episodes of fatigue, anemia, and frequent infections; history of lymphadenopathy and splenomegaly"
        },
        "Disease Information": {
            "Disease": "Leukemia",
            "Severity Level": "Major Severity",
            "Symptoms": "Fever, anemia, frequent infections, lymph node enlargement, fatigue, bone pain, oral bleeding",
            "Duration": "Symptoms have intensified over the past few weeks",
            "Curability": "Yes",
            "Severity Score": 58
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "48 IU /L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.7 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "95 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "2.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "28% (35 − 50)",
                "Hemoglobin (Hb)": "85 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "70 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "45% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "30% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "4.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "20% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.05 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "1% (0 − 1)",
                "Mean Platelet Volume (MPV)": "12 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "750 ng/mL (20 − 500 for males)",
                "CRP": "20 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.8 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "AB",
                "Specific Antigen": "None",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Bone Marrow Aspiration": "Presence of myeloblasts and abnormal proliferation of immature myeloid cells",
            "Cytogenetic Analysis": "Positive for complex karyotype abnormalities",
            "Immunophenotyping": "Presence of CD13, CD33 antigens",
            "Chest X-ray": "Normal",
            "Respiratory Function Test": "Normal",
            "Serum Antibody Test": "Negative for associated viral infections",
            "Nucleic Acid Amplification Test": "Negative",
            "CT Scan": "No infiltration observed",
            "Ultrasound of Abdomen": "Splenomegaly observed",
            "Oral Pharyngeal Examination": "Swelling and bleeding of gums",
            "Allergen Test": "Normal"
        },
        "Treatment Plan": "Liam Chen has been diagnosed with acute myeloid leukemia, necessitating immediate and intensive treatment to address rapid disease progression. He will undergo induction chemotherapy, aiming for a swift reduction of the leukemia cell burden and achieving hematologic remission. Chemotherapy will consist of an anthracycline such as Daunorubicin combined with Cytarabine (Ara-C), monitored closely for adverse effects. Supportive care is essential, including blood transfusions for anemia and platelet transfusions to manage bleeding risks. Monitoring for signs of secondary infection is crucial, with prophylactic antibiotics if needed. Nutritional support will be prioritized to maintain overall health and recovery potential, including high-protein meals and possible intravenous nutrition. Given the severity of his condition, hematopoietic stem cell transplantation is considered post-remission, provided a suitable donor can be found. Continuous monitoring through blood tests and bone marrow biopsies will be conducted to assess treatment response, and cytogenetic analysis will guide therapeutic adjustments. Family support and education are vital to ensure adherence to the treatment plan. Post-recovery, regular health check-ups will be scheduled to monitor for minimal residual disease and early signs of relapse.",
        "User Profile": {
            "id": 0,
            "trust_in_healthcare": 0.344,
            "health_literacy": 0.684,
            "openness": 0.793,
            "conscientiousness": 0.486,
            "extraversion": 0.104,
            "agreeableness": 0.648,
            "neuroticism": 0.262,
            "region": "Minnesota"
        },
        "Relations": {
            "strong": [
                32,
                29,
                61
            ],
            "moderate": [
                20,
                66,
                40,
                69,
                28,
                44,
                63,
                19,
                41,
                4,
                17,
                26,
                1,
                35,
                2,
                13,
                36
            ],
            "weak": [
                43,
                33,
                60,
                42,
                16,
                7,
                49,
                51,
                22,
                52,
                38,
                18,
                30,
                11,
                64,
                54,
                25,
                5,
                9,
                65,
                45,
                21,
                53,
                12,
                27,
                55,
                14,
                56,
                39,
                37,
                50,
                62,
                47,
                48,
                57,
                6,
                24,
                31,
                34,
                58,
                10,
                15,
                8,
                46,
                3,
                59,
                23,
                68,
                67
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "James Wu",
            "Age": "47",
            "Gender": "Male",
            "Medical History": "High blood pressure, Chronic sinusitis"
        },
        "Disease Information": {
            "Disease": "Nasopharyngeal carcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Nasal congestion, tinnitus, hearing loss, blood in mucus, headache, neck lumps",
            "Duration": "Symptoms have been present for approximately six weeks, progressively worsening",
            "Curability": "Yes",
            "Severity Score": 70
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "90 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "38% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "55% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.7 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "500 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "EBV",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Nasopharyngoscope Exam": "Lesion with nodular and rough surface on nasopharynx, easily bleeds",
            "MRI Scan": "Mass in nasopharyngeal area with extent into adjacent structures, indicative of Type II non-keratinizing carcinoma",
            "EBV Serology": "Positive for EBV-associated antibodies",
            "Chest CT": "No signs of lung or mediastinal lymph node metastasis detected",
            "Abdominal Ultrasound": "No abdominal metastases detected",
            "PET/CT Scan": "No evidence of distant metastases"
        },
        "Treatment Plan": "James Wu has been diagnosed with nasopharyngeal carcinoma, a malignancy characterized by symptoms including nasal congestion, blood in mucus, and hearing loss, alongside the presence of cervical lymphadenopathy. Given the diagnosis of major severity and the positive indications for radiotherapy, a comprehensive treatment plan involving intensity-modulated radiation therapy (IMRT) is recommended as the primary approach, owing to the tumor's high sensitivity to radiation. In parallel, induction chemotherapy using a platinum-based regimen may be administered to reduce tumor size and maximize treatment efficacy, followed by concurrent chemoradiotherapy. The use of targeted therapy, potentially employing EGFR inhibitors like cetuximab or immunotherapeutic agents such as PD-1 inhibitors, may be considered to further address tumor growth and manage residual disease. Regular monitoring of EBV DNA levels in the bloodstream will guide ongoing treatment effectiveness and modifications. Supportive care to manage side effects from treatment, including nutritional support, management of dry mouth, and nasal irrigation, will be integral. Psychological support for James and his family will be offered to aid in maintaining a positive outlook and adherence to the treatment regimen. Routine follow-up examinations will be scheduled to monitor for any recurrence or metastasis, with adjustments to the treatment plan as needed.",
        "User Profile": {
            "id": 3,
            "trust_in_healthcare": 0.613,
            "health_literacy": 0.281,
            "openness": 0.746,
            "conscientiousness": 0.453,
            "extraversion": 0.859,
            "agreeableness": 0.776,
            "neuroticism": 0.503,
            "region": "Illinois"
        },
        "Relations": {
            "strong": [
                13,
                4,
                42
            ],
            "moderate": [
                38,
                29,
                8,
                53,
                40,
                21,
                37,
                64,
                52,
                58,
                11,
                5,
                36,
                66,
                10,
                0,
                3,
                47,
                57,
                25,
                7,
                59,
                54
            ],
            "weak": [
                62,
                12,
                34,
                32,
                44,
                49,
                50,
                22,
                31,
                30,
                55,
                43,
                35,
                19,
                56,
                6,
                68,
                26,
                17,
                61,
                2,
                63,
                41,
                65,
                60,
                46,
                39,
                45,
                67,
                51,
                14,
                28,
                15,
                16,
                23,
                24,
                48,
                18,
                20,
                69,
                33,
                27,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "John Carter",
            "Age": "68",
            "Gender": "Male",
            "Medical History": "Chronic smoker, occupational exposure to chemical dyes"
        },
        "Disease Information": {
            "Disease": "Bladder cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless gross hematuria, frequent urination, urgency, dysuria, difficulty urinating, lower back pain and discomfort due to ureteral obstruction",
            "Duration": "Intermittent hematuria lasting several months, with increasing frequency of symptoms",
            "Curability": "Yes",
            "Severity Score": 59
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU /L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "11% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "230 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "520 ng/mL (20 − 500 for males)",
                "CRP": "4 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "NMP22 positive",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Urine Tests": {
                "Routine Urinalysis": "Microscopic hematuria",
                "Urine Cytology": "Presence of tumor cells",
                "Bladder Tumor Antigen (BTA)": "Positive"
            },
            "Imaging Examinations": {
                "Ultrasound": "Bladder mass detected",
                "CT Urography": "Bladder wall thickening and mass with potential muscle invasion",
                "MRI": "Muscle invasion and adjacent organ involvement",
                "Whole-body Bone Imaging": "No bone metastasis",
                "PET-CT": "No lymph node or distant metastases detected"
            },
            "Cystoscopy": "Visible bladder tumor, biopsy confirms urothelial carcinoma",
            "Nuclear Matrix Protein 22 (NMP22)": "Positive"
        },
        "Treatment Plan": "John Carter is diagnosed with major severity bladder cancer with muscle invasion. Urgent surgical intervention is recommended, specifically radical cystectomy and pelvic lymph node dissection, due to potential muscle involvement identified via imaging. Pre-operative evaluations indicate surgery as the primary method for managing the cancer, followed by adjuvant systemic chemotherapy with a platinum-based regimen such as gemcitabine and cisplatin to address any microscopic metastatic disease. Concurrently, systemic immunotherapy with PD-L1 inhibitors may be considered if chemotherapy resistance is observed. Radiation therapy could be employed as an adjunct if surgery is deemed unfeasible or if residual cancerous tissues persist post-surgery. Preoperative counseling to discuss potential urinary diversion options post-cystectomy should be conducted, emphasizing the importance of stoma care post-procedure. John is urged to quit smoking and reduce exposure to chemical dyes to mitigate cancer progression and recurrence. Comprehensive follow-ups will be initiated, including cystoscopy, urine cytology, and imaging studies to monitor for recurrence and manage any complications arising from urinary diversion. Nutritional guidance and support to maintain a healthy diet post-treatment should be provided, alongside a plan for gradual physical activity tailored to John’s preferences and health status. Educational resources on bladder cancer management and support groups may be offered as part of holistic care, ensuring John remains informed and supported throughout his treatment journey.",
        "User Profile": {
            "id": 6,
            "trust_in_healthcare": 0.115,
            "health_literacy": 0.758,
            "openness": 0.92,
            "conscientiousness": 0.529,
            "extraversion": 0.276,
            "agreeableness": 0.851,
            "neuroticism": 0.238,
            "region": "New York"
        },
        "Relations": {
            "strong": [
                60,
                5
            ],
            "moderate": [
                66,
                4,
                54,
                37,
                7,
                25,
                47,
                17,
                65,
                39,
                0,
                45,
                13,
                52,
                3,
                6,
                30,
                53,
                49,
                36,
                55,
                48,
                44
            ],
            "weak": [
                64,
                57,
                10,
                40,
                12,
                56,
                22,
                15,
                42,
                51,
                1,
                23,
                29,
                11,
                63,
                21,
                61,
                20,
                41,
                62,
                16,
                14,
                28,
                32,
                38,
                19,
                26,
                68,
                34,
                59,
                27,
                67,
                69,
                43,
                35,
                8,
                58,
                50,
                33,
                46,
                31,
                18,
                24,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Leonard Thompson",
            "Age": "62",
            "Gender": "Male",
            "Medical History": "Chronic smoking, previous episodes of bladder irritation, history of exposure to industrial chemicals"
        },
        "Disease Information": {
            "Disease": "Bladder tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Painless hematuria, bladder irritation, difficulty urinating",
            "Duration": "Symptoms have been present intermittently over the past two months",
            "Curability": "Yes",
            "Severity Score": 48
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU /L (13 − 35)",
                "Urea": "6.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "44% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.4 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.88 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Ferritin": "400 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Urine Cytology": "Presence of atypical cells",
            "MRI Examination": "Solid nodules located in the bladder trigone",
            "CT Scan": "No signs of invasion outside the bladder",
            "Ultrasound": "Low-echo mass detected in the bladder wall",
            "Cystography": "Presence of spherical filling defect in bladder",
            "Cystoscopy": "Biopsy confirms transitional cell carcinoma"
        },
        "Treatment Plan": "Leonard Thompson has been diagnosed with a bladder tumor characterized predominantly by painless hematuria, bladder irritation, and difficulty urinating. Given the moderate severity, the treatment plan will primarily focus on surgical intervention alongside potential chemotherapy. Transurethral resection of the bladder tumor (TURBT) is recommended to remove the superficial tumor effectively, minimizing the risk of recurrence. Post-surgery, intravesical chemotherapy using agents like epirubicin will be administered to further reduce recurrence risk. Regular follow-up appointments, including cystoscopic evaluations every three months, will be mandatory to monitor any potential recurrence and to assess the effectiveness of the treatment provided. Leonard will be advised to cease smoking and limit exposure to industrial chemicals that could exacerbate the condition. Nutritional support, moderate exercise, and maintaining a positive outlook will be essential components of his recovery regimen. The multidisciplinary team, including urology and oncology specialists, will continue to oversee Leonard's progress, with adjustments made to the treatment plan based on his response and subsequent imaging results. Active communication and education about symptom monitoring and preventative measures will be provided to Leonard and his family, ensuring optimal adherence to the treatment protocol.",
        "User Profile": {
            "id": 9,
            "trust_in_healthcare": 0.212,
            "health_literacy": 0.305,
            "openness": 0.671,
            "conscientiousness": 0.892,
            "extraversion": 0.913,
            "agreeableness": 0.645,
            "neuroticism": 1,
            "region": "California"
        },
        "Relations": {
            "strong": [
                10,
                37,
                47,
                23
            ],
            "moderate": [
                59,
                25,
                15,
                68,
                65,
                34,
                14,
                53,
                67,
                29,
                13,
                38,
                11,
                4,
                1,
                60,
                2
            ],
            "weak": [
                30,
                21,
                64,
                57,
                5,
                55,
                66,
                6,
                49,
                8,
                52,
                43,
                48,
                45,
                7,
                39,
                31,
                24,
                12,
                16,
                22,
                17,
                19,
                62,
                54,
                36,
                58,
                40,
                46,
                56,
                69,
                32,
                42,
                44,
                35,
                26,
                0,
                41,
                27,
                33,
                28,
                20,
                63,
                51,
                50,
                18,
                61,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "John Doe",
            "Age": "55",
            "Gender": "Male",
            "Medical History": "Ulcerative colitis, rectal polyps"
        },
        "Disease Information": {
            "Disease": "Colon cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Changes in bowel habits, blood in the stool, abdominal pain, weight loss",
            "Duration": "Symptoms have been present for several months, progressively worsening",
            "Curability": "Yes",
            "Severity Score": 53
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7−40)",
                "AST (Aspartate Aminotransferase)": "29 IU/L (13−35)",
                "Urea": "5.6 mmol/L (2.6−8.8)",
                "Creatinine (Cr)": "75 μmol/L (41−81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5−9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5−5.5)",
                "Hematocrit (Hct)": "40% (35−50)",
                "Hemoglobin (Hb)": "130 g/L (115−150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125−350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20−50)",
                "Neutrophil Percentage (NEUT%)": "65% (40−75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8−6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2−1.0)",
                "Monocyte Percentage (MONO%)": "8% (3−10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02−0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 - 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0−0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0−1)",
                "Mean Platelet Volume (MPV)": "10 fL (9−13)",
                "Lactate Dehydrogenase": "190 U/L (135−225)",
                "Muscle Enzymes (CK)": "88 U/L (22−198 for males)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "11 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20−500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0−20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0−0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "CEA elevated",
                "Blood Silver Level": "80 μg/L (50−150)"
            },
            "Colonoscopy Exam": "Presence of adenocarcinoma in the colon with luminal stenosis",
            "CT Scan": "Evidence of extramural invasion and possible lymph node involvement",
            "MRI": "Confirmed local tissue invasion, no distant metastasis observed",
            "Endoscopic Ultrasound": "Depth of infiltration reaches muscularis layer",
            "Fecal Occult Blood Test": "Positive",
            "Histopathological Examination": "Tubular adenocarcinoma",
            "Tumor Marker Test": "Elevated CA19-9 levels",
            "Immunohistochemistry": "Mismatch repair protein status normal",
            "Genetic Monitoring": "Wild-type K-ras and BRAF genes",
            "PET-CT": "No distant metastasis"
        },
        "Treatment Plan": "John Doe has been diagnosed with colon cancer, categorized as major severity due to invasive growth and luminal stenosis observed during colonoscopy. An individualized treatment plan is crafted considering his medical history of ulcerative colitis and rectal polyps, as well as his overall physical condition. Immediate surgical intervention is suggested to remove the tumor, with a preference for laparoscopic minimally invasive surgery due to its reduced recovery time and effective outcomes for early-stage lesions. Following surgical resection, chemotherapy with an FOLFOX regimen, combining oxaliplatin, leucovorin, and 5-fluorouracil, is recommended to eradicate potential micro-metastases and prolong disease-free survival. Nutritional support is crucial during treatment, with a focus on high-fiber, nutrient-rich diets to combat malnutrition and cachexia while managing bowel habits post-surgery. Pain management will be tailored individually, with regular monitoring through tumor marker tests, specifically CEA and CA19-9 levels, to assess treatment efficacy and detect recurrence. Psychological support and lifestyle guidance will be offered to promote a positive mindset and adherence to the treatment protocol. Regular follow-up examinations, including CT and MRI scans, are essential for ongoing assessment and adjustment of treatment strategies. Family education about stoma care will be provided if necessary, ensuring comprehensive management post-discharge. With steadfast adherence to the treatment protocol, John can achieve significant improvements in health and quality of life, while ensuring regular follow-ups to monitor progress and adapt strategies as necessary.",
        "User Profile": {
            "id": 12,
            "trust_in_healthcare": 0.438,
            "health_literacy": 0.695,
            "openness": 0.927,
            "conscientiousness": 0.701,
            "extraversion": 0.805,
            "agreeableness": 0.799,
            "neuroticism": 0.294,
            "region": "Pennsylvania"
        },
        "Relations": {
            "strong": [
                66
            ],
            "moderate": [
                52,
                5,
                36,
                49,
                65,
                47,
                2,
                53,
                1,
                60,
                21,
                57,
                25,
                13,
                7,
                22,
                44,
                17,
                11,
                38
            ],
            "weak": [
                0,
                10,
                40,
                37,
                3,
                29,
                59,
                62,
                64,
                55,
                34,
                6,
                45,
                54,
                61,
                42,
                51,
                19,
                16,
                23,
                20,
                14,
                48,
                30,
                39,
                58,
                8,
                67,
                28,
                12,
                31,
                15,
                26,
                41,
                27,
                56,
                35,
                24,
                68,
                63,
                46,
                32,
                43,
                69,
                50,
                33,
                18,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "John Smith",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Viral hepatitis, primary sclerosing cholangitis"
        },
        "Disease Information": {
            "Disease": "Bile duct cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Jaundice, right upper abdominal pain, nausea, dark yellow urine, itchy skin, lethargy, weight loss",
            "Duration": "Symptoms have been present for several weeks and are worsening",
            "Curability": "No",
            "Severity Score": 57
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "120 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "150 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.4 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Positive",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "115 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "68% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.58 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "320 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "85 U/L (22 − 198)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "No specific antigen detected",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Dilation of intrahepatic bile ducts and a mass seen within the liver",
            "MRI": "Mass lesion in the liver consistent with cholangiocarcinoma, mild ascites",
            "ERCP": "Obstruction in bile duct with stent placement needed",
            "PTC": "Intrahepatic ductal dilation with obstructive mass",
            "Liver Function Tests": "Increased total bilirubin and alkaline phosphatase",
            "Tumor Markers": "Elevated CA19-9, normal CEA",
            "Endoscopic Ultrasound": "Tumor infiltration observed near bile duct",
            "Coagulation Test": "Prolonged prothrombin time",
            "Complete Blood Count": "Anemia and mild leukocytosis",
            "Hepatorenal Syndrome Evaluation": "No evidence of hepatorenal syndrome",
            "Pathological Examination": "Adenocarcinoma of bile duct"
        },
        "Treatment Plan": "John Smith has been diagnosed with cholangiocarcinoma, which has resulted in the obstruction of bile ducts and significant jaundice. The primary goal of treatment is symptom relief and maintaining quality of life. Given the advanced stage of the disease, surgical resection is not feasible. Placement of a biliary stent via ERCP has been performed to relieve jaundice and bile duct obstruction. Nutritional support will be provided to address malnutrition and deficiencies, focusing on easy-to-digest, low-fat foods, supplemented by vitamins and proteins as needed. Chemotherapy regimens including gemcitabine and cisplatin may be initiated to manage disease progression and improve longevity. Vitamin K supplementation is necessary to improve coagulation function. Pain management is crucial, with analgesics prescribed for abdominal pain. Regular monitoring of blood tests, liver function, and imaging studies will be essential to gauge the patient’s response to treatment. Supportive care with psychological counseling will be offered to address mental health and ensure a positive outlook. Bile duct drainage site care will be meticulously maintained to prevent infection. Palliative care options may be explored further to enhance comfort, and home care support is advised to assist with daily living activities and disease management.",
        "User Profile": {
            "id": 15,
            "trust_in_healthcare": 0.549,
            "health_literacy": 0.777,
            "openness": 0.739,
            "conscientiousness": 0.815,
            "extraversion": 0.714,
            "agreeableness": 0.96,
            "neuroticism": 0.068,
            "region": "Tennessee"
        },
        "Relations": {
            "strong": [
                47,
                52,
                4
            ],
            "moderate": [
                7,
                60,
                57,
                65,
                2,
                25,
                45,
                6,
                55,
                40,
                54,
                10,
                1,
                44,
                53,
                36,
                62,
                11
            ],
            "weak": [
                66,
                37,
                23,
                17,
                3,
                21,
                12,
                49,
                39,
                22,
                30,
                64,
                48,
                38,
                42,
                0,
                56,
                8,
                34,
                16,
                29,
                61,
                15,
                13,
                63,
                51,
                59,
                14,
                20,
                26,
                28,
                68,
                58,
                31,
                27,
                41,
                35,
                19,
                33,
                50,
                24,
                67,
                46,
                43,
                32,
                69,
                18
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Linda Thompson",
            "Age": "68",
            "Gender": "Female",
            "Medical History": "Chronic cholecystitis, gallstones, diabetes"
        },
        "Disease Information": {
            "Disease": "Gallbladder cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Persistent abdominal pain, palpable mass in the upper right abdomen, progressive jaundice, anorexia, weight loss",
            "Duration": "Symptoms have been worsening progressively over the past three months",
            "Curability": "No",
            "Severity Score": 94
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "65 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "80 IU/L (13 − 35)",
                "Urea": "7.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "9.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "125 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "6.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "11 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "85 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 300 for females)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.35 ng/mL (< 0.5)",
                "D-dimer": "1.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Irregular hypoechoic mass at the gallbladder fundus with liver invasion",
            "CT Scan": "Tumor invasion into liver and bile ducts, lymph node metastasis",
            "MRI": "Mass extending beyond gallbladder walls, biliary tract dilation",
            "Tumor Marker Test": {
                "CA-199": "800 U/mL (< 37)",
                "CEA": "100 ng/mL (< 5)"
            },
            "PET-CT": "High uptake indicating metastasis to lymph nodes and liver"
        },
        "Treatment Plan": "Linda Thompson has been diagnosed with advanced gallbladder cancer with metastasis, necessitating an immediate and well-coordinated treatment plan centered around palliation rather than curability. Radical surgery is not feasible due to the late stage of disease progression and extensive metastasis, hence palliative care aimed at symptom management and quality of life improvement is paramount. Linda will be initiated on chemotherapy regimen tailored to control tumor growth and alleviate symptoms, potentially using gemcitabine-based therapy, complemented by radiotherapy to manage local tumor invasion and reduce pain. Analgesic and antispasmodic medications will be administered to manage persistent abdominal pain and discomfort, alongside nutritional support to counteract weight loss and anorexia. Enzyme supplements and hepatoprotective agents will be provided to support liver function. Endoscopic biliary stenting or nasobiliary drainage might be necessitated to relieve jaundice and improve bile drainage. Regular monitoring through imaging and blood tests will be essential to evaluate the effectiveness of treatment and adjust the therapeutic approach accordingly, ensuring adverse effects are minimized and Linda's comfort is prioritized. Linda and her family will be guided through this challenging phase, emphasizing the importance of supportive care, regular follow-up appointments, and psychological support to help cope with the diagnosis and maintain a positive outlook.",
        "User Profile": {
            "id": 18,
            "trust_in_healthcare": 0.895,
            "health_literacy": 0.756,
            "openness": 0.355,
            "conscientiousness": 0.354,
            "extraversion": 0.495,
            "agreeableness": 0.605,
            "neuroticism": 0.741,
            "region": "Michigan"
        },
        "Relations": {
            "strong": [
                39
            ],
            "moderate": [
                7,
                55,
                57,
                52,
                8,
                47,
                25,
                12,
                60,
                54,
                5,
                38,
                29,
                36,
                11,
                40
            ],
            "weak": [
                30,
                56,
                64,
                22,
                23,
                21,
                53,
                15,
                2,
                49,
                66,
                62,
                34,
                65,
                37,
                4,
                58,
                14,
                19,
                68,
                67,
                3,
                45,
                28,
                61,
                17,
                1,
                42,
                10,
                24,
                13,
                44,
                69,
                50,
                48,
                31,
                26,
                16,
                59,
                43,
                0,
                32,
                46,
                33,
                35,
                51
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Richard Thompson",
            "Age": "68",
            "Gender": "Male",
            "Medical History": "History of smoking, Clonorchis sinensis infection, gallstones"
        },
        "Disease Information": {
            "Disease": "Bile duct tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless jaundice, dark urine, yellowing of the sclera and skin, clay-colored stools, skin itching, fatigue, anorexia, weight loss, palpable abdominal mass",
            "Duration": "Symptoms have been progressively worsening over the past few weeks",
            "Curability": "No",
            "Severity Score": 70
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "70 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "85 IU/L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.6% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "270 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "5 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Imaging Studies": {
                "Abdominal Ultrasound": "Dilation of bile ducts above the tumor",
                "CT Scan": "Mass found in the bile duct with potential liver metastasis",
                "MRI": "Shows bile duct tumor extent, non-resectable",
                "Endoscopic Ultrasound": "Bile duct obstruction confirmed",
                "ERCP": "Bile duct obstruction with non-obstructive mass below it",
                "PTC": "Bile duct condition above obstruction assessed",
                "PET-CT": "Confirms malignant potential with no distant metastasis",
                "Choledochoscopy": "Non-resectable mass confirmed in bile duct"
            }
        },
        "Treatment Plan": "Richard Thompson has been diagnosed with a bile duct tumor, which has been classified as non-resectable due to its location and extent of involvement, as shown by MRI and PET-CT. Given the severity of his condition, immediate palliative care is necessary. The primary treatment goal is to manage symptoms and improve quality of life. Endoscopic retrograde cholangiopancreatography (ERCP) will be performed to insert a stent to alleviate the obstruction and manage jaundice. Percutaneous transhepatic biliary drainage (PTBD) is planned to further relieve biliary obstruction. Neoadjuvant chemotherapy may be considered to potentially downstage the tumor, making it more amenable to future surgical intervention though the likelihood of curative resection remains low. In addition, nutritional support, as well as medication for symptom control, including anti-pruritics for itching and analgesics for pain management, will be provided. Regular follow-up with oncology and hepatobiliary teams will ensure dynamic adaptation of the treatment plan, focusing on maintaining Richard's quality of life and managing any complications that may arise.",
        "User Profile": {
            "id": 21,
            "trust_in_healthcare": 0.803,
            "health_literacy": 0.912,
            "openness": 0.829,
            "conscientiousness": 0.489,
            "extraversion": 0.455,
            "agreeableness": 0.54,
            "neuroticism": 0.408,
            "region": "Louisiana"
        },
        "Relations": {
            "strong": [
                6,
                5,
                47,
                39
            ],
            "moderate": [
                55,
                52,
                25,
                2,
                66,
                57,
                54,
                11,
                60,
                4,
                12,
                49,
                40,
                65,
                36,
                8,
                1,
                21,
                56,
                64,
                17,
                22,
                37,
                0,
                53
            ],
            "weak": [
                29,
                23,
                38,
                44,
                62,
                13,
                61,
                3,
                45,
                30,
                19,
                42,
                10,
                15,
                26,
                28,
                50,
                34,
                51,
                58,
                63,
                27,
                48,
                14,
                16,
                32,
                69,
                43,
                46,
                24,
                41,
                35,
                68,
                20,
                67,
                59,
                31,
                33,
                18,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "John Doe",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Hypertension, Type 2 diabetes"
        },
        "Disease Information": {
            "Disease": "Malignant lymphoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless progressive lymph node enlargement, night sweats, unexplained fever, weight loss, fatigue",
            "Duration": "Symptoms have been present for approximately 6 months, with gradual worsening",
            "Curability": "Yes",
            "Severity Score": 54
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (70 − 110)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "9.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (4.5 − 5.5)",
                "Hematocrit (Hct)": "38% (40 − 50)",
                "Hemoglobin (Hb)": "120 g/L (135 − 175)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (150 − 400)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 40)",
                "Neutrophil Percentage (NEUT%)": "60% (50 − 70)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.2 × 10^9/L (1.0 − 3.0)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.4 × 10^9/L (2.0 − 7.0)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (2 − 8)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.5)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4 − 5.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0.01 − 0.1)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (7.5 − 11.5)",
                "Lactate Dehydrogenase": "260 U/L (100 − 220)",
                "Muscle Enzymes (CK)": "150 U/L (90 − 180)",
                "Myoglobin": "70 ng/mL (28 − 72)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "500 ng/mL (20 − 320 for males)",
                "CRP": "5 mg/L (< 10 mg/L)",
                "ESR": "50 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mild mediastinal lymphadenopathy",
            "Chest Computerized Tomography": "Enlarged cervical and supra-clavicular lymph nodes",
            "Serological Diagnosis": "Elevated LDH levels",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for relevant viral antibodies",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative for EBV",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Mild tonsillar hypertrophy",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "John Doe has been diagnosed with malignant lymphoma, presenting with major severity due to persistent systemic and localized symptoms such as painless lymph node enlargement, unexplained fever, night sweats, and weight loss. Given the stage and severity of his condition, a combination of therapies is recommended to maximize efficacy and improve quality of life. Chemotherapy will be initiated with the CHOP regimen, known to be effective in treating non-Hodgkin lymphoma, administered in cycles every three weeks alongside Rituximab (R-CHOP regimen) to target CD20-positive B-cell lymphoma, if applicable. Supportive care will include managing side effects with antiemetics for nausea, analgesics for pain management, and growth factors to address potential blood count suppression. In cases of treatment resistance or significant residual disease, local radiotherapy may be considered to target specific lymph node regions. Regular monitoring for treatment response through imaging and laboratory tests will be critical. Additionally, the patient will be offered nutritional support, psychological counseling, and education about the disease and its treatment plan, involving family members to ensure comprehensive care. Future options, including possible participation in clinical trials for novel therapies or stem cell transplantation, may be evaluated based on treatment progress and response.",
        "User Profile": {
            "id": 24,
            "trust_in_healthcare": 0.927,
            "health_literacy": 0.057,
            "openness": 0.318,
            "conscientiousness": 0.201,
            "extraversion": 0.656,
            "agreeableness": 0.586,
            "neuroticism": 0.67,
            "region": "Illinois"
        },
        "Relations": {
            "strong": [
                12,
                6,
                39
            ],
            "moderate": [
                38,
                52,
                64,
                21,
                1,
                10,
                67,
                11,
                56,
                54,
                55,
                68,
                58,
                30,
                62,
                57,
                7,
                48,
                22,
                45,
                47
            ],
            "weak": [
                59,
                34,
                53,
                15,
                13,
                36,
                37,
                3,
                35,
                40,
                42,
                25,
                50,
                26,
                19,
                17,
                29,
                32,
                66,
                28,
                5,
                60,
                4,
                14,
                46,
                31,
                69,
                49,
                43,
                65,
                24,
                61,
                16,
                23,
                9,
                0,
                18,
                41,
                33,
                51,
                2,
                44,
                63,
                20,
                27
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Emily Johnson",
            "Age": "4",
            "Gender": "Female",
            "Medical History": "Frequent respiratory infections, persistent fatigue, and pallor over the past few months"
        },
        "Disease Information": {
            "Disease": "Childhood Leukemia",
            "Severity Level": "Major Severity",
            "Symptoms": "Unexplained low-grade fever, anemia, bleeding, lymphadenopathy, hepatosplenomegaly, and fatigue",
            "Duration": "Symptoms have manifested progressively over the past three months with an acute phase lasting six weeks",
            "Curability": "Yes",
            "Severity Score": 57
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "3.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "32 μmol/L (28 − 60 for children)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.0 for children)",
                "Total Cholesterol (TC)": "3.9 mmol/L (< 4.8 for children)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "15.0 × 10^9/L (5.0 − 12.0 for children)",
                "Red Blood Cell Ct. (RBC)": "3.2 × 10^12/L (4.0 − 5.2 for children)",
                "Hematocrit (Hct)": "28% (35 − 45 for children)",
                "Hemoglobin (Hb)": "90 g/L (110 − 140 for children)",
                "Platelet Ct. (PLT)": "50 × 10^9/L (150 − 450)",
                "Lymphocyte Percentage (LYMPH%)": "60% (25 − 50)",
                "Neutrophil Percentage (NEUT%)": "20% (30 − 60)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "9.0 × 10^9/L (1.5 − 7.0)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.5 − 8.0)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.1 − 0.8)",
                "Monocyte Percentage (MONO%)": "10% (2 − 8)",
                "Eosinophil Abs. Ct. (EO#)": "0.02 × 10^9/L (0.02 − 0.5)",
                "Eosinophil Percentage (EO%)": "0.5% (0.5 − 5)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.1)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "7.8 fL (7.4 − 10.4)",
                "Lactate Dehydrogenase": "600 U/L (100 − 350)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Bone Marrow Biopsy": "Hypercellular marrow with 80% lymphoblasts",
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Normal",
            "Serological Diagnosis": "Positive for specific leukemia markers",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Cerebrospinal Fluid Examination": "No evidence of central nervous system involvement",
            "Serum Antibody Test": "Positive for leukemia marker antibodies",
            "Nucleic Acid Amplification Test": "Negative for viral infections",
            "Eosinophil Count in Sputum": "Normal"
        },
        "Treatment Plan": "Emily Johnson has been diagnosed with childhood acute lymphoblastic leukemia (ALL) with major severity. An immediate induction chemotherapy regimen will be initiated to rapidly reduce the tumor burden and control symptoms such as low-grade fever, anemia, and bleeding. The treatment will follow specific pediatric protocols tailored to her risk stratification, including phases of induction, consolidation, intensification, and maintenance therapy. Intrathecal chemotherapy will be implemented to prevent central nervous system leukemia. Close monitoring of blood counts and liver and kidney function will guide the management of any side effects. Antibiotics and antifungal medications will be administered to prevent opportunistic infections due to the immunocompromised state. Family education on infection prevention and Emily's mental health is essential. Hematopoietic stem cell transplantation will be considered if standard chemotherapy outcomes are suboptimal, with regular follow-ups to monitor treatment response and adjust the plan accordingly. Nutritional support and psychological counseling will be provided to ensure optimal recovery and quality of life.",
        "User Profile": {
            "id": 27,
            "trust_in_healthcare": 0.29,
            "health_literacy": 0.131,
            "openness": 0,
            "conscientiousness": 0.052,
            "extraversion": 0.051,
            "agreeableness": 0.12,
            "neuroticism": 0.477,
            "region": "Alabama"
        },
        "Relations": {
            "strong": [
                46,
                33,
                18,
                24
            ],
            "moderate": [
                35,
                56,
                32,
                41,
                69,
                22,
                0,
                20,
                58,
                43,
                50,
                63,
                15,
                38,
                48,
                28,
                19,
                42,
                30,
                14,
                34,
                51,
                17,
                8,
                36
            ],
            "weak": [
                12,
                67,
                13,
                45,
                26,
                16,
                39,
                55,
                21,
                40,
                31,
                68,
                61,
                66,
                64,
                10,
                11,
                29,
                23,
                27,
                60,
                1,
                6,
                49,
                59,
                62,
                57,
                44,
                7,
                65,
                54,
                25,
                52,
                53,
                37,
                2,
                4,
                47,
                3,
                5
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "John Doe",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Chronic obstructive pulmonary disease, Hypertension, Former smoker with a 40-pack-year history"
        },
        "Disease Information": {
            "Disease": "Lung cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent cough, hemoptysis, chest pain, wheezing, shortness of breath",
            "Duration": "Symptoms have been gradually worsening over the past 3 months",
            "Curability": "Yes",
            "Severity Score": 56
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "40 IU/L (7−40)",
                "AST (Aspartate Aminotransferase)": "38 IU/L (13−35)",
                "Urea": "5.5 mmol/L (2.6−8.8)",
                "Creatinine (Cr)": "80 μmol/L (41−81)",
                "Triglycerides (TG)": "1.6 mmol/L (<1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (<5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5−9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5−5.5)",
                "Hematocrit (Hct)": "45% (35−50)",
                "Hemoglobin (Hb)": "135 g/L (115−150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125−350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20−50)",
                "Neutrophil Percentage (NEUT%)": "60% (40−75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8−6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2−1.0)",
                "Monocyte Percentage (MONO%)": "7% (3−10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02−0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4−8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0−0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0−1)",
                "Mean Platelet Volume (MPV)": "10 f l (9−13)",
                "Lactate Dehydrogenase": "230 U/L (135−225)",
                "Muscle Enzymes (CK)": "150 U/L (22−198 for males)",
                "Myoglobin": "70 ng/mL (<90 ng/mL)",
                "Troponin I": "10 ng/L (<14 ng/L)",
                "Ferritin": "320 ng/mL (20−500 for males)",
                "CRP": "8 mg/L (<3 mg/L)",
                "ESR": "30 mm/hr (0−20)",
                "Procalcitonin": "0.4 ng/mL (<0.5)",
                "D-dimer": "0.7 mg/L FEU (0−0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Chest X-ray Exam": "Presence of a mass in the right upper lobe with possible atelectasis",
            "Chest Computerized Tomography": "Mass in the right upper lobe, with mediastinal lymph node involvement, no pleural effusion",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bronchoscopy": "Visible tumor in the bronchial area, biopsy taken for histological examination",
            "Sputum Examination": "Positive for malignant cells",
            "Serum Tumor Markers": "Elevated carcinoembryonic antigen (CEA)",
            "Pulmonary Function Test": "Reduced lung function with obstructive pattern",
            "Genetic Testing": "Positive for EGFR mutation"
        },
        "Treatment Plan": "John Doe has been diagnosed with non-small cell lung cancer (NSCLC), showing extensive involvement of the mediastinal lymph nodes. Given his smoking history and chronic obstructive pulmonary disease, a personalized multidisciplinary treatment approach is recommended. Immediate initiation of targeted therapy with gefitinib, an EGFR tyrosine kinase inhibitor, is advised due to the presence of an EGFR mutation. Chemotherapy may be considered to complement targeted therapy, with options such as pemetrexed combined with platinum-based agents, tailored to the specific histological subtype and the patient's overall health status. Surgical intervention in the form of lobectomy may be considered if the tumor's progression is localized and amenable post-targeted therapy response. Continuous low-flow oxygen therapy and dietary modifications should be implemented to address dyspnea and improve nutritional status. Follow-up pulmonary function tests, imaging, and regular monitoring of tumor markers will be conducted to assess therapy effectiveness and adjust treatment as needed. Lifestyle changes, including smoking cessation and pulmonary rehabilitation exercises, are essential to enhance recovery and quality of life, with support systems provided to ensure the patient's adherence to the care plan. Regular follow-up appointments will focus on tracking progress and adapting the treatment approach as necessary to achieve the best possible outcomes.",
        "User Profile": {
            "id": 30,
            "trust_in_healthcare": 0.269,
            "health_literacy": 0.147,
            "openness": 0.416,
            "conscientiousness": 0.859,
            "extraversion": 0.774,
            "agreeableness": 0.34,
            "neuroticism": 0.5,
            "region": "California"
        },
        "Relations": {
            "strong": [
                3,
                15,
                45,
                37
            ],
            "moderate": [
                68,
                67,
                48,
                34,
                11,
                25,
                23,
                59,
                38,
                56,
                60,
                21,
                47,
                8,
                55,
                65,
                57,
                14,
                30
            ],
            "weak": [
                5,
                4,
                13,
                1,
                22,
                17,
                12,
                36,
                35,
                53,
                66,
                58,
                64,
                62,
                52,
                2,
                40,
                43,
                46,
                6,
                49,
                26,
                39,
                29,
                7,
                28,
                54,
                42,
                16,
                24,
                32,
                44,
                27,
                0,
                41,
                50,
                31,
                33,
                20,
                69,
                18,
                63,
                19,
                9,
                51,
                61
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Lily Thompson",
            "Age": "59",
            "Gender": "Female",
            "Medical History": "Chronic bronchitis, former smoker, exposure to kitchen fumes"
        },
        "Disease Information": {
            "Disease": "Lung adenocarcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Chronic cough, hemoptysis, chest pain, fatigue, decreased appetite, shortness of breath",
            "Duration": "Symptoms have been present for several months, with increasing intensity",
            "Curability": "No",
            "Severity Score": 62
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "150 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "9 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198 for females)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for females)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Not detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Presence of peripheral lung masses and nodules",
            "Chest Computerized Tomography": "Lung masses with possible invasion of surrounding tissues",
            "Serological Diagnosis": "Elevated tumor markers",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Abnormal cells detected",
            "Nasopharyngeal Examination": "Unremarkable",
            "Serum Antibody Test": "Negative for common respiratory pathogens",
            "Pulmonary Function Test": "Reduced lung capacity",
            "Nucleic Acid Amplification Test": "Negative for respiratory viruses",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Unremarkable",
            "Nasal Endoscopy": "Unremarkable"
        },
        "Treatment Plan": "Lily Thompson's diagnosis of lung adenocarcinoma, characterized by major severity with symptoms indicative of advanced disease, prompts an immediate and meticulous approach to her care, prioritizing an integrative treatment regime. Given Lily's former smoking history and chronic bronchitis, it is essential to individualize her treatment strategy through comprehensive multidisciplinary collaboration incorporating thoracic surgery, oncology, and respiratory medicine inputs. The suggestion of potential surgical intervention, focusing on localized tumor resection, will be evaluated in conjunction with neoadjuvant chemotherapy aimed at reducing tumor size and improving surgical outcomes. Immunotherapy targeting specific oncogenic driver genes may be considered if genetic testing reveals actionable mutations, potentially integrating PD-1/PD-L1 inhibitors as a pivotal treatment element. Post-surgery, adjuvant therapies including radiotherapy and systemic chemotherapy will be implemented to manage and mitigate the risk of local recurrence or metastatic progression, complemented by supportive care measures such as nutritional support, respiratory physiotherapy, and palliative care to enhance quality of life. Attention to Lily’s nutritional status, potentially addressing deficiencies, underscores the holistic aspect of this treatment plan, while maintaining vigilant surveillance through routine imaging and tumor marker assessments to gauge treatment efficacy and adjust the strategy as needed. Long-term follow-up and prevention strategies, including smoking cessation and regulation of environmental exposures, will be integral to her care approach, ensuring proactive management and optimal recovery prospects.",
        "User Profile": {
            "id": 33,
            "trust_in_healthcare": 0.915,
            "health_literacy": 0.326,
            "openness": 0.624,
            "conscientiousness": 0.889,
            "extraversion": 0.452,
            "agreeableness": 0.323,
            "neuroticism": 0.314,
            "region": "New Jersey"
        },
        "Relations": {
            "strong": [
                62
            ],
            "moderate": [
                14,
                10,
                36,
                55,
                25,
                34,
                56,
                57,
                21,
                66,
                54,
                52,
                22,
                8,
                7,
                38,
                45,
                6,
                49,
                65,
                50,
                60,
                48,
                3,
                4
            ],
            "weak": [
                1,
                64,
                58,
                47,
                5,
                12,
                15,
                37,
                39,
                40,
                42,
                53,
                35,
                17,
                29,
                43,
                44,
                27,
                26,
                13,
                30,
                0,
                63,
                61,
                67,
                59,
                41,
                68,
                2,
                16,
                20,
                32,
                46,
                28,
                33,
                23,
                24,
                19,
                69,
                31,
                18,
                51,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "John Smith",
            "Age": "67",
            "Gender": "Male",
            "Medical History": "Chronic lymphadenopathy, rheumatoid arthritis, history of EBV infection"
        },
        "Disease Information": {
            "Disease": "Non-Hodgkin lymphoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless enlargement of superficial and mediastinal lymph nodes, night sweats, fatigue, weight loss, and abdominal pain due to retroperitoneal lymph node involvement",
            "Duration": "Symptoms have progressively worsened over the past 6 months",
            "Curability": "Yes",
            "Severity Score": 68
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "90 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "11 ng/L (< 14 ng/L)",
                "Ferritin": "550 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Enlarged mediastinal lymph nodes",
            "Chest Computerized Tomography": "Multiple enlarged lymph nodes in mediastinal and abdominal regions",
            "Serological Diagnosis": "Elevated LDH levels indicating poor prognosis",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "John Smith has been diagnosed with aggressive non-Hodgkin lymphoma, specifically diffuse large B-cell lymphoma, presenting with pronounced lymphadenopathy and systemic symptoms including fatigue and weight loss. Chemotherapy is the primary treatment strategy, with the R-CHOP regimen comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone being initiated to target the malignant B cells effectively. This treatment will follow a cycle of 2 to 3 weeks, with close monitoring of blood cell counts and potential adverse effects such as neutropenia and infection. Supportive care is crucial during chemotherapy, with nutritional support ensuring high-calorie, high-protein intake, and adequate hydration to bolster the patient’s strength and manage potential side effects. Antipyretics may be administered to address any fever, and pain relief measures will be implemented to improve comfort. John will receive regular imaging assessments and blood tests to evaluate the treatment's efficacy and adjust plans accordingly. Additionally, should the lymphoma prove refractory or relapsing, hematopoietic stem cell transplantation will be considered as a further step to restore normal hematopoietic functions. Family support and maintaining a positive outlook are essential components of John's treatment journey, with periodic consultations and lifestyle adjustments facilitating optimal recovery. Post-treatment, John may be advised on pulmonary rehabilitation and regular medical check-ups to monitor well-being and prevent recurrence of the disease.",
        "User Profile": {
            "id": 36,
            "trust_in_healthcare": 0.78,
            "health_literacy": 0.244,
            "openness": 0.508,
            "conscientiousness": 0.086,
            "extraversion": 0.151,
            "agreeableness": 0.945,
            "neuroticism": 0.648,
            "region": "Indiana"
        },
        "Relations": {
            "strong": [
                8,
                64
            ],
            "moderate": [
                39,
                56,
                54,
                6,
                52,
                30,
                58,
                7,
                38,
                53,
                11,
                55,
                45,
                10,
                62,
                1,
                47,
                61,
                42,
                60
            ],
            "weak": [
                5,
                67,
                22,
                48,
                13,
                66,
                15,
                2,
                37,
                21,
                32,
                26,
                57,
                40,
                34,
                65,
                68,
                36,
                49,
                3,
                0,
                14,
                4,
                29,
                25,
                63,
                50,
                33,
                41,
                17,
                69,
                59,
                19,
                44,
                35,
                9,
                43,
                31,
                18,
                20,
                28,
                46,
                23,
                51,
                16,
                24,
                27
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Jessica Lee",
            "Age": "48",
            "Gender": "Female",
            "Medical History": "Persistent HPV infection, history of smoking, high parity"
        },
        "Disease Information": {
            "Disease": "Cervical cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Contact bleeding, abnormal vaginal bleeding, frequent urination, lower abdominal pain, fatigue, anemia",
            "Duration": "Symptoms have progressively worsened over the past 6 months",
            "Curability": "No",
            "Severity Score": 53
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "90 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.6 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "115 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "180 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "11% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "High-risk HPV 16",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Pelvic Ultrasound": "Large tumor with parametrial invasion",
            "MRI": "Tumor spreading into pelvic wall with hydronephrosis",
            "Serological Diagnosis": "Elevated SCC antigen levels",
            "HPV Testing": "Positive for HPV types 16 and 18",
            "Colposcopy": "Irregular lesions on cervix",
            "Biopsy": "Squamous cell carcinoma",
            "Cancer Marker Examination": "Elevated CA125 and CA199",
            "Urinary Function Test": "Obstructive pattern",
            "Pathological Examination": "Stage III pathology confirmed"
        },
        "Treatment Plan": "Jessica Lee's cervical cancer has been diagnosed at stage III, with significant local invasion affecting the pelvic region, necessitating aggressive treatment. Due to the advanced stage and major severity of her symptoms, including vaginal bleeding, frequent urination, and fatigue, concurrent chemoradiotherapy is recommended as the primary treatment strategy. This will include external beam radiotherapy combined with intracavitary brachytherapy to maximize tumor cell eradication locally, complemented by chemotherapy agents such as cisplatin and paclitaxel to enhance tumor sensitivity and further inhibit cancer progression. As surgical intervention is not feasible given the tumor's extent and her current health status, the treatment will focus on eliminating cancer cells while maintaining quality of life through symptom management, such as pain relief and addressing anemia. HPV vaccination will be discussed for prevention of further HPV infections, and genetic counseling may be offered. Regular follow-up examinations, including imaging and cancer marker tests, will be conducted to assess tumor response and modify the treatment plan accordingly. Nutritional support to combat anemia and improve overall health will be provided, while psychological support and family involvement are encouraged to aid in her recovery and mental well-being. Lifestyle modifications, including smoking cessation and physical activity as tolerated, are recommended to enhance her body's resilience against cancer progression and treatment side effects. Post-treatment, consistent monitoring will continue to ensure optimal management and quality of life, with emphasis on prevention, detection of recurrence, and overall health improvement.",
        "User Profile": {
            "id": 39,
            "trust_in_healthcare": 0.254,
            "health_literacy": 0.299,
            "openness": 0.836,
            "conscientiousness": 0.112,
            "extraversion": 0.807,
            "agreeableness": 0.509,
            "neuroticism": 0.594,
            "region": "New York"
        },
        "Relations": {
            "strong": [
                1,
                38
            ],
            "moderate": [
                32,
                29,
                22,
                59,
                53,
                58,
                4,
                37,
                64,
                25,
                21,
                43,
                3,
                66,
                10,
                54,
                52,
                36,
                2,
                0,
                68,
                67,
                18,
                34
            ],
            "weak": [
                49,
                19,
                8,
                30,
                56,
                65,
                42,
                12,
                14,
                11,
                35,
                40,
                57,
                39,
                55,
                7,
                47,
                46,
                6,
                15,
                69,
                28,
                23,
                51,
                45,
                31,
                5,
                44,
                60,
                17,
                62,
                24,
                50,
                41,
                48,
                16,
                9,
                61,
                63,
                33,
                27,
                20,
                26
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Michael Thompson",
            "Age": "55",
            "Gender": "Male",
            "Medical History": "Chronic Hepatitis B, Type 2 Diabetes, Cirrhosis, Heavy Alcohol Consumption"
        },
        "Disease Information": {
            "Disease": "Liver cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent dull ache in liver area, fatigue, loss of appetite, jaundice, fever, abdominal bloating",
            "Duration": "Symptoms have been progressively worsening over the past 3 months",
            "Curability": "No",
            "Severity Score": 66
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "110 IU/L (7 – 40)",
                "AST (Aspartate Aminotransferase)": "130 IU/L (13 – 35)",
                "Urea": "5.5 mmol/L (2.6 – 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 – 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Positive",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 – 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 – 5.5)",
                "Hematocrit (Hct)": "38% (35 – 50)",
                "Hemoglobin (Hb)": "120 g/L (115 – 150)",
                "Platelet Ct. (PLT)": "90 × 10^9/L (125 – 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 – 50)",
                "Neutrophil Percentage (NEUT%)": "72% (40 – 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.9 × 10^9/L (1.3 – 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.24 × 10^9/L (1.8 – 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 – 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 – 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 – 0.52)",
                "Eosinophil Percentage (EO%)": "0.7% (0.4 – 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 – 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 – 1)",
                "Mean Platelet Volume (MPV)": "10.5 fL (9 – 13)",
                "Lactate Dehydrogenase": "250 U/L (135 – 225)",
                "Muscle Enzymes (CK)": "198 U/L (22 – 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "13 ng/L (< 14 ng/L)",
                "Ferritin": "700 ng/mL (20 – 500 for males)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "50 mm/hr (0 – 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "1.2 mg/L FEU (0 – 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "AFP 500 ng/ml (>400 ng/ml)",
                "Blood Silver Level": "60 μg/L (50 – 150)"
            },
            "Ultrasound": "Enlarged liver with multiple focal lesions",
            "CT Scan": "Large hepatocellular carcinoma in right lobe with intrahepatic metastasis",
            "MRI": "Heterogeneous mass with central necrosis in the liver",
            "Liver Biopsy": "Confirmed poorly differentiated hepatocellular carcinoma",
            "Serum Alpha-fetoprotein (AFP)": "Elevated to 500 ng/ml",
            "Liver Function Test": "Impaired",
            "Hepatitis Panel": "Chronic Hepatitis B infection",
            "Ascites Fluid Analysis": "Mildly elevated protein content",
            "Bilirubin Level": "Elevated indicating jaundice",
            "Abdominal Ultrasound": "Presence of ascites and enlarged spleen",
            "Endoscopy": "No varices observed"
        },
        "Treatment Plan": "Michael Thompson has been diagnosed with advanced primary liver cancer. Given his significant medical history of chronic Hepatitis B, cirrhosis, and type 2 diabetes, a multi-disciplinary treatment approach is necessary. Unfortunately, due to the major severity and stage of the disease, curative surgical options are limited. Palliative care will focus on improving quality of life and managing symptoms. Antiviral therapy will be maintained to manage his Hepatitis B infection, and supportive care for liver function will be emphasized, including the use of liver-protective medications. Targeted therapy with Sorafenib may be considered to slow disease progression, and radiotherapy might be explored as part of a comprehensive treatment plan focusing on palliative benefits. In addition, Michael will receive nutritional support to manage his diabetes and improve his overall nutrition status, helping to combat fatigue and loss of appetite. Pain management and psychological support will also be integral parts of the treatment to enhance his quality of life. Regular follow-ups with imaging and serum AFP tests are necessary to monitor disease progression and adjust treatments as necessary. Family education on recognizing symptoms of deterioration and supporting Michael's mental health is crucial during this challenging time.",
        "User Profile": {
            "id": 42,
            "trust_in_healthcare": 0.155,
            "health_literacy": 0.383,
            "openness": 0.162,
            "conscientiousness": 0.81,
            "extraversion": 0.103,
            "agreeableness": 0.219,
            "neuroticism": 0.964,
            "region": "New Jersey"
        },
        "Relations": {
            "strong": [
                34
            ],
            "moderate": [
                22,
                59,
                11,
                23,
                38,
                25,
                65,
                15,
                68,
                48,
                17,
                36,
                3,
                45,
                49,
                66,
                60,
                10,
                58
            ],
            "weak": [
                21,
                35,
                30,
                55,
                67,
                43,
                29,
                37,
                56,
                57,
                18,
                39,
                69,
                6,
                42,
                33,
                50,
                13,
                64,
                24,
                4,
                62,
                12,
                44,
                32,
                47,
                0,
                26,
                8,
                16,
                7,
                1,
                20,
                40,
                2,
                5,
                31,
                41,
                9,
                28,
                19,
                61,
                46,
                53,
                52
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Alice Johnson",
            "Age": "68",
            "Gender": "Female",
            "Medical History": "Hypertension, history of frequent infections, mild anemia"
        },
        "Disease Information": {
            "Disease": "Myelodysplastic Syndromes",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Fatigue, weakness, frequent infections, mild anemia, occasional bleeding episodes",
            "Duration": "Symptoms have been persisting and gradually worsening over the past 6 months",
            "Curability": "Yes",
            "Severity Score": 37
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "3.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "33% (35 − 50)",
                "Hemoglobin (Hb)": "98 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "95 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.1 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "12% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None identified",
                "Blood Silver Level": "100 μg/L (50 − 150)"
            },
            "Bone Marrow Aspiration": "Dysplasia in erythroid lineage with increased ring sideroblasts",
            "Bone Marrow Biopsy": "Hyperactive proliferation with abnormal cell development",
            "Flow Cytometry": "Abnormal phenotype suggesting monoclonal populations in myeloid lineages",
            "Gene Mutation Detection": "Presence of SF3B1 mutation",
            "Cytogenetic Analysis": "Chromosomal abnormalities typical for MDS",
            "Chest X-ray Exam": "Normal",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Respiratory Function Test": "Normal"
        },
        "Treatment Plan": "Alice Johnson has been diagnosed with myelodysplastic syndromes (MDS) with moderate severity, characterized by anemia, frequent infections, and occasional bleeding episodes. The primary treatment focus will be to improve hematopoiesis and enhance her quality of life. Alice will commence treatment with the demethylating agent azacitidine to help reduce transfusion requirements and delay disease progression. Immunomodulators such as lenalidomide will be considered if further symptom management is required, especially for cytogenetic abnormalities. Supportive care will involve regular blood transfusions to manage anemia and platelet transfusions in case of significant bleeding. Prophylactic antibiotics will be administered to reduce the risk of infections due to neutropenia. Alice will be strongly advised to adhere to environmental hygiene standards to prevent infections and avoid activities that could lead to bleeding. Regular monitoring through complete blood count, bone marrow examinations, and cytogenetic analysis will be essential to assess treatment efficacy and modify plans as necessary. Alice and her family will be educated on identifying symptoms of complications and the importance of regular follow-up visits. If her condition progresses, hematopoietic stem cell transplantation may be considered, depending on her overall health status and availability of a suitable donor. Psychological support will also be provided to maintain a positive outlook, which can significantly impact her overall well-being and response to treatment.",
        "User Profile": {
            "id": 45,
            "trust_in_healthcare": 0.289,
            "health_literacy": 0.379,
            "openness": 0.168,
            "conscientiousness": 0.697,
            "extraversion": 0.497,
            "agreeableness": 0.044,
            "neuroticism": 0.753,
            "region": "California"
        },
        "Relations": {
            "strong": [
                10
            ],
            "moderate": [
                30,
                34,
                23,
                45,
                68,
                38,
                14,
                56,
                3,
                37,
                48,
                55,
                36,
                47,
                67,
                25,
                17,
                65,
                60,
                22,
                35,
                59,
                11
            ],
            "weak": [
                6,
                57,
                49,
                18,
                21,
                39,
                8,
                43,
                58,
                66,
                40,
                12,
                29,
                64,
                2,
                13,
                7,
                5,
                52,
                26,
                24,
                69,
                4,
                62,
                33,
                1,
                9,
                54,
                46,
                53,
                42,
                50,
                0,
                31,
                28,
                32,
                16,
                19,
                20,
                41,
                44,
                27,
                61,
                63,
                51
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Samuel Thompson",
            "Age": "19",
            "Gender": "Male",
            "Medical History": "Previously healthy, no significant medical history"
        },
        "Disease Information": {
            "Disease": "Malignant bone tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Severe localized pain in the distal femur, noticeable swelling and a palpable mass, impaired joint movement, and tenderness",
            "Duration": "Symptoms have rapidly progressed over the past three weeks",
            "Curability": "Yes",
            "Severity Score": 58
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "29 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.6 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "260 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "200 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "X-ray Exam": "Lytic bone lesions noted with 'sunburst' pattern around the distal femur",
            "MRI Scan": "Mass extending beyond bone into surrounding soft tissue, with periosteal elevation",
            "Bone Scan": "Increased uptake in the distal femur",
            "CT Scan": "Destructive lesion in the distal femur with soft tissue mass",
            "Biopsy Results": "High-grade osteosarcoma confirmed with presence of osteoid matrix",
            "PET-CT": "Increased metabolic activity in the distal femur, no distant metastases detected"
        },
        "Treatment Plan": "Samuel Thompson has been diagnosed with osteosarcoma in the distal femur, requiring a comprehensive treatment plan that includes neoadjuvant chemotherapy, surgical resection, and adjuvant chemotherapy. He will initially undergo neoadjuvant chemotherapy to reduce the tumor size and eradicate microscopic disease. This will be followed by limb-sparing surgery, aiming to resect the tumor with clear margins while preserving limb function. Post-surgical adjuvant chemotherapy will be administered to minimize the risk of recurrence. Multidisciplinary follow-up care will include regular imaging studies to monitor for recurrence and assess his response to treatment. Pain management and physiotherapy will be integral components of his care to maintain joint mobility and overall quality of life. Samuel will be educated about the importance of adherence to treatment and scheduled follow-ups to ensure optimal recovery and monitoring of potential long-term complications.",
        "User Profile": {
            "id": 48,
            "trust_in_healthcare": 0.096,
            "health_literacy": 0.776,
            "openness": 0.293,
            "conscientiousness": 0.938,
            "extraversion": 0.61,
            "agreeableness": 0.794,
            "neuroticism": 0.396,
            "region": "Nevada"
        },
        "Relations": {
            "strong": [
                20,
                28,
                19
            ],
            "moderate": [
                33,
                24,
                26,
                41,
                31,
                60,
                27,
                35,
                44,
                69,
                0,
                40,
                21,
                51,
                4,
                62,
                46,
                17,
                47,
                36
            ],
            "weak": [
                42,
                29,
                61,
                59,
                25,
                10,
                5,
                6,
                11,
                3,
                63,
                57,
                14,
                66,
                2,
                7,
                22,
                1,
                55,
                30,
                8,
                37,
                18,
                34,
                38,
                45,
                48,
                43,
                15,
                13,
                39,
                53,
                52,
                9,
                23,
                65,
                54,
                49,
                32,
                50,
                67,
                56,
                68,
                12,
                64,
                58
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "John Doe",
            "Age": "58",
            "Gender": "Male",
            "Medical History": "Chronic osteomyelitis, hypertension, recurrent respiratory infections"
        },
        "Disease Information": {
            "Disease": "Myeloma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent and progressively worsening bone pain, osteoporosis, pathological fractures, anemia, hypercalcemia, kidney damage, recurrent infections, increased serum globulin levels, radicular syndrome",
            "Duration": "Symptoms have been continuously intensifying over the past several months",
            "Curability": "No",
            "Severity Score": 69
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7-40)",
                "AST (Aspartate Aminotransferase)": "29 IU/L (13-35)",
                "Urea": "8.5 mmol/L (2.6-8.8)",
                "Creatinine (Cr)": "110 μmol/L (41-81)",
                "Triglycerides (TG)": "1.9 mmol/L (<1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (<5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5-9.5)",
                "Red Blood Cell Ct. (RBC)": "3.3 × 10^12/L (3.5-5.5)",
                "Hematocrit (Hct)": "32% (35-50)",
                "Hemoglobin (Hb)": "95 g/L (115-150)",
                "Platelet Ct. (PLT)": "150 × 10^9/L (125-350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20-50)",
                "Neutrophil Percentage (NEUT%)": "67% (40-75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.0 × 10^9/L (1.3-3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8-6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2-1.0)",
                "Monocyte Percentage (MONO%)": "9% (3-10)",
                "Eosinophil Abs. Ct. (EO#)": "0.07 × 10^9/L (0.02-0.52)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4-8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0-0.06)",
                "Basophil Percentage (BASO%)": "0.8% (0-1)",
                "Mean Platelet Volume (MPV)": "10 fL (9-13)",
                "Lactate Dehydrogenase": "240 U/L (135-225)",
                "Muscle Enzymes (CK)": "150 U/L (22-198 for males)",
                "Myoglobin": "78 ng/mL (<90 ng/mL)",
                "Troponin I": "12 ng/L (<14 ng/L)",
                "Ferritin": "550 ng/mL (20-500 for males)",
                "CRP": "20 mg/L (<3 mg/L)",
                "ESR": "60 mm/hr (0-20)",
                "Procalcitonin": "0.3 ng/mL (<0.5)",
                "D-dimer": "0.9 mg/L FEU (0-0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None Detected",
                "Blood Silver Level": "65 μg/L (50-150)"
            },
            "Bone Marrow Biopsy": "Presence of abnormal plasma cells confirmed, suggesting myeloma infiltration",
            "Serological Diagnosis": "Elevated serum immunoglobulin levels",
            "Imaging Examination (MRI)": "Multiple bone lesions with involvement of the axial skeleton",
            "Urine Protein Electrophoresis": "Presence of Bence-Jones proteins",
            "CT Scan": "Detection of minor bone damage and extramedullary involvement",
            "PET/CT": "Active lesion observed in multiple sites, including the spine and rib cage",
            "Pulmonary Function Test": "Normal",
            "Renal Function Test": "Impaired renal function due to monoclonal immunoglobulin deposition",
            "Nerve Conduction Study": "Peripheral neuropathy consistent with radicular symptoms"
        },
        "Treatment Plan": "John Doe has been diagnosed with multiple myeloma with major severity, characterized by significant bone pain, anemia, kidney damage, and recurrent infections. The primary treatment approach is chemotherapy, potentially combined with autologous stem cell transplantation if deemed suitable, to achieve disease remission. Bortezomib-based chemotherapy regimens will be initiated, possibly with thalidomide and dexamethasone to enhance therapeutic efficacy. Considering potential transplant eligibility, high-dose chemotherapy followed by autologous stem cell transplantation as consolidation therapy may be pursued if the patient's condition permits, in order to achieve a deeper remission. Maintenance therapy post-transplantation will involve lenalidomide or bortezomib monotherapy to sustain remission and prevent relapse, with periodic monitoring of serum M protein levels to assess disease progression. Pain management strategies, including analgesics such as morphine, will be employed to alleviate bone pain and neuralgia, while supportive care for anemia, consisting of erythropoietin administration, may be employed to improve hematologic function. Attention to kidney function is crucial, with dietary modifications implemented to reduce renal stress, alongside close monitoring for hypercalcemia and hyperuricemia, ensuring sufficient hydration to mitigate renal complications. Routine skeletal imaging and bone marrow assessments will aid in evaluating treatment response and adapting therapeutic strategies as needed. John will be encouraged to adopt a gentle exercise routine with careful monitoring to prevent bone fractures, complemented by nutritional support and infection prevention measures to optimize overall health. Regular follow-ups and monitoring every 3–6 months are advised, ensuring timely adjustments to the treatment plan based on his response, and John will be educated on recognizing potential signs of deterioration, adhering to prescribed medications, and the importance of ongoing care.",
        "User Profile": {
            "id": 51,
            "trust_in_healthcare": 0.241,
            "health_literacy": 0.856,
            "openness": 0.378,
            "conscientiousness": 0.695,
            "extraversion": 0.012,
            "agreeableness": 0.225,
            "neuroticism": 0.169,
            "region": "Illinois"
        },
        "Relations": {
            "strong": [
                60,
                36,
                45
            ],
            "moderate": [
                66,
                14,
                22,
                48,
                15,
                44,
                49,
                25,
                65,
                2,
                4,
                55,
                57,
                0,
                10,
                40
            ],
            "weak": [
                38,
                5,
                23,
                34,
                20,
                35,
                11,
                7,
                39,
                21,
                28,
                56,
                47,
                6,
                52,
                61,
                62,
                1,
                69,
                50,
                16,
                8,
                42,
                41,
                59,
                30,
                26,
                58,
                3,
                37,
                68,
                13,
                43,
                12,
                29,
                64,
                33,
                9,
                53,
                18,
                63,
                32,
                67,
                27,
                54,
                24,
                46,
                19,
                51,
                31
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Samantha White",
            "Age": "29",
            "Gender": "Female",
            "Medical History": "History of HPV infections; smoker; multiple sexual partners"
        },
        "Disease Information": {
            "Disease": "Cervical intraepithelial neoplasia",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Increased vaginal discharge, slight vaginal bleeding after intercourse",
            "Duration": "Symptoms have been noticed steadily for the past 4 weeks",
            "Curability": "Yes",
            "Severity Score": 29
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.3 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.95 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "9.5 fl (9 − 13)",
                "Lactate Dehydrogenase": "160 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198 for females)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "80 ng/mL (20 − 500 for females)",
                "CRP": "1 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "High-risk HPV Types 16 and 18",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Colposcopy Exam": "Lesion observed in transformation zone with white epithelium",
            "Cervical Cytology": "High-grade squamous intraepithelial lesion",
            "HPV Testing": "Positive for high-risk HPV types 16 and 18",
            "Histological Examination": "Confirmed cervical intraepithelial neoplasia",
            "Cervical Biopsy": "High-grade lesion with potential for malignancy",
            "Liquid-Based Cytology": "Abnormal cells detected",
            "Cervical Curettage": "Presence of squamous-cell abnormalities",
            "Colposcopy Imaging": "Localized lesion with visible transformation zone"
        },
        "Treatment Plan": "Samantha White has been diagnosed with moderate cervical intraepithelial neoplasia, linked to high-risk HPV infections. The treatment entails an immediate focus on surgical intervention with options such as Loop Electrosurgical Excision Procedure (LEEP) or cold knife conization to remove the lesioned tissue and provide samples for pathological analysis. Samantha will be counseled through the treatment process, focusing on the potential impact on future pregnancies due to this procedure, including risks such as cervical incompetence or preterm birth. While maintaining a stable partnership and proper sexual hygiene will be emphasized to reduce the risk of reinfection, the patient will also be encouraged to quit smoking and adopt a healthier lifestyle to improve her immune response. Regular follow-ups will be necessary to assess the success of the procedure, including repeated cytology and HPV tests every 4-6 months to ensure no residual lesions or recurrence. Furthermore, Samantha will be advised on the importance of HPV vaccination if eligible and educating herself about the disease to alleviate any psychological stress. After recovery, regular gynecological visits, balanced nutrition, and avoiding high-risk sexual behaviors will be key components of her ongoing preventive care strategy.",
        "User Profile": {
            "id": 54,
            "trust_in_healthcare": 0.127,
            "health_literacy": 0.309,
            "openness": 0.066,
            "conscientiousness": 0.242,
            "extraversion": 0.199,
            "agreeableness": 0.023,
            "neuroticism": 0.746,
            "region": "Wisconsin"
        },
        "Relations": {
            "strong": [
                69
            ],
            "moderate": [
                43,
                35,
                32,
                9,
                58,
                34,
                13,
                15,
                14,
                38,
                22,
                28,
                41,
                50,
                29
            ],
            "weak": [
                0,
                31,
                68,
                56,
                59,
                33,
                36,
                42,
                46,
                64,
                30,
                23,
                19,
                67,
                55,
                39,
                48,
                24,
                20,
                21,
                16,
                45,
                40,
                17,
                26,
                49,
                66,
                8,
                61,
                65,
                1,
                12,
                44,
                25,
                6,
                10,
                37,
                11,
                63,
                60,
                54,
                57,
                62,
                3,
                53,
                2,
                51,
                7,
                52,
                4,
                27
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Jason Roberts",
            "Age": "17",
            "Gender": "Male",
            "Medical History": "No prior significant medical history, occasional joint pain misattributed to growing pains"
        },
        "Disease Information": {
            "Disease": "Osteosarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent bone pain, swelling at the distal femur, limited joint movement, visible mass with increased local skin temperature",
            "Duration": "Symptoms have been worsening over the past two months, with pain intensifying at night",
            "Curability": "Yes",
            "Severity Score": 65
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.3 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.15 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "9 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "110 U/L (22 − 198 for males)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "480 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Imaging Tests": {
                "X-ray": "Irregular bone destruction and periosteal reaction at the distal femur",
                "CT Scan": "Mineralization within the tumor, localized bone destruction",
                "MRI": "Invasion into surrounding soft tissue, tumor mass at distal femur",
                "Bone Scan": "Increased radionuclide uptake in the distal femur",
                "PET Scan": "High metabolic activity at the site of the mass"
            },
            "Pathological Examination": "High-grade osteosarcoma confirmed via needle biopsy",
            "Chest CT": "No signs of metastasis",
            "Histology": "Presence of osteoid material indicative of osteosarcoma",
            "Blood Markers": {
                "Alkaline Phosphatase": "200 U/L (45 − 115)",
                "Lactate Dehydrogenase": "Elevated"
            },
            "Nutritional Assessment": "Adequate nutritional status with potential need for increased caloric intake during treatment"
        },
        "Treatment Plan": "Jason Roberts has been diagnosed with major severity osteosarcoma located in the distal femur and requires a comprehensive treatment approach. Preoperative chemotherapy will be initiated to assess the tumor's response and reduce its size prior to surgery. A combination of methotrexate, doxorubicin, and cisplatin will be administered to target the high-grade malignancy effectively. Following a thorough assessment, limb-sparing surgery is considered feasible and optimal for preserving function, given the tumor's location and current status. Rotationplasty or prosthesis replacement will be assessed based on intraoperative findings and feasibility. Post-surgery, adjuvant chemotherapy will continue to address any microscopic metastatic lesions and prevent recurrence, with cycles planned according to the tumor's histological response to initial chemotherapy. Regular imaging, blood tests, and clinical evaluations will monitor the response and guide any necessary adjustments to chemotherapy regimens. Psychological support and counseling will be provided to assist Jason and his family with the emotional aspects of treatment and recovery. Nutritional support will focus on optimal calorie and protein intake to support healing and ongoing treatment. Adherence to the treatment protocol, regular follow-up appointments, and cooperation from Jason and his family are crucial for successful treatment outcomes. Physical therapy will be implemented post-surgery to regain limb function, with gradual increases in physical activity as tolerated. If required, additional surgical interventions such as removal of any detected metastatic lesions in the lungs will be considered based on follow-up imaging and clinical assessments.",
        "User Profile": {
            "id": 57,
            "trust_in_healthcare": 0.491,
            "health_literacy": 0.538,
            "openness": 0.797,
            "conscientiousness": 0.31,
            "extraversion": 0.505,
            "agreeableness": 0.592,
            "neuroticism": 0.889,
            "region": "Pennsylvania"
        },
        "Relations": {
            "strong": [
                20,
                29
            ],
            "moderate": [
                16,
                69,
                28,
                51,
                31,
                0,
                32,
                66,
                63,
                27,
                24,
                61,
                43,
                33,
                13,
                6,
                38,
                1,
                41,
                4
            ],
            "weak": [
                49,
                46,
                64,
                52,
                8,
                37,
                7,
                47,
                65,
                25,
                55,
                18,
                40,
                53,
                3,
                36,
                21,
                30,
                22,
                54,
                26,
                58,
                9,
                59,
                39,
                67,
                12,
                2,
                35,
                34,
                11,
                14,
                42,
                15,
                68,
                17,
                44,
                56,
                23,
                57,
                5,
                60,
                10,
                62,
                50,
                45,
                48
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Sarah Johnson",
            "Age": "17",
            "Gender": "Female",
            "Medical History": "No significant medical history"
        },
        "Disease Information": {
            "Disease": "Bone tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent bone pain, noticeable swelling and mass in the affected limb, localized tenderness, reduced limb function, and occasional low-grade fever",
            "Duration": "Symptoms have progressively worsened over the past 3 months",
            "Curability": "Yes",
            "Severity Score": 58
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.6 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "320 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "80 ng/mL (12 − 150 for females)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "X-ray Exam": "Irregular moth-eaten appearance with unclear boundaries in femur",
            "CT Scan": "Lesions in the femur with sunburst pattern indicative of osteosarcoma",
            "MRI": "Tumor extent with surrounding soft tissue involvement",
            "Bone Scan": "Increased uptake in affected femur with no metastatic spread",
            "Biopsy": "Histopathology confirms osteosarcoma",
            "Serological Diagnosis": "Normal",
            "Bacterial Culture": "Normal",
            "Pulmonary Function Test": "Normal",
            "Urinary Analysis": "Normal",
            "Ultrasound": "Normal surrounding soft tissue structure"
        },
        "Treatment Plan": "Sarah Johnson has been diagnosed with osteosarcoma in the femur, requiring an aggressive treatment approach due to its major severity. The primary treatment will include limb-sparing surgery to resect the tumor while preserving limb function, considering her preference and the tumor's location. Preoperative neoadjuvant chemotherapy will be initiated to shrink the tumor size and enhance surgical outcomes, followed by postoperative adjuvant chemotherapy to reduce the risk of recurrence. Regular imaging assessments will monitor her response to treatment, with adjustments made if necessary. Limb preservation will be prioritized since there is no neurovascular bundle involvement, and a comprehensive rehabilitation plan will be established to support her recovery and improve limb function post-surgery. Sarah and her family will receive counseling to understand the treatment process, potential side effects, and the importance of follow-up care. Proactive measures will be taken to manage complications and optimize her overall wellbeing throughout the treatment journey.",
        "User Profile": {
            "id": 60,
            "trust_in_healthcare": 0.371,
            "health_literacy": 0.659,
            "openness": 0.29,
            "conscientiousness": 0.997,
            "extraversion": 0.151,
            "agreeableness": 0.741,
            "neuroticism": 0.182,
            "region": "Pennsylvania"
        },
        "Relations": {
            "strong": [
                16,
                19,
                41
            ],
            "moderate": [
                33,
                61,
                60,
                44,
                0,
                28,
                26,
                63,
                17,
                40,
                31,
                27,
                51,
                42,
                62,
                66,
                24,
                4
            ],
            "weak": [
                36,
                69,
                48,
                22,
                35,
                45,
                29,
                9,
                21,
                2,
                11,
                14,
                50,
                32,
                5,
                18,
                34,
                57,
                52,
                46,
                65,
                47,
                39,
                10,
                54,
                7,
                1,
                30,
                56,
                6,
                59,
                49,
                15,
                64,
                53,
                12,
                3,
                55,
                43,
                25,
                58,
                8,
                37,
                38,
                13,
                23,
                67,
                68
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "James Thompson",
            "Age": "55",
            "Gender": "Male",
            "Medical History": "Chronic inflammation around the anus, history of HPV infection"
        },
        "Disease Information": {
            "Disease": "Perianal cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Anal discomfort, itching, rectal bleeding, palpable lumps at the anal margin, mild pain",
            "Duration": "Symptoms have persisted and gradually worsened over the past 6 months",
            "Curability": "Yes",
            "Severity Score": 75
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.4 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "280 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.8 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "175 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "90 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.25 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative for cancer-specific antigens",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "No significant abnormalities",
            "Abdominal and Pelvic Computerized Tomography (CT)": "Localized mass in perianal region, suggestive of perianal cancer, no distant metastasis",
            "Serological Diagnosis": "Negative for viral markers",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Anal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "No abnormal findings",
            "Anoscopy and Rectoscopy": "Visible lesions with ulcerations and characteristic signs of perianal cancer",
            "Serum Antibody Test": "Negative for HIV antibodies",
            "Pelvic MRI": "Enhanced lesion in the perianal area with no evident pelvic lymph node involvement",
            "Nucleic Acid Amplification Test": "Negative for prevalent viral pathogens",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "James Thompson has been diagnosed with perianal cancer with a severity that warrants a comprehensive treatment approach. Given the localized presentation and the absence of distant metastasis, the treatment will primarily involve concurrent chemoradiotherapy to target the tumor and any potential regional lymph node involvement. This will include the administration of mitomycin and fluorouracil concomitant with pelvic radiotherapy, considering James's overall good health status and his non-HIV-positive status, which suggests he may better tolerate the treatment. Surgery may be considered if the tumor shows local progression, with surgical resection or abdominoperineal resection as potential options. James will also be advised on maintaining a diet that is light yet nutritious, ensuring adequate rest, and engaging in light activities to support his physical and mental well-being throughout the treatment. Psychological support and stress-relief practices will be encouraged to alleviate any anxiety related to the diagnosis and treatment process. Regular follow-up appointments will be crucial to monitor the efficacy of the treatment, assess for any adverse effects, and make necessary adjustments to the therapeutic regimen. Family involvement is important to provide emotional support and assist with daily care needs. Post-treatment, James will be encouraged to adopt lifestyle changes such as safe sexual practices and potentially receive the HPV vaccine to reduce the risk of future occurrences.",
        "User Profile": {
            "id": 63,
            "trust_in_healthcare": 0.527,
            "health_literacy": 0.042,
            "openness": 0.255,
            "conscientiousness": 0.584,
            "extraversion": 0.614,
            "agreeableness": 0.491,
            "neuroticism": 0.317,
            "region": "Texas"
        },
        "Relations": {
            "strong": [
                42
            ],
            "moderate": [
                36,
                57,
                56,
                38,
                59,
                34,
                22,
                58,
                62,
                45,
                48,
                10,
                11,
                66,
                8,
                4,
                1
            ],
            "weak": [
                53,
                13,
                14,
                50,
                64,
                68,
                25,
                40,
                55,
                6,
                52,
                67,
                35,
                3,
                7,
                28,
                30,
                49,
                29,
                39,
                15,
                5,
                37,
                60,
                44,
                65,
                17,
                54,
                16,
                41,
                43,
                12,
                23,
                47,
                31,
                46,
                24,
                0,
                32,
                63,
                2,
                20,
                19,
                61,
                26,
                18,
                69,
                33
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Elizabeth Wang",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "History of hepatitis B infection, cholecystectomy"
        },
        "Disease Information": {
            "Disease": "Liver tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Abdominal discomfort, jaundice, weight loss, decreased appetite",
            "Duration": "Symptoms have developed progressively over the past 6 months",
            "Curability": "No",
            "Severity Score": 69
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "95 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "120 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.7 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Positive",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "180 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "75% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.8 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "12% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "550 ng/mL (15 − 150 for females)",
                "CRP": "35 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "Alpha-fetoprotein (AFP)",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Large liver mass with hyperechoic areas",
            "CT Scan": "Liver mass with heterogeneous enhancement patterns",
            "MRI Exam": "Solid mass in right liver lobe with irregular margins",
            "Serological Diagnosis": "Elevated alpha-fetoprotein (AFP)",
            "Tumor Marker Detection": "Raised carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9)",
            "Biopsy Test": "Positive for hepatocellular carcinoma",
            "PET-CT": "No evidence of distant metastasis",
            "Liver Function Test": "Impaired liver function with elevated bilirubin levels",
            "Coagulation Function Test": "Mild coagulopathy detected",
            "Virology": "Hepatitis B virus DNA positive"
        },
        "Treatment Plan": "Elizabeth Wang has been diagnosed with a malignant liver tumor, specifically hepatocellular carcinoma, characterized by major severity due to progressive symptoms over the last six months. Given the current condition and medical history, including hepatitis B infection, a comprehensive treatment plan is necessary, with surgical resection as the primary treatment modality. The tumor is resectable, and liver function appears adequate for surgery. Hepatoprotective treatment will be administered pre-surgery to optimize liver function. Post-surgery, close monitoring for complications and disease recurrence is paramount, with periodic imaging and tumor marker assessments. Antiviral treatment for hepatitis B will be initiated to manage viral load and reduce liver inflammation. Targeted therapy with sorafenib may be considered alongside other systemic treatments if surgery is insufficient or recurrence occurs. Nutritional support, psychological counseling, and lifestyle modifications are vital components of the management strategy to enhance recovery and quality of life, including a balanced diet, cessation of alcohol, smoking, and regular physical activity. Follow-up care, incorporating regular check-ups and imaging studies, is essential in tracking Elizabeth's progress and making necessary adjustments to the treatment regimen. Additionally, educating Elizabeth and her family about treatment adherence, potential symptoms of deterioration, and the importance of continued medical evaluations will further support her recovery journey and long-term health.",
        "User Profile": {
            "id": 66,
            "trust_in_healthcare": 0.351,
            "health_literacy": 0.446,
            "openness": 0.188,
            "conscientiousness": 0.106,
            "extraversion": 0.444,
            "agreeableness": 0.271,
            "neuroticism": 0.159,
            "region": "Iowa"
        },
        "Relations": {
            "strong": [
                36,
                38,
                66
            ],
            "moderate": [
                58,
                14,
                56,
                34,
                21,
                45,
                57,
                48,
                13,
                17,
                40,
                11,
                60,
                52,
                49,
                4,
                42,
                35,
                15,
                50,
                53,
                68,
                67,
                30
            ],
            "weak": [
                55,
                6,
                10,
                39,
                8,
                23,
                65,
                29,
                59,
                62,
                28,
                1,
                7,
                64,
                12,
                18,
                44,
                25,
                0,
                54,
                5,
                61,
                37,
                9,
                2,
                43,
                32,
                20,
                69,
                31,
                24,
                3,
                46,
                19,
                16,
                47,
                41,
                51,
                26,
                63,
                33,
                27
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Evelyn Smith",
            "Age": "62",
            "Gender": "Female",
            "Medical History": "History of chronic hepatitis B and gallstones"
        },
        "Disease Information": {
            "Disease": "Hilar cholangiocarcinoma",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Dull pain and discomfort in the right upper abdomen, jaundice, dark yellow urine, grayish-white stools, severe itching of the skin",
            "Duration": "Symptoms have been progressively worsening over the past 3 weeks",
            "Curability": "No",
            "Severity Score": 93
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "85 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "90 IU/L (13 − 35)",
                "Urea": "5.3 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Positive",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.7 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "32% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.3 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "4% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "9 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for females)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Carcinoembryonic antigen (CEA)",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Abdominal Ultrasound": "Intrahepatic bile duct dilation with obstructive lesions",
            "CT Scan": "Mass at the hepatic hilum with invasion of nearby blood vessels",
            "MRI": "Tumor in the hepatic hilum with signs of vascular encroachment",
            "PET-CT": "Increased uptake in the hepatic hilum area",
            "ERCP": "Stenosis in the hepatic hilum with confirmed obstruction",
            "Liver Function Test": "Elevated bilirubin levels indicating jaundice",
            "Tumor Markers": {
                "Alpha-Fetoprotein (AFP)": "Normal",
                "Carcinoembryonic Antigen (CEA)": "High",
                "CA19-9": "Elevated"
            },
            "IgG4 Level": "Within normal range",
            "Autoimmune Antibodies Test": "Negative"
        },
        "Treatment Plan": "Evelyn Smith has been diagnosed with hilar cholangiocarcinoma, a condition with a complex and challenging prognosis due to its location and progression. After assessing her medical status and reviewing the imaging results, surgical intervention is not feasible at this advanced stage, with indications of vascular invasion. Treatment will focus on palliative measures to manage symptoms and improve quality of life. Placement of biliary stents through percutaneous transhepatic cholangial drainage (PTCD) will be crucial in relieving jaundice symptoms and maintaining bile duct patency. Chemotherapy using gemcitabine combined with platinum-based agents will be administered to slow tumor progression and reduce systemic symptoms. Additionally, Evelyn will receive external beam radiotherapy for palliative purposes, aiming to reduce tumor size and associated bile duct obstruction. Radiofrequency ablation may be considered if localized tumor control can be achieved, followed by stent placement to ensure bile duct patency. Close monitoring of liver function tests and tumor markers will be required to assess treatment efficacy and modify approaches as needed. A multidisciplinary team will support Evelyn's care, ensuring comprehensive management of her symptoms, including addressing severe skin itching with appropriate topical treatments and antihistamines to improve comfort. Nutritional support and regular follow-ups are vital in maintaining her overall health and engaging in moderate activity to enhance physical resilience. Her adherence to medical advice and regular evaluations will be key to optimizing her management and improving quality of life during treatment.",
        "User Profile": {
            "id": 69,
            "trust_in_healthcare": 0.021,
            "health_literacy": 0.714,
            "openness": 0.171,
            "conscientiousness": 0.571,
            "extraversion": 0.777,
            "agreeableness": 0.045,
            "neuroticism": 0.969,
            "region": "California"
        },
        "Relations": {
            "strong": [
                15,
                3,
                68
            ],
            "moderate": [
                14,
                34,
                25,
                10,
                55,
                59,
                47,
                37,
                57,
                38,
                65,
                36,
                67,
                6,
                5,
                22,
                30,
                17,
                60,
                49,
                43,
                40
            ],
            "weak": [
                45,
                69,
                4,
                7,
                66,
                21,
                35,
                24,
                58,
                2,
                39,
                48,
                29,
                13,
                18,
                52,
                46,
                56,
                28,
                31,
                8,
                11,
                1,
                53,
                16,
                26,
                19,
                42,
                44,
                64,
                50,
                0,
                12,
                33,
                9,
                32,
                54,
                62,
                27,
                20,
                41,
                61,
                51,
                63
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Liam Thompson",
            "Age": "4",
            "Gender": "Male",
            "Medical History": "No significant medical history, diagnosed with hepatoblastoma upon discovery of abdominal mass"
        },
        "Disease Information": {
            "Disease": "Hepatoblastoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Abdominal mass, occasional abdominal pain, mild anemia, loss of appetite",
            "Duration": "Symptoms observed for the past 3 months, with rapid tumor growth noted",
            "Curability": "Yes",
            "Severity Score": 52
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "55 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "60 IU/L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "50 μmol/L (41 − 81)",
                "Triglycerides (TG)": "0.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.7 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.1 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "35% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "275 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.65 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "9% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Alpha-fetoprotein (AFP)": "2000 ng/mL (very high)",
                "CRP": "4 mg/L (< 3 mg/L)",
                "ESR": "22 mm/hr (0 − 20)",
                "Procalcitonin": "0.05 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Abdominal Ultrasound": "Large solid mass in the liver with rich vascular supply and possible vascular invasion",
            "Abdominal CT Scan": "Single large hypervascular liver mass with areas of calcification and cystic necrosis",
            "Chest X-ray": "No evidence of lung metastasis",
            "MRI of Abdomen": "Confirms findings of CT with detailed assessment of surrounding tissue involvement",
            "Pathological Examination": "Biopsy confirms epithelial type hepatoblastoma",
            "Serum Antibody Test": "Negative for hepatitis markers"
        },
        "Treatment Plan": "Liam Thompson has been diagnosed with hepatoblastoma, which is currently staged at PRETEXT stage III with major severity due to the size of the tumor and rapid growth observed. The primary objective in treating Liam is to achieve resection post-chemotherapy. An initial biopsy confirmed the diagnosis, followed by the administration of neoadjuvant chemotherapy to reduce the tumor size, facilitating a later surgical resection. The chemotherapy regimen is based on his risk stratification and will start with the C5VD protocol, including cisplatin, 5-fluorouracil, vincristine, and doxorubicin. Continuous monitoring of serum alpha-fetoprotein (AFP) levels will help assess treatment response. If the tumor size decreases sufficiently, surgical resection will be planned. During this period, Liam's liver function and general health will be closely monitored to adjust the treatment plan as necessary, with supportive care to manage chemotherapy side effects. Nutritional support and regular follow-ups with pediatric oncology and surgery teams will ensure the best care for Liam, aiming for a curative outcome.",
        "User Profile": {
            "id": 72,
            "trust_in_healthcare": 0.304,
            "health_literacy": 0.81,
            "openness": 0.227,
            "conscientiousness": 0.625,
            "extraversion": 0.916,
            "agreeableness": 0.381,
            "neuroticism": 0.776,
            "region": "Virginia"
        },
        "Relations": {
            "strong": [
                46,
                33,
                51
            ],
            "moderate": [
                16,
                31,
                28,
                69,
                19,
                9,
                27,
                57,
                25,
                20,
                55,
                23,
                38,
                14,
                6,
                59,
                68
            ],
            "weak": [
                21,
                29,
                67,
                3,
                36,
                41,
                10,
                37,
                26,
                22,
                43,
                15,
                35,
                0,
                13,
                18,
                4,
                47,
                8,
                34,
                30,
                49,
                40,
                11,
                7,
                1,
                39,
                17,
                58,
                66,
                63,
                32,
                65,
                60,
                48,
                42,
                52,
                45,
                50,
                61,
                56,
                53,
                5,
                44,
                62,
                12,
                2,
                64,
                54
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Alan Thompson",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Chronic smoking habit, history of alcohol use, previous episodes of hoarseness and throat pain"
        },
        "Disease Information": {
            "Disease": "Throat cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent hoarseness, foreign body sensation in throat, difficulty swallowing, neck pain, occasional blood-tinged sputum",
            "Duration": "Symptoms have been worsening over the past 6 months",
            "Curability": "No",
            "Severity Score": 65
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "33 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "25 IU/L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.8 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "45% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "160 U/L (22 − 198 for males)",
                "Myoglobin": "45 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "350 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Not detected",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "No significant abnormalities",
            "Laryngeal CT Exam": "Mass found in glottis region with possible invasion to adjacent structures",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Laryngoscopy Exam": "Visible mass in the glottic area with irregular borders",
            "Biopsy": "Confirmed squamous cell carcinoma",
            "Pulmonary Function Test": "Normal",
            "Nasal Endoscopy": "Normal",
            "Ultrasound Examination": "Enlarged cervical lymph nodes detected"
        },
        "Treatment Plan": "Alan Thompson has been diagnosed with stage III glottic laryngeal cancer, characterized by persistent hoarseness, difficulty swallowing, and neck pain. Given the major severity of his condition and tumor location, a multidisciplinary approach is required. Initial management will include a total laryngectomy to remove the cancerous growth, considering the likelihood of lymph node metastasis. Preoperative radiotherapy will be employed to shrink the tumor size. Post-surgical care will involve intensive speech therapy and the use of alternative speaking methods due to the loss of natural vocal function. Chemotherapy regimens involving cisplatin and 5-fluorouracil will be administered postoperatively to reduce recurrence risks. Supportive care includes nutritional support, pain management, and psychological counseling to assist in coping with the lifestyle changes and emotional stress of the condition. Regular follow-up appointments are scheduled for monitoring potential recurrence and ensuring the efficacy of the treatment strategy. Alan will also be educated on lifestyle modifications to cease smoking and alcohol use to prevent further health complications.",
        "User Profile": {
            "id": 75,
            "trust_in_healthcare": 0.215,
            "health_literacy": 0.838,
            "openness": 0.636,
            "conscientiousness": 0.628,
            "extraversion": 0.689,
            "agreeableness": 0.499,
            "neuroticism": 0.754,
            "region": "New Jersey"
        },
        "Relations": {
            "strong": [
                37,
                55,
                47,
                3
            ],
            "moderate": [
                6,
                14,
                5,
                60,
                7,
                10,
                23,
                11,
                65,
                2,
                38,
                57,
                29,
                4,
                15,
                39,
                68,
                52,
                17,
                13,
                30,
                49
            ],
            "weak": [
                59,
                45,
                66,
                67,
                21,
                36,
                1,
                34,
                56,
                24,
                43,
                22,
                64,
                8,
                40,
                32,
                58,
                0,
                28,
                53,
                44,
                69,
                48,
                19,
                16,
                54,
                12,
                35,
                31,
                46,
                26,
                33,
                42,
                41,
                62,
                18,
                27,
                50,
                63,
                61,
                51,
                20,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "James Taylor",
            "Age": "29",
            "Gender": "Male",
            "Medical History": "History of occasional night sweats and fatigue, no prior immune system diseases or noticeable lymph node enlargement."
        },
        "Disease Information": {
            "Disease": "Hodgkin Lymphoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Painless enlargement of cervical lymph nodes, occasional fever and night sweats, mild fatigue",
            "Duration": "Symptoms have been present intermittently over the past 3 weeks",
            "Curability": "Yes",
            "Severity Score": 39
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "ESR": "30 mm/hr (0 − 20)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ABO Group": "A",
                "Rh Type": "Positive"
            },
            "Chest X-ray Exam": "Slight enlargement of mediastinal lymph nodes",
            "Chest Computerized Tomography": "Enlargement of cervical and mediastinal lymph nodes, no significant organ involvement",
            "Serological Diagnosis": "Elevated LDH levels",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bone Marrow Biopsy": "Presence of Reed-Sternberg cells",
            "CT Scan": "Enlarged cervical lymph nodes observed",
            "MRI": "No signs of extranodal organ involvement",
            "PET/CT": "Localized activity in cervical lymph nodes",
            "Liver and Kidney Function Tests": "Normal",
            "Bone Marrow Aspiration": "No significant bone marrow disruption"
        },
        "Treatment Plan": "James Taylor has been diagnosed with Moderate Severity Hodgkin Lymphoma, presenting primarily with cervical lymph node enlargement, occasional fever, and mild systemic symptoms. The treatment plan involves starting with the ABVD chemotherapy regimen for 4 cycles due to his favorable early staging, aiming to achieve remission. Following chemotherapy, involved field radiotherapy will be administered to ensure clearance of residual cancerous tissues. Regular monitoring of blood counts, liver and kidney function will be crucial to manage potential adverse effects of the treatment. James will receive supportive care to mitigate symptoms such as nausea and fatigue, with nutritional support emphasizing high-calorie, high-protein diets. Psychological support will be provided to encourage a positive mindset and adherence to treatment. James should avoid occupational exposure to chemicals and maintain a healthy lifestyle to reduce recurrence risk. Family members will be advised to support him consistently throughout the treatment process, emphasizing regular follow-up visits and timely medical attention if new symptoms emerge. Continuous reevaluation with PET/CT will be conducted to assess response and adjust treatment as necessary, ensuring optimal management of his Hodgkin Lymphoma.",
        "User Profile": {
            "id": 78,
            "trust_in_healthcare": 0.971,
            "health_literacy": 0.897,
            "openness": 0.228,
            "conscientiousness": 0.926,
            "extraversion": 0.194,
            "agreeableness": 0.764,
            "neuroticism": 0.515,
            "region": "California"
        },
        "Relations": {
            "strong": [
                40
            ],
            "moderate": [
                20,
                61,
                27,
                44,
                16,
                0,
                33,
                62,
                60,
                28,
                31,
                47,
                34,
                11,
                42,
                12,
                8,
                1,
                50,
                35,
                10,
                69,
                63,
                29
            ],
            "weak": [
                41,
                39,
                6,
                7,
                17,
                36,
                24,
                15,
                14,
                21,
                4,
                66,
                19,
                55,
                65,
                25,
                5,
                56,
                57,
                30,
                2,
                18,
                3,
                48,
                54,
                49,
                45,
                59,
                32,
                38,
                22,
                64,
                58,
                9,
                52,
                23,
                51,
                46,
                37,
                13,
                43,
                53,
                68,
                67
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Ethan Smith",
            "Age": "8",
            "Gender": "Male",
            "Medical History": "No significant past medical history; recent onset of a painless lump in the arm"
        },
        "Disease Information": {
            "Disease": "Rhabdomyosarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless lump on the arm, occasional mild swelling, weakness in the affected limb",
            "Duration": "Symptoms have been present for approximately one month",
            "Curability": "Yes",
            "Severity Score": 72
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "60 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.2 mmol/L (< 5.18)",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "55% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Imaging Exams": {
                "Ultrasound": "Solid mass in the upper arm, no vascular invasion",
                "MRI": "5 cm soft tissue mass in the left arm, non-invasive appearance",
                "CT Scan": "Chest and abdomen clear, no signs of metastasis"
            },
            "Pathological Tissue Examination": "Confirmed embryonal rhabdomyosarcoma",
            "Bone Marrow Cytology": "Normal",
            "Cerebrospinal Fluid Examination": "Normal",
            "Echocardiography": "Normal heart function"
        },
        "Treatment Plan": "Ethan Smith has been diagnosed with embryonal rhabdomyosarcoma located in his arm, characterized by a significant, but non-metastatic tumor that necessitates a combination of surgery, chemotherapy, and possibly radiotherapy. The recommended treatment plan includes an initial surgery to remove the tumor as completely as possible while preserving function of the surrounding muscle and nerve tissue. Postoperative treatment will involve multi-agent chemotherapy, using the VAC regimen (vincristine, actinomycin D, and cyclophosphamide) to target and eradicate any microscopic residual cancer cells. Given the risk of local recurrence, radiotherapy may be considered if residual tumor tissue is confirmed or if surgical margins are unclear. Continuous monitoring through imaging studies is essential to assess the response to therapy and ensure no new lesions develop. Ethan and his family will be educated on the importance of adhering to scheduled treatments, recognizing potential side effects, and maintaining follow-up appointments to enhance the effectiveness of the treatment and improve prognosis. Nutritional support and physical rehabilitation will also be advised to ensure optimal recovery and strengthen his overall health.",
        "User Profile": {
            "id": 81,
            "trust_in_healthcare": 0.974,
            "health_literacy": 0.821,
            "openness": 1,
            "conscientiousness": 0.938,
            "extraversion": 0.522,
            "agreeableness": 0.328,
            "neuroticism": 0.356,
            "region": "California"
        },
        "Relations": {
            "strong": [
                51,
                26
            ],
            "moderate": [
                16,
                19,
                28,
                20,
                24,
                66,
                11,
                46,
                47,
                63,
                49,
                0,
                7,
                33,
                4,
                10,
                40
            ],
            "weak": [
                65,
                69,
                29,
                36,
                55,
                34,
                17,
                35,
                61,
                31,
                5,
                2,
                41,
                3,
                1,
                60,
                44,
                50,
                21,
                62,
                25,
                54,
                45,
                52,
                53,
                15,
                6,
                38,
                48,
                22,
                13,
                57,
                37,
                32,
                43,
                8,
                58,
                9,
                42,
                56,
                59,
                14,
                23,
                39,
                64,
                12,
                18,
                30,
                68,
                67
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Thomas Smith",
            "Age": "26",
            "Gender": "Male",
            "Medical History": "Previously healthy, no significant family history of cancer"
        },
        "Disease Information": {
            "Disease": "Synovial sarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless mass near the knee, difficulty moving the leg, swelling",
            "Duration": "Symptoms noticed over the past two months, progressively increasing in size",
            "Curability": "Yes",
            "Severity Score": 57
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "25 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "75 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Solid mass with increased vascularity in the lower limb",
            "MRI Exam": "Tumor with clear demarcation from surrounding tissues but close to major vessels",
            "Chest X-ray": "No signs of lung metastasis",
            "CT Scan": "Confirms the size of the mass, no evidence of calcification",
            "Bone Scan": "No bone involvement detected",
            "Biopsy": "Positive for SYT-SSX1 fusion gene",
            "Pathological Examination": "Presence of spindle cells, characteristics of monophasic synovial sarcoma"
        },
        "Treatment Plan": "Thomas Smith has been diagnosed with synovial sarcoma located near the knee, indicating a major severity level. The primary treatment approach will be surgical excision, ensuring a safe margin of 1cm beyond the tumor boundary. The surgical team will aim to preserve limb function while achieving complete tumor removal; however, partial limb function may be sacrificed to ensure complete excision. Preoperative imaging has shown no involvement of major blood vessels, which could facilitate limb-sparing surgery. Post-surgical therapy will include radiotherapy to target any remaining cancer cells and reduce recurrence risk. The patient is eligible for adjuvant chemotherapy with the ADM+IFO regimen to further enhance therapeutic outcomes and minimize chances of metastasis. Regular follow-ups every 3 months for the first year, including MRI scans and physical exams, will be conducted to monitor progress and detect any signs of recurrence. Thomas is advised to maintain a balanced diet high in protein and engage in moderate physical activity to prevent atrophy and enhance recovery. He and his family will be educated on recognizing symptoms of recurrence and the importance of adhering to the treatment protocol for optimal recovery. Regular consultation with the oncology team and a nutritionist will be arranged to ensure comprehensive care and support.",
        "User Profile": {
            "id": 84,
            "trust_in_healthcare": 0.237,
            "health_literacy": 0.861,
            "openness": 0.31,
            "conscientiousness": 0.386,
            "extraversion": 0.643,
            "agreeableness": 0.38,
            "neuroticism": 0.317,
            "region": "Michigan"
        },
        "Relations": {
            "strong": [
                16,
                69
            ],
            "moderate": [
                20,
                29,
                19,
                24,
                0,
                40,
                35,
                36,
                21,
                41,
                51,
                27,
                22,
                66,
                57,
                26,
                38,
                17
            ],
            "weak": [
                46,
                18,
                6,
                61,
                31,
                55,
                53,
                25,
                13,
                10,
                8,
                58,
                7,
                32,
                43,
                4,
                59,
                60,
                44,
                56,
                50,
                23,
                1,
                45,
                42,
                11,
                52,
                33,
                34,
                9,
                2,
                68,
                39,
                63,
                67,
                37,
                5,
                15,
                49,
                47,
                14,
                48,
                30,
                54,
                3
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Jessica Lin",
            "Age": "39",
            "Gender": "Female",
            "Medical History": "Previous neck ultrasound showing enlarged thyroid with nodules, anxiety about thyroid health"
        },
        "Disease Information": {
            "Disease": "Thyroid cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Painless neck mass, difficulty swallowing, hoarseness, slight facial flushing",
            "Duration": "Symptoms observed over the past 3 months",
            "Curability": "Yes",
            "Severity Score": 41
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.2 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "3.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "11 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "120 U/L (22 − 198 for females)",
                "Myoglobin": "55 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "80 ng/mL (20 − 500 for females)",
                "CRP": "3 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Thyroglobulin",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Examination": "Presence of irregular thyroid nodules with microcalcifications",
            "Neck X-ray": "Observation of thyroid enlargement, normal tracheal positioning",
            "Computed Tomography (CT)": "Thyroid nodules with slight extrathyroidal extension; no cervical lymph node involvement",
            "Thyroid Function Test": "Normal thyroxine levels, elevated TSH",
            "Thyroid Autoantibody Test": "Negative for TgAb and TPOAb",
            "Tumor Marker Test": "Elevated thyroglobulin levels, normal calcitonin",
            "Fine-Needle Aspiration Cytology": "Papillary carcinoma cells identified, benign cellular morphology confirmed",
            "Molecular Marker Test": "BRAF mutation detected",
            "Laryngoscopy": "Normal vocal cord function"
        },
        "Treatment Plan": "Jessica Lin has been diagnosed with papillary thyroid carcinoma with moderate severity. Surgical intervention will be the primary treatment modality, consisting of a total thyroidectomy given the presence of extrathyroidal extension, ensuring complete removal of malignant tissues. In preparation for surgery, a preoperative assessment including comprehensive blood work, imaging, and laryngoscopy has been conducted to confirm vocal cord functionality and evaluate any potential surgical complications. Post-surgical management will include the administration of levothyroxine to suppress TSH levels, preventing recurrence and facilitating hormone balance. Regular follow-up care is crucial for monitoring thyroglobulin levels and ensuring no residual malignant activity, with neck ultrasonography and periodic blood tests scheduled. Due to the presence of BRAF mutation, which may affect the tumor's aggressiveness, close observation and potential enrollment in targeted therapy clinical trials may be considered if necessary. Nutritional support and psychological counseling will be provided to assist Jessica in maintaining a positive outlook and managing stress effectively during recovery. Education regarding post-operative care, thyroid hormone replacement therapy, and lifestyle modifications will be imparted, with an emphasis on adherence to medical advice and avoidance of iodine excess. Long-term monitoring will include regular thyroid function tests to fine-tune hormone replacement therapy and ensure optimal recovery and disease management.",
        "User Profile": {
            "id": 87,
            "trust_in_healthcare": 0.422,
            "health_literacy": 0.472,
            "openness": 0.681,
            "conscientiousness": 0.572,
            "extraversion": 0.49,
            "agreeableness": 0.599,
            "neuroticism": 0.924,
            "region": "Michigan"
        },
        "Relations": {
            "strong": [
                32
            ],
            "moderate": [
                19,
                0,
                43,
                13,
                1,
                49,
                25,
                6,
                28,
                34,
                66,
                36,
                38,
                37,
                3,
                69,
                31
            ],
            "weak": [
                59,
                35,
                55,
                65,
                40,
                42,
                47,
                4,
                14,
                22,
                53,
                58,
                21,
                11,
                44,
                64,
                41,
                30,
                57,
                61,
                7,
                18,
                15,
                52,
                50,
                68,
                60,
                8,
                10,
                24,
                23,
                2,
                26,
                54,
                16,
                33,
                63,
                39,
                62,
                20,
                5,
                45,
                12,
                56,
                17,
                67,
                51,
                46,
                48,
                27
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Emily Jenkins",
            "Age": "68",
            "Gender": "Female",
            "Medical History": "Hypertension, Osteoporosis"
        },
        "Disease Information": {
            "Disease": "Acute leukemia",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Anemia, fever, continuous gum bleeding, pallor, fatigue, dizziness, hepatosplenomegaly",
            "Duration": "Symptoms have been worsening over the past 3 weeks",
            "Curability": "No",
            "Severity Score": 89
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU/L (7-40)",
                "AST (Aspartate Aminotransferase)": "40 IU/L (13-35)",
                "Urea": "8.5 mmol/L (2.6-8.8)",
                "Creatinine (Cr)": "88 μmol/L (41-81)",
                "Triglycerides (TG)": "1.2 mmol/L (<1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (<5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "50 × 10^9/L (3.5-9.5)",
                "Red Blood Cell Ct. (RBC)": "2.5 × 10^12/L (3.5-5.5)",
                "Hematocrit (Hct)": "30% (35-50)",
                "Hemoglobin (Hb)": "90 g/L (115-150)",
                "Platelet Ct. (PLT)": "50 × 10^9/L (125-350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20-50)",
                "Neutrophil Percentage (NEUT%)": "65% (40-75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "12.5 × 10^9/L (1.3-3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "32.5 × 10^9/L (1.8-6.3)",
                "Monocyte Abs. Ct. (MONO#)": "3.0 × 10^9/L (0.2-1.0)",
                "Monocyte Percentage (MONO%)": "6% (3-10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02-0.52)",
                "Eosinophil Percentage (EO%)": "0.2% (0.4-8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0-0.06)",
                "Basophil Percentage (BASO%)": "0.1% (0-1)",
                "Mean Platelet Volume (MPV)": "10 fL (9-13)",
                "Lactate Dehydrogenase": "320 U/L (135-225)",
                "Muscle Enzymes (CK)": "180 U/L (22-198 for females)",
                "Myoglobin": "75 ng/mL (<90 ng/mL)",
                "Troponin I": "10 ng/L (<14 ng/L)",
                "Ferritin": "700 ng/mL (20-500 for females)",
                "CRP": "25 mg/L (<3 mg/L)",
                "ESR": "50 mm/hr (0-20)",
                "Procalcitonin": "0.8 ng/mL (<0.5)",
                "D-dimer": "1.2 mg/L FEU (0-0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50-150)"
            },
            "Chest X-ray Exam": "Mild pleural effusion and cardiomegaly",
            "Chest Computerized Tomography": "Leukemic infiltration observed in the spleen and liver",
            "Serological Diagnosis": "Elevated uric acid levels",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Mildly impaired",
            "Sputum Examination": "No viral particles detected",
            "Nasopharyngeal Examination": "No significant findings",
            "Serum Antibody Test": "No abnormalities detected",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative for common viral infections",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Gingival inflammation and bleeding",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Emily Jenkins has been diagnosed with acute myeloid leukemia, presenting with severe symptoms such as anemia, continuous bleeding, and signs of systemic infiltration, requiring an aggressive treatment approach. The current state of her condition, combined with her age and underlying medical history, necessitates immediate induction therapy aimed at achieving hematological remission. This will involve initiating a chemotherapy regimen tailored to her specific leukemic profile, which may include cytarabine and daunorubicin (7+3 regimen) as the first line of induction therapy. Due to her severe anemia and low platelet counts, transfusions of packed red blood cells and platelet concentrates will be administered to manage hematological deficits and reduce the risk of complications from bleeding. Infection control is paramount; therefore, prophylactic antibiotics and antifungal agents will be prescribed to mitigate the risk of severe infections, considering her neutropenic status. Nutritional support will emphasize maintaining high caloric and protein intake, supplemented by hydration therapy to manage elevated uric acid levels and minimize renal complications. Regular monitoring of blood counts, liver and renal functions, and response to chemotherapy will guide treatment adjustments. As post-remission therapy options, hematopoietic stem cell transplantation will be evaluated based on her overall response to induction therapy and physical condition. Supportive therapies, including Granulocyte Colony-Stimulating Factor (G-CSF), may be considered to enhance neutrophil recovery post-chemotherapy. Emily and her family will be educated on managing potential side effects of chemotherapy, recognizing signs of infection or bleeding, and the importance of routine follow-ups to closely monitor her health status and adjust treatments as necessary. Emotional support and counseling services will be provided to help her cope with the psychological aspects of her diagnosis and treatment.",
        "User Profile": {
            "id": 90,
            "trust_in_healthcare": 0.301,
            "health_literacy": 0.336,
            "openness": 0.035,
            "conscientiousness": 0.475,
            "extraversion": 0.502,
            "agreeableness": 0.913,
            "neuroticism": 0.824,
            "region": "Arizona"
        },
        "Relations": {
            "strong": [
                15,
                38
            ],
            "moderate": [
                67,
                56,
                68,
                37,
                12,
                25,
                10,
                60,
                6,
                34,
                45,
                14,
                55,
                36,
                59,
                8,
                22,
                64,
                42,
                3,
                48,
                23
            ],
            "weak": [
                21,
                33,
                39,
                54,
                2,
                53,
                31,
                29,
                1,
                47,
                13,
                40,
                65,
                57,
                58,
                62,
                5,
                52,
                0,
                11,
                35,
                43,
                7,
                4,
                17,
                18,
                49,
                66,
                19,
                9,
                24,
                16,
                32,
                26,
                50,
                44,
                41,
                28,
                20,
                61,
                69,
                63,
                46,
                51,
                27
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Emily Davis",
            "Age": "23",
            "Gender": "Female",
            "Medical History": "No significant medical history; routine gynecological examinations"
        },
        "Disease Information": {
            "Disease": "Teratoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Abdominal pain, palpable abdominal mass, occasional bloating",
            "Duration": "Symptoms have been present for approximately three weeks",
            "Curability": "Yes",
            "Severity Score": 41
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "34 IU/L (13 − 35)",
                "Urea": "5.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "74 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.4 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "280 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "150 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "130 U/L (22 − 198 for females)",
                "Myoglobin": "45 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "120 ng/mL (20 − 500 for females)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Pelvic Ultrasound": "Hypoechoic area with scattered calcifications within the ovary, suggesting the presence of a dermoid cyst",
            "Abdominal CT Scan": "Well-defined mass in the left ovary with fat and calcification components, consistent with a mature teratoma",
            "Serum Tumor Markers": {
                "AFP": "Normal",
                "hCG": "Normal",
                "CA125": "Elevated at 48 U/mL (0-35 U/mL)"
            },
            "Pathology Report": "Mature cystic teratoma with no signs of malignancy",
            "MRI": "Not required based on current clinical findings",
            "Chest X-ray": "Clear without signs of metastasis",
            "Laparoscopy": "Confirmed mass identification with biopsy indicating benign teratoma"
        },
        "Treatment Plan": "Emily Davis has been diagnosed with a mature ovarian teratoma, a benign condition with a favorable prognosis. The recommended treatment is surgical removal of the teratoma through minimally invasive means, such as laparoscopy, to preserve ovarian function and ensure complete excision of the tumor. The surgery is aimed at removing the affected ovarian tissue while preserving the contralateral ovary to maintain fertility, given Emily's age and desire for future fertility. Postoperative monitoring will involve regular follow-up visits to check for any signs of recurrence, using both physical examinations and imaging studies as necessary. Complete recovery is expected with no requirement for adjuvant chemotherapy due to the benign nature of the teratoma. Emily will be counseled on the importance of maintaining regular gynecological check-ups to monitor her overall reproductive health.",
        "User Profile": {
            "id": 93,
            "trust_in_healthcare": 0.658,
            "health_literacy": 0.389,
            "openness": 0.106,
            "conscientiousness": 0.628,
            "extraversion": 0.922,
            "agreeableness": 0.872,
            "neuroticism": 0.826,
            "region": "Iowa"
        },
        "Relations": {
            "strong": [
                24
            ],
            "moderate": [
                19,
                41,
                29,
                16,
                33,
                42,
                20,
                30,
                1,
                63,
                59,
                26,
                36,
                61,
                18,
                28,
                40,
                68,
                21,
                57
            ],
            "weak": [
                69,
                43,
                34,
                53,
                3,
                35,
                6,
                22,
                37,
                47,
                46,
                50,
                13,
                4,
                38,
                8,
                32,
                62,
                23,
                55,
                25,
                49,
                67,
                51,
                64,
                0,
                14,
                58,
                15,
                10,
                52,
                44,
                5,
                27,
                11,
                12,
                60,
                54,
                39,
                56,
                66,
                9,
                48,
                7,
                45,
                65,
                17,
                2
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Emily Johnson",
            "Age": "35",
            "Gender": "Female",
            "Medical History": "Family history of thyroid issues, radiation exposure during childhood"
        },
        "Disease Information": {
            "Disease": "Papillary Thyroid Carcinoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Thyroid nodule detection during physical examination, slight neck lymph node enlargement",
            "Duration": "Symptoms have been present for approximately 6 months, with gradual progression",
            "Curability": "Yes",
            "Severity Score": 50
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "20 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "25 IU/L (13 − 35)",
                "Urea": "5.1 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Thyroid Stimulating Hormone (TSH)": "2.5 mIU/L (0.4 − 4.0)",
                "Thyroglobulin (TG)": "50 ng/mL (1.4 − 78)",
                "Anti-Thyroglobulin Antibodies (TGAb)": "20 IU/mL (< 115)",
                "CRP": "2.0 mg/L (< 3 mg/L)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Thyroid Ultrasound": "Presence of a solid hypoechoic nodule with microcalcifications",
            "Fine Needle Aspiration Biopsy": "Papillary thyroid carcinoma cells identified",
            "CT Scan": "No evidence of extrathyroid extension or distant metastasis",
            "Laryngoscopy": "Normal vocal cord mobility, no nerve invasion detected"
        },
        "Treatment Plan": "Emily Johnson has been diagnosed with papillary thyroid carcinoma presenting as a moderate severity condition due to the presence of a thyroid nodule and minor lymph node involvement. The treatment plan includes surgical intervention, specifically a thyroid lobectomy to remove the affected lobe, given the absence of extrathyroidal extension and lymph node metastasis. Post-surgery, endocrine therapy with levothyroxine will be initiated to suppress TSH and prevent tumor regrowth. Monitoring of serum thyroglobulin levels and periodic neck ultrasounds will be conducted to ensure no recurrence or metastasis. The patient will be educated on managing potential symptoms of hypothyroidism and the importance of regular follow-up appointments. In addition, maintaining a balanced diet, regular check-ups, and a healthy lifestyle will be emphasized to support recovery and overall health. Emotional support and stress management techniques will be recommended to enhance the treatment outcome and quality of life.",
        "User Profile": {
            "id": 99,
            "trust_in_healthcare": 0.313,
            "health_literacy": 0.144,
            "openness": 0.819,
            "conscientiousness": 0.225,
            "extraversion": 0.073,
            "agreeableness": 0.496,
            "neuroticism": 0.74,
            "region": "Connecticut"
        },
        "Relations": {
            "strong": [
                29,
                43
            ],
            "moderate": [
                0,
                13,
                18,
                41,
                64,
                69,
                19,
                58,
                1,
                59,
                35,
                42,
                38,
                63,
                66,
                49,
                61
            ],
            "weak": [
                9,
                12,
                50,
                37,
                25,
                34,
                22,
                39,
                65,
                8,
                53,
                21,
                28,
                14,
                33,
                44,
                68,
                56,
                31,
                36,
                11,
                10,
                54,
                6,
                55,
                7,
                45,
                20,
                3,
                2,
                30,
                67,
                46,
                40,
                47,
                4,
                51,
                17,
                48,
                60,
                15,
                26,
                52,
                24,
                62,
                16,
                27,
                23,
                57
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Emily Thompson",
            "Age": "8",
            "Gender": "Female",
            "Medical History": "Frequent respiratory infections, history of anemia"
        },
        "Disease Information": {
            "Disease": "Acute Lymphoblastic Leukemia",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Pallor, fatigue, frequent infections, petechiae, nosebleeds, hepatosplenomegaly, fever",
            "Duration": "Symptoms have been present for several weeks with increasing intensity",
            "Curability": "Yes",
            "Severity Score": 87
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "35 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "60 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "White Blood Cell Ct. (WBC)": "100 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "28% (35 − 50)",
                "Hemoglobin (Hb)": "90 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "50 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "80% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "10% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "80 × 10^9/L (1.3 − 3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "10 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "11 fL (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "50 mm/hr (0 − 20)",
                "Procalcitonin": "0.6 ng/mL (< 0.5)"
            },
            "Bone Marrow Examination": "Presence of immature lymphocytes ≥ 20%, indicative of ALL",
            "Cytochemical Tests": "PAS staining ++ with coarse granules",
            "Immunophenotyping": "Positive for B-lineage ALL",
            "Cytogenetics": "Clonal chromosome abnormalities detected",
            "Cerebrospinal Fluid Examination": "No evidence of CNS leukemia",
            "Chest X-ray Exam": "Normal",
            "Ultrasound": "Mild hepatosplenomegaly",
            "CT Scan": "No intracranial involvement",
            "MRI": "Normal head vascular condition"
        },
        "Treatment Plan": "Emily Thompson is diagnosed with B-lineage Acute Lymphoblastic Leukemia requiring immediate and aggressive treatment due to the severity of her symptoms and critical blood abnormalities. Systemic chemotherapy will be initiated with the VDCLP regimen, including cyclophosphamide, vincristine, daunorubicin, PEG-asparaginase, and prednisone, to target leukemic cells aggressively. Due to the high white blood cell count, initial treatment may involve the use of a cell separator to address white blood cell stasis syndrome. Hydration therapy will be employed to prevent hyperuricemic nephropathy, along with monitoring for complications such as electrolyte imbalances. Granulocyte colony-stimulating factor (G-CSF) will be used to shorten periods of neutropenia post-chemotherapy. Supportive care will include transfusions for maintaining hemoglobin levels and managing her low platelet count with platelet transfusions to prevent bleeding. Nutritional support and infection prevention are crucial, with placement in a sterile ward to minimize infection risk due to neutropenia. Following initial induction therapy, intensification and consolidation therapies will be tailored according to response, possibly integrating targeted therapies. Emily’s family will be educated on the importance of a balanced diet, infection prevention, and supportive care to assist her recovery. Continuous follow-up and routine blood tests will be necessary to monitor and adapt her treatment plan as needed, aiming for remission and considering stem cell transplantation if indicated for long-term management.",
        "User Profile": {
            "id": 102,
            "trust_in_healthcare": 0.228,
            "health_literacy": 0.461,
            "openness": 0.304,
            "conscientiousness": 0.944,
            "extraversion": 0.147,
            "agreeableness": 0.9,
            "neuroticism": 0.75,
            "region": "Colorado"
        },
        "Relations": {
            "strong": [
                20,
                16
            ],
            "moderate": [
                24,
                9,
                26,
                41,
                31,
                0,
                30,
                63,
                19,
                14,
                46,
                42,
                18,
                60,
                44,
                62,
                69,
                29
            ],
            "weak": [
                43,
                35,
                32,
                61,
                34,
                12,
                15,
                27,
                28,
                11,
                38,
                59,
                25,
                40,
                51,
                17,
                65,
                6,
                39,
                64,
                55,
                21,
                47,
                10,
                3,
                8,
                1,
                36,
                49,
                48,
                58,
                45,
                4,
                13,
                50,
                5,
                37,
                22,
                54,
                56,
                66,
                2,
                57,
                7,
                23,
                67,
                68,
                53,
                52
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Jessica Liu",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "Family history of breast cancer, postmenopausal, history of benign breast cysts"
        },
        "Disease Information": {
            "Disease": "Invasive breast carcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless breast lump, nipple discharge, axillary lymph node enlargement, peau d'orange appearance of the breast skin",
            "Duration": "Symptoms have been present and gradually worsening over the past six months",
            "Curability": "Yes",
            "Severity Score": 58
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "22 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.1 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.6 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "198 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "5 ng/L (< 14 ng/L)",
                "Ferritin": "150 ng/mL (20 − 500 for females)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "BRCA1 Mutation",
                "Blood Silver Level": "110 μg/L (50 − 150)"
            },
            "Mammogram": "Irregular dense mass with microcalcifications in the upper outer quadrant of the right breast",
            "Ultrasonography": "Hypoechoic mass with irregular borders and increased vascularity in the right breast",
            "MRI Scan": "Enhancing mass with rim-like enhancement characteristics in the right breast tissue",
            "Biopsy": "Invasive ductal carcinoma with no special type, grade 2 differentiation",
            "Hormone Receptor Test": "ER-positive, PR-negative, HER2/neu-negative",
            "Chest X-ray": "No metastatic lesions observed",
            "Bone Scan": "Normal",
            "CT Scan": "No distant metastasis observed",
            "Complete Physical": "Overall physical health satisfactory except noted breast findings"
        },
        "Treatment Plan": "Jessica Liu has been diagnosed with major severity invasive ductal carcinoma of the right breast. Given the nature of her cancer, a comprehensive treatment plan focused on surgery followed by adjunctive therapies is recommended. The patient will undergo a right-sided modified radical mastectomy to ensure complete removal of the tumor while assessing axillary lymph nodes for potential metastasis. Post-surgery, Jessica will receive chemotherapy aimed at reducing any residual microscopic disease, using a regimen tailored to her specific cancer characteristics and overall health status. Endocrine therapy with Tamoxifen will be commenced due to the ER-positive status of the tumor, to help prevent recurrence by blocking estrogen receptors. Regular follow-ups will include physical exams and imaging to monitor for any signs of recurrence. A diet rich in vegetables, fruits, and lean proteins will be recommended to support her immune system, and moderate exercise will be encouraged to maintain physical health and manage weight. Psychological support and family counseling are advised to aid Jessica emotionally throughout her treatment journey. Her treatment plan will be reviewed and adjusted as necessary based on her response to the therapies, emphasizing a multidisciplinary approach for optimal management and outcome.",
        "User Profile": {
            "id": 105,
            "trust_in_healthcare": 0.52,
            "health_literacy": 0.349,
            "openness": 0.151,
            "conscientiousness": 0.82,
            "extraversion": 0.399,
            "agreeableness": 0.098,
            "neuroticism": 0.729,
            "region": "California"
        },
        "Relations": {
            "strong": [
                15,
                14,
                36
            ],
            "moderate": [
                58,
                49,
                38,
                10,
                22,
                23,
                21,
                40,
                59,
                42,
                11,
                55,
                3,
                62,
                48,
                66,
                68,
                45,
                35,
                65,
                47
            ],
            "weak": [
                29,
                56,
                30,
                44,
                50,
                18,
                17,
                43,
                1,
                64,
                13,
                57,
                6,
                8,
                4,
                60,
                25,
                67,
                37,
                26,
                39,
                32,
                12,
                69,
                31,
                5,
                7,
                33,
                53,
                41,
                54,
                28,
                46,
                24,
                0,
                20,
                9,
                52,
                16,
                19,
                2,
                27,
                61,
                63,
                51
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Zhang Wei",
            "Age": "36",
            "Gender": "Female",
            "Medical History": "Previous occurrences of unexplained fever and night sweats, history of fatigue"
        },
        "Disease Information": {
            "Disease": "Lymphoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless progressive enlargement of cervical lymph nodes, fever, night sweats, weight loss, fatigue",
            "Duration": "Symptoms have been present for the past 3 months, progressively worsening",
            "Curability": "No",
            "Severity Score": 68
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "125 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "55% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "35% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.75 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "1.75 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.9% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Ferritin": "435 ng/mL (13 − 150 for females)",
                "CRP": "42 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Multiple enlarged lymph nodes in the mediastinal region",
            "Serological Diagnosis": "Elevated β2-microglobulin levels indicating potential poor prognosis",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bone Marrow Biopsy": "Presence of lymphoma infiltration",
            "Lymph Node Biopsy": "Confirmed non-Hodgkin lymphoma with lymphocyte proliferation",
            "PET-CT Scan": "Diffuse lymph node involvement with increased metabolic activity",
            "Pulmonary Function Test": "Normal",
            "Abdominal Ultrasound": "Enlarged lymph nodes in the abdominal region",
            "MRI": "Abnormal lymph node structure in splenic region"
        },
        "Treatment Plan": "Zhang Wei is diagnosed with non-Hodgkin lymphoma, characterized by the major severity level, due to the presence of systemic symptoms such as fever, night sweats, and weight loss, as well as significant lymph node involvement. Her treatment plan involves an individualized approach using a combination of chemotherapy and immunotherapy. The chosen regimen includes R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone), with close monitoring of her response to therapy and possible adjustments based on tolerance and effectiveness. Given the potential poor prognosis indicated by elevated β2-microglobulin levels, regular PET-CT scans will be conducted to assess treatment efficacy. Supportive care will focus on maintaining nutritional status, hydration, and managing any side effects from treatments. Zhang and her family will be advised on infection prevention strategies due to the weakened immune system, with oral hygiene and dietary precautions in place to support her overall health. Psychological support will also be provided to help her cope with her condition and treatment course. Regular follow-up visits will be essential to reassess her condition, treatment strategy, and any potential needs for advanced therapies like autologous hematopoietic stem cell transplantation if remission is achieved.",
        "User Profile": {
            "id": 108,
            "trust_in_healthcare": 0.037,
            "health_literacy": 0.245,
            "openness": 0.098,
            "conscientiousness": 0.725,
            "extraversion": 0.495,
            "agreeableness": 0.126,
            "neuroticism": 0.304,
            "region": "Oregon"
        },
        "Relations": {
            "strong": [
                18
            ],
            "moderate": [
                43,
                36,
                34,
                45,
                22,
                14,
                15,
                48,
                0,
                29,
                50,
                28,
                42,
                59,
                38,
                21,
                11,
                10,
                17,
                41,
                16,
                32,
                68,
                9,
                1
            ],
            "weak": [
                58,
                66,
                8,
                69,
                13,
                46,
                23,
                40,
                30,
                62,
                49,
                26,
                55,
                56,
                60,
                20,
                57,
                31,
                33,
                67,
                24,
                25,
                4,
                44,
                37,
                12,
                61,
                19,
                3,
                63,
                65,
                27,
                7,
                6,
                53,
                52,
                2,
                54,
                5,
                47,
                39,
                64,
                51
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Alice Zhang",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "Frequent gastrointestinal discomfort, anemia, family history of breast cancer"
        },
        "Disease Information": {
            "Disease": "Ovarian cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Abdominal bloating, decreased appetite, anemia, abdominal mass, fatigue",
            "Duration": "Symptoms have been gradually worsening over the past 3 months",
            "Curability": "Yes",
            "Severity Score": 65
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "34 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "6.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "32% (35 − 50)",
                "Hemoglobin (Hb)": "105 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "245 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "18% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "0.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "12% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "185 U/L (22 − 198 for females)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "500 ng/mL (20 − 500 for females)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "55 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.9 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Tumor Marker CA125": "235 U/mL (< 35)",
                "HE4": "90 pmol/L (< 140)"
            },
            "Ultrasound Exam": "Complex pelvic mass with mixed solid and cystic components",
            "Pelvic MRI": "Large irregular mass in the left ovary with signs of local metastasis",
            "CA125 Test": "Elevated CA125 levels consistent with epithelial ovarian cancer",
            "CT Scan": "Evidence of ascites and peritoneal spread",
            "Biopsy": "Confirmatory histopathological findings of serous adenocarcinoma",
            "Pathological Findings": "Invasive epithelial carcinoma with high-grade features",
            "Endoscopy": "Presence of subclinical metastasis in the gastrointestinal tract",
            "Chest X-ray": "Minimal pleural effusion detected",
            "PET-CT": "Elevated metabolic activity in pelvic region indicative of malignancy"
        },
        "Treatment Plan": "Alice Zhang faces a challenging diagnosis of major severity ovarian cancer, requiring a well-coordinated and proactive treatment approach to improve her prognosis and manage the disease effectively. Given the advanced nature of her symptoms, characterized by abdominal discomfort and bloating, as well as significant elevation in tumor markers, initiating treatment with aggressive surgical intervention, including debulking and possible hysterectomy, is paramount to reduce tumor load and optimize subsequent therapies. Following surgical intervention, Alice will undergo a regimen of combination chemotherapy, preferably using paclitaxel and carboplatin, aimed at targeting residual malignancies and preventing further metastasis. Continuous monitoring through CA125 levels and imaging scans will be critical in assessing treatment efficacy and adjusting protocols promptly. Her treatment plan will integrate targeted therapies, including trial use of PARP inhibitors such as olaparib, depending on genetic testing outcomes for BRCA mutations, enhancing maintenance therapy post-surgery and chemotherapy. Alice will benefit from supportive care to mitigate chemotherapy side effects and maintain her nutritional and lifestyle status, including management of fatigue and anemia through dietary adjustments and iron supplements. Emotional and psychological support is essential, providing counseling services to handle the anxiety and stress arising from her condition and treatment journey. Regular follow-ups every three months in the first two years post-treatment, shifting to semi-annual in the subsequent years, will be essential for monitoring recurrence, with potential lifestyle modifications and rehabilitation programs to enhance her quality of life and aid in recovery.",
        "User Profile": {
            "id": 111,
            "trust_in_healthcare": 0.509,
            "health_literacy": 0.621,
            "openness": 0.168,
            "conscientiousness": 0.502,
            "extraversion": 0.502,
            "agreeableness": 0.321,
            "neuroticism": 0.248,
            "region": "South Carolina"
        },
        "Relations": {
            "strong": [
                22
            ],
            "moderate": [
                66,
                58,
                57,
                34,
                49,
                40,
                21,
                38,
                4,
                17,
                11,
                55,
                60,
                52,
                14,
                56,
                48,
                64,
                15,
                42,
                45,
                35,
                6
            ],
            "weak": [
                50,
                29,
                68,
                44,
                23,
                62,
                30,
                1,
                5,
                39,
                7,
                13,
                65,
                25,
                0,
                10,
                28,
                59,
                43,
                53,
                47,
                2,
                8,
                61,
                54,
                31,
                67,
                20,
                37,
                18,
                12,
                16,
                24,
                26,
                69,
                19,
                46,
                32,
                41,
                3,
                9,
                27,
                51,
                63,
                33
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Samuel Johnson",
            "Age": "67",
            "Gender": "Male",
            "Medical History": "Chronic Bronchitis, Previous history of smoking"
        },
        "Disease Information": {
            "Disease": "Squamous cell carcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent dry cough, hemoptysis, shortness of breath, chest tightness, chest pain, cachexia",
            "Duration": "Symptoms have been persisting for several months, with recent significant worsening",
            "Curability": "No",
            "Severity Score": 72
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7-40)",
                "AST (Aspartate Aminotransferase)": "25 IU/L (13-35)",
                "Urea": "6.2 mmol/L (2.6-8.8)",
                "Creatinine (Cr)": "88 μmol/L (41-81)",
                "Triglycerides (TG)": "1.7 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "9.0 × 10^9/L (3.5-9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5-5.5)",
                "Hematocrit (Hct)": "40% (35-50)",
                "Hemoglobin (Hb)": "130 g/L (115-150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125-350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20-50)",
                "Neutrophil Percentage (NEUT%)": "65% (40-75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.7 × 10^9/L (1.3-3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.85 × 10^9/L (1.8-6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.78 × 10^9/L (0.2-1.0)",
                "Monocyte Percentage (MONO%)": "9% (3-10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02-0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4-8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0-0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0-1)",
                "Mean Platelet Volume (MPV)": "10 fl (9-13)",
                "Lactate Dehydrogenase": "280 U/L (135-225)",
                "Muscle Enzymes (CK)": "190 U/L (22-198 for males)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20-500 for males)",
                "CRP": "20 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0-20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0-0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Squamous Cell Carcinoma Antigen",
                "Blood Silver Level": "70 μg/L (50-150)"
            },
            "Chest X-ray Exam": "Central lung mass with bronchial narrowing and cavitation",
            "Chest Computerized Tomography": "Large central mass with necrotic changes, bronchial obstruction",
            "Serological Diagnosis": "Elevated Squamous Cell Carcinoma Antigen",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Sputum": "Normal",
            "Respiratory Function Test": "Severely impaired",
            "Sputum Examination": "Presence of malignant cells",
            "Bronchoscopy": "Tumor observed obstructing bronchial passage",
            "Pulmonary Function Test": "Impaired gas exchange and reduced lung capacity",
            "Nucleic Acid Amplification Test": "Negative",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Samuel Johnson has been diagnosed with major severity lung squamous cell carcinoma, heavily influenced by his history of smoking and chronic bronchitis, requiring a strategic management plan. Given the advanced stage of the carcinoma with significant bronchial obstruction, and cachexia, Samuel will benefit from a comprehensive approach employing multimodal treatment strategies. Palliative care focusing on symptom management and improving quality of life will be prioritized due to the non-curative nature of the disease at this stage. Bronchial artery infusion chemotherapy will be considered, employing drugs such as cisplatin or carboplatin in combination with paclitaxel to target the tumor. Radiation therapy may be applied to reduce symptoms and manage tumor growth, though surgical options are limited due to advanced stage and systemic involvement. Nutritional support and pain management are critical, ensuring adequate intake despite dysphagia and addressing cachexia. Psychological support to maintain mental well-being during treatment is essential. Regular follow-ups to monitor progression, adjust treatment protocols, and manage emerging symptoms will be conducted. Family education on care strategies and signs of complication is integral to Samuel's treatment plan, ensuring all measures are taken to maintain his comfort and dignity as the disease progresses.",
        "User Profile": {
            "id": 114,
            "trust_in_healthcare": 0.092,
            "health_literacy": 0.398,
            "openness": 0.723,
            "conscientiousness": 0.582,
            "extraversion": 0.992,
            "agreeableness": 0.582,
            "neuroticism": 0.756,
            "region": "Kentucky"
        },
        "Relations": {
            "strong": [
                25
            ],
            "moderate": [
                10,
                3,
                68,
                15,
                2,
                67,
                30,
                1,
                13,
                59,
                38,
                23,
                57,
                55,
                56,
                29,
                48,
                65,
                47,
                60
            ],
            "weak": [
                45,
                4,
                53,
                5,
                11,
                52,
                14,
                64,
                21,
                6,
                66,
                7,
                8,
                39,
                49,
                34,
                12,
                54,
                22,
                32,
                36,
                43,
                19,
                58,
                31,
                24,
                0,
                17,
                35,
                16,
                28,
                46,
                62,
                42,
                40,
                69,
                41,
                63,
                18,
                44,
                33,
                20,
                26,
                51,
                27,
                50,
                61,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Gary Bennett",
            "Age": "56",
            "Gender": "Male",
            "Medical History": "Hypertension, prolonged fatigue, night sweats, weight loss"
        },
        "Disease Information": {
            "Disease": "Chronic myeloid leukemia",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Fatigue, low-grade fever, weight loss, splenomegaly, night sweats",
            "Duration": "Symptoms have been present for several months with gradual escalation",
            "Curability": "Yes",
            "Severity Score": 35
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "50 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.0 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "350 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "35 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "5 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "10% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "3 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Bcr-Abl fusion gene",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Normal",
            "Serological Diagnosis": "Presence of Bcr-Abl fusion gene",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for common viral infections",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Positive for Bcr-Abl fusion gene",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Gary Bennett has been diagnosed with chronic myeloid leukemia (CML) in the chronic phase, requiring ongoing intervention to maintain disease control and quality of life. Treatment will center around the initiation of a tyrosine kinase inhibitor (TKI), with Imatinib being the first-line choice due to its established efficacy in chronic-phase CML. This oral medication will be administered daily, with close monitoring for potential side effects such as edema, gastrointestinal discomfort, and fatigue. Regular check-ups are essential for evaluating hematologic, cytogenetic, and molecular responses to the therapy, ensuring that the presence of the Bcr-Abl fusion gene decreases over time. Given the possibility of achieving a stable deep molecular response with sustained treatment, Gary may, later on, discuss medication discontinuation options with his oncologist. Additionally, recommended lifestyle adjustments include avoiding potential triggers such as radiation and chemical exposure, alongside maintaining a nutritious diet and regular physical activity to bolster overall health. Supportive care measures, including addressing any psychological stress and fostering social connections, will be encouraged to improve Gary's coping mechanisms and emotional well-being. Although allogeneic hematopoietic stem cell transplantation remains a potential cure, it is reserved for cases where TKIs fail or disease progresses to an accelerated or blast phase. Routine monitoring and collaborative communication with healthcare providers are key to effectively managing Gary’s treatment and ensuring a good quality of life.",
        "User Profile": {
            "id": 120,
            "trust_in_healthcare": 0.427,
            "health_literacy": 0.305,
            "openness": 0.404,
            "conscientiousness": 0.345,
            "extraversion": 0.683,
            "agreeableness": 0.271,
            "neuroticism": 0.762,
            "region": "Ohio"
        },
        "Relations": {
            "strong": [
                22,
                34,
                58,
                36
            ],
            "moderate": [
                15,
                21,
                13,
                14,
                55,
                30,
                8,
                10,
                68,
                66,
                59,
                1,
                25,
                67,
                11,
                57,
                49,
                6,
                62,
                64
            ],
            "weak": [
                37,
                56,
                53,
                65,
                45,
                29,
                23,
                3,
                4,
                12,
                52,
                17,
                35,
                48,
                43,
                39,
                69,
                47,
                40,
                32,
                28,
                18,
                19,
                42,
                60,
                0,
                50,
                7,
                46,
                24,
                5,
                54,
                31,
                44,
                9,
                33,
                2,
                61,
                16,
                26,
                41,
                51,
                27,
                20,
                63
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Henry Thompson",
            "Age": "68",
            "Gender": "Male",
            "Medical History": "Hypertension, benign prostatic hyperplasia, history of family prostate cancer"
        },
        "Disease Information": {
            "Disease": "Prostate cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Frequent urination, difficulty urinating, pelvic discomfort, erectile dysfunction",
            "Duration": "Symptoms gradually worsened over the past three months",
            "Curability": "Yes",
            "Severity Score": 47
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "88 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.7 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.2 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "45% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.77 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.44 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.8% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Prostate-specific antigen (PSA)": "15 ng/mL (0 − 4)",
                "Ferritin": "220 ng/mL (20 − 500 for males)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "18 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Prostate Ultrasound": "Hypoechoic nodules in the prostate gland",
            "MRI Scan": "Localized prostate irregularity with no signs of metastasis",
            "Biopsy": "Presence of adenocarcinoma cells, Gleason score 6",
            "Pelvic X-ray": "No evidence of bone metastasis",
            "Rectal Examination": "Hard nodules detected in prostate"
        },
        "Treatment Plan": "Henry Thompson has been diagnosed with prostate cancer, characterized by moderate severity symptoms such as frequent urination and erectile dysfunction. Given the localized nature of the cancer, radical prostatectomy is recommended as the primary treatment strategy, alongside a comprehensive evaluation to ensure the cancer is contained within the prostate. Considering the patient's age and general health, minimally invasive laparoscopic surgery or robotic-assisted surgery are preferred for efficient recovery and reduced postoperative trauma. Post-surgery, hormone therapy will be administered using anti-androgen drugs to prevent cancer recurrence and manage potential cancer cell activity. Regular postoperative care, including routine PSA monitoring and follow-up examinations every three months, is crucial for tracking the patient's progress and ensuring successful treatment outcomes. Pain management will be addressed with prescribed medications, while lifestyle adjustments, including dietary modifications and exercise, will support overall health and recovery. Psychological support and education regarding lifestyle changes and adherence to follow-up schedules will be provided to Henry and his family, promoting a positive outlook and ensuring optimal long-term management. Nutritional counseling and support for maintaining a healthy weight will be endorsed to enhance recovery and prevent further complications. Henry will be encouraged to participate in non-strenuous activities to maintain physical fitness and reduce stress, with close monitoring for any signs of cancer progression or treatment side effects.",
        "User Profile": {
            "id": 123,
            "trust_in_healthcare": 0.796,
            "health_literacy": 0.669,
            "openness": 0.306,
            "conscientiousness": 0.147,
            "extraversion": 0.168,
            "agreeableness": 0.55,
            "neuroticism": 0.675,
            "region": "Massachusetts"
        },
        "Relations": {
            "strong": [
                6,
                12,
                7
            ],
            "moderate": [
                56,
                55,
                8,
                52,
                64,
                57,
                25,
                47,
                60,
                49,
                58,
                2,
                36,
                54,
                22,
                65,
                11,
                67
            ],
            "weak": [
                38,
                69,
                21,
                30,
                66,
                40,
                14,
                15,
                17,
                37,
                45,
                61,
                48,
                5,
                34,
                13,
                50,
                3,
                32,
                23,
                42,
                62,
                10,
                4,
                26,
                29,
                68,
                44,
                1,
                0,
                59,
                18,
                19,
                53,
                28,
                33,
                43,
                20,
                24,
                16,
                41,
                9,
                31,
                46,
                63,
                35,
                51,
                27
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Lily O'Hara",
            "Age": "46",
            "Gender": "Female",
            "Medical History": "Family history of breast cancer, obesity, excessive alcohol consumption"
        },
        "Disease Information": {
            "Disease": "Breast cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Breast lump, nipple discharge, axillary lymphadenopathy, unexplained weight loss, fatigue, and anemia",
            "Duration": "Symptoms have progressively worsened over the last 6 months",
            "Curability": "Yes",
            "Severity Score": 65
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "29 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "110 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "95 U/L (22 − 198 for females)",
                "Myoglobin": "60 ng/mL (< 70 ng/mL)",
                "Troponin I": "9 ng/L (< 14 ng/L)",
                "Ferritin": "150 ng/mL (15 − 150 for females)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Mammography": "Irregular mass with microcalcifications in the upper outer quadrant of the right breast",
            "Ultrasound": "Hypoechoic lesion in the right breast with irregular borders",
            "MRI": "Enhanced uptake in the right breast mass indicating potential malignancy",
            "Biopsy": "Invasive ductal carcinoma confirmed",
            "Immunohistochemistry": "HER-2 positive, ER positive, PR positive",
            "Tumor Marker Tests": "Elevated CA15-3 levels",
            "Chest X-ray": "Clear",
            "Bone Scan": "No evidence of metastatic bone disease",
            "Liver Function Test": "Normal",
            "Brain MRI": "Normal"
        },
        "Treatment Plan": "Lily O'Hara has been diagnosed with invasive ductal carcinoma of the breast, and the treatment plan will involve a multidisciplinary approach. Given the HER-2 positive status, targeted therapy with trastuzumab is recommended to inhibit oncogenic signaling and reduce tumor growth, in conjunction with chemotherapy using anthracycline and taxane-based regimens to address systemic micrometastatic disease. Endocrine therapy with tamoxifen will be administered due to ER and PR positive receptor status to prevent estrogen-driven growth of cancer cells. Surgical management will consist of a modified radical mastectomy to remove the tumor and affected tissues, preserving overall function and appearance, with potential lymph node dissection to assess regional involvement. Post-operative radiation therapy will target any residual cancer cells in the chest area to prevent local recurrence. Lily will receive comprehensive health education to empower her, with psychological support emphasized to manage the emotional impact of the diagnosis. Nutritional guidance to maintain a healthy weight and lifestyle changes, including regular physical activity and cessation of alcohol use, will be integral to the plan to further reduce recurrence risk. Regular follow-ups are crucial to monitor treatment efficacy, with imaging tests and blood marker evaluations planned periodically to detect any signs of disease progression or recurrence. Lily will be educated on breast self-examination techniques to help recognize changes timely, facilitating prompt intervention if needed. This comprehensive regimen aims to maximize her chances of remission and optimize her quality of life.",
        "User Profile": {
            "id": 126,
            "trust_in_healthcare": 0.651,
            "health_literacy": 0.809,
            "openness": 0.214,
            "conscientiousness": 0.392,
            "extraversion": 0.454,
            "agreeableness": 0.732,
            "neuroticism": 0.041,
            "region": "California"
        },
        "Relations": {
            "strong": [
                44,
                36,
                42,
                34
            ],
            "moderate": [
                26,
                62,
                22,
                1,
                52,
                61,
                57,
                6,
                0,
                5,
                47,
                50,
                4,
                55,
                7,
                21
            ],
            "weak": [
                60,
                28,
                29,
                17,
                11,
                58,
                66,
                54,
                20,
                39,
                38,
                56,
                16,
                30,
                15,
                23,
                2,
                8,
                49,
                64,
                10,
                35,
                13,
                31,
                25,
                12,
                45,
                48,
                63,
                53,
                41,
                19,
                51,
                59,
                14,
                46,
                27,
                69,
                3,
                68,
                33,
                32,
                24,
                18,
                43,
                37,
                65,
                67,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Emily Johnson",
            "Age": "23",
            "Gender": "Female",
            "Medical History": "No significant medical history"
        },
        "Disease Information": {
            "Disease": "Breast Fibroadenoma",
            "Severity Level": "Minor Severity",
            "Symptoms": "Round, smooth, well-defined, and mobile painless lump in the breast tissue, occasionally a sense of fullness or dull pain related to the menstrual cycle",
            "Duration": "The lump was discovered during a self-exam one month ago and has remained the same size",
            "Curability": "Yes",
            "Severity Score": 16
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "25 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "20 IU /L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "0.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "120 U/L (22 − 198 for females)",
                "Myoglobin": "45 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "40 ng/mL (12 − 150 for females)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "10 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Breast Ultrasound": "A well-circumscribed, encapsulated hypoechoic area consistent with fibroadenoma",
            "Mammogram": "Not applicable",
            "MRI Exam": "Not conducted",
            "Fine-needle Aspiration Cytology": "Non-malignant epithelial and stromal cells observed",
            "Additional Scans": "Not performed",
            "Pathology Report": "Consistent with simple fibroadenoma, negative for cancerous cells"
        },
        "Treatment Plan": "Emily Johnson is diagnosed with a simple breast fibroadenoma, presenting as a minor severity condition. Due to the benign nature of the fibroadenoma and the absence of any alarming features, the recommended approach is conservative management through regular follow-up observation. Emily should have a breast ultrasound every six months to monitor any changes in the size or characteristics of the fibroadenoma. There is no immediate indication for surgical intervention, as the fibroadenoma has not shown signs of rapid growth and remains asymptomatic other than occasional mild discomfort associated with her menstrual cycle. Lifestyle modifications are also advised, including maintaining a balanced diet rich in high-protein and low-fat foods, avoiding caffeine and alcohol, ensuring adequate hydration, managing stress, and engaging in regular exercise to support her overall health. Emily will be educated on how to perform self-examinations to monitor the fibroadenoma and instructed to report any significant changes in size, texture, or associated symptoms. Should there be any rapid enlargement or additional concerning features in the future, a re-evaluation and potential minimally invasive surgical options may be considered. Annual breast checkups are recommended to ensure early detection and management of any new developments.",
        "User Profile": {
            "id": 129,
            "trust_in_healthcare": 0.296,
            "health_literacy": 0.068,
            "openness": 0.501,
            "conscientiousness": 0.669,
            "extraversion": 0.08,
            "agreeableness": 0.811,
            "neuroticism": 0.316,
            "region": "Virginia"
        },
        "Relations": {
            "strong": [
                63,
                20,
                32
            ],
            "moderate": [
                42,
                31,
                0,
                44,
                16,
                61,
                33,
                28,
                35,
                50,
                29,
                43,
                69,
                60,
                62,
                18,
                21,
                19,
                46
            ],
            "weak": [
                64,
                9,
                66,
                11,
                1,
                26,
                17,
                45,
                40,
                24,
                53,
                48,
                2,
                4,
                34,
                12,
                54,
                36,
                51,
                14,
                10,
                22,
                13,
                49,
                58,
                7,
                59,
                47,
                56,
                25,
                30,
                8,
                3,
                27,
                39,
                5,
                37,
                15,
                38,
                6,
                55,
                52,
                65,
                57,
                68,
                67,
                23
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Emily Thompson",
            "Age": "47",
            "Gender": "Female",
            "Medical History": "No prior history of breast disease; occasional alcohol consumption; history of late childbirth at age 32"
        },
        "Disease Information": {
            "Disease": "Breast Tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Painless breast lump, local skin dimpling, axillary lymph node enlargement",
            "Duration": "Symptoms have been present for approximately 3 months",
            "Curability": "Yes",
            "Severity Score": 55
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "32 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.1 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.6 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "64% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "9% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "8 ng/L (< 14 ng/L)",
                "Ferritin": "150 ng/mL (20 − 500)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "22 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Examination": "Hypoechoic mass with irregular borders in the upper outer quadrant of the right breast",
            "Mammography": "Dense lump with spiculated margins in the right breast",
            "MRI": "Multifocal high signal intensity masses in the right breast, suggestive of breast cancer",
            "Fine Needle Aspiration": "Positive for malignant cells",
            "Core Needle Biopsy": "Invasive ductal carcinoma",
            "Excisional Biopsy": "Confirmed invasive ductal carcinoma with clear margins",
            "Tumor Marker Test": "Elevated CA 15-3 levels",
            "Sentinel Lymph Node Biopsy": "Positive for cancer cells",
            "Breast Cancer Genetic Test": "Positive for BRCA1 mutation"
        },
        "Treatment Plan": "Emily Thompson has been diagnosed with invasive ductal carcinoma of the right breast with axillary lymph node involvement, necessitating a comprehensive treatment approach. Given the major severity of her condition, a surgical intervention via modified radical mastectomy is recommended to effectively remove the tumor and prevent further spread, followed by axillary lymph node dissection to address lymph node metastasis. Post-surgical chemotherapy with an anthracycline combined with a taxane regimen will be initiated to target residual cancer cells, with cyclophosphamide and doxorubicin being used in conjunction with paclitaxel, coupled with regular monitoring through blood tests to ensure adequate liver and kidney function. Radiation therapy will be considered based on the results of post-surgical histological analysis to reduce the risk of local recurrence, focusing on the chest wall and regional lymph nodes. Due to the presence of the BRCA1 mutation, endocrine therapy with tamoxifen or aromatase inhibitors such as anastrozole will be employed to limit estrogen receptor-positive cancer cell growth. Additionally, targeted therapy using trastuzumab will be administered given the HER2 expression, with cardiac monitoring in place due to potential cardiac toxicity. Nutritional support and psychosocial care will be provided to ensure holistic management of her condition, with regular follow-ups scheduled to monitor treatment response and adjust accordingly. Emily's adherence to the treatment protocol, lifestyle adjustments including increased physical activity and dietary modifications, and vigilance in recognizing signs of deterioration are crucial for optimal management and recovery. Her family will be educated on the importance of emotional support during this journey, ensuring Emily's transition into post-treatment rehabilitation with a focus on recovery and long-term health benefits.",
        "User Profile": {
            "id": 132,
            "trust_in_healthcare": 0.58,
            "health_literacy": 0.22,
            "openness": 0.01,
            "conscientiousness": 0.553,
            "extraversion": 0.259,
            "agreeableness": 0.865,
            "neuroticism": 0.179,
            "region": "Texas"
        },
        "Relations": {
            "strong": [
                21,
                50,
                62,
                40
            ],
            "moderate": [
                44,
                34,
                1,
                56,
                36,
                58,
                22,
                41,
                61,
                48,
                63,
                35,
                30,
                29,
                57
            ],
            "weak": [
                31,
                11,
                45,
                53,
                60,
                64,
                66,
                54,
                12,
                0,
                32,
                20,
                59,
                14,
                13,
                4,
                26,
                38,
                8,
                6,
                33,
                5,
                2,
                39,
                18,
                49,
                55,
                17,
                16,
                7,
                43,
                10,
                52,
                47,
                28,
                68,
                15,
                9,
                67,
                25,
                3,
                37,
                19,
                65,
                69,
                24,
                51,
                23,
                46,
                27
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Emily Thompson",
            "Age": "35",
            "Gender": "Female",
            "Medical History": "History of hydatidiform mole pregnancy, recent miscarriage"
        },
        "Disease Information": {
            "Disease": "Choriocarcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Abnormal vaginal bleeding, elevated serum hCG levels, presence of lung metastasis symptoms such as dyspnea and chest pain",
            "Duration": "Symptoms have been persistent for approximately 8 weeks",
            "Curability": "Yes",
            "Severity Score": 54
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "68 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "240 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "65 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for females)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Evidence of small nodular opacities in bilateral lung fields",
            "Chest Computerized Tomography": "Multiple small nodular opacities consistent with metastatic disease",
            "Serological Diagnosis": "Elevated serum hCG levels",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Mild impairment due to lung metastasis",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Normal",
            "Pulmonary Function Test": "Mild obstruction",
            "Nucleic Acid Amplification Test": "Negative for common pathogens",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Emily Thompson has been diagnosed with major severity choriocarcinoma, exhibiting persistent abnormal vaginal bleeding and symptoms of lung metastasis. Immediate initiation of chemotherapy is recommended, utilizing a combination regimen tailored to her specific condition, including methotrexate and actinomycin D, to effectively target the malignant cells and manage metastatic spread, particularly to lung tissue. Strict monitoring of blood hCG levels will guide treatment efficacy and intervals of chemotherapy administration, anticipated to extend over several weeks with necessary adjustments. Due to the metastatic involvement of the lungs, adjunctive thoracic radiotherapy may be considered to alleviate respiratory symptoms and reduce tumor burden, complemented by supportive care to manage chemotherapy-induced side effects such as nausea and gastrointestinal discomfort. Follow-up imaging studies, including CT scans of the chest, liver, and brain, will be integral in assessing response to treatment and potential disease progression. Contraceptive measures are crucial during and post-treatment, with strict adherence to follow-up schedules for ongoing evaluation and potential further intervention if resistance or recurrence is noted. Emily and her healthcare team will work closely to manage symptoms, adhere to the chemotherapy protocol, and explore surgical options if necessary to remove resistant lesions. Psychological support and counseling will be provided to Emily to assist in coping with the emotional and physical challenges of her diagnosis and treatment journey.",
        "User Profile": {
            "id": 135,
            "trust_in_healthcare": 0.219,
            "health_literacy": 0.108,
            "openness": 0.668,
            "conscientiousness": 0.468,
            "extraversion": 0.406,
            "agreeableness": 0.06,
            "neuroticism": 0.991,
            "region": "South Carolina"
        },
        "Relations": {
            "strong": [
                32,
                69,
                18,
                29
            ],
            "moderate": [
                35,
                13,
                58,
                64,
                14,
                68,
                38,
                55,
                0,
                49,
                36,
                34,
                46,
                19,
                41
            ],
            "weak": [
                59,
                15,
                11,
                25,
                1,
                23,
                67,
                3,
                65,
                21,
                10,
                45,
                66,
                37,
                22,
                30,
                31,
                42,
                33,
                50,
                9,
                28,
                24,
                63,
                48,
                6,
                17,
                8,
                7,
                56,
                54,
                39,
                16,
                40,
                61,
                47,
                12,
                62,
                4,
                53,
                2,
                57,
                60,
                20,
                52,
                44,
                51,
                27,
                26,
                5
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Linda Taylor",
            "Age": "47",
            "Gender": "Female",
            "Medical History": "No prior significant breast diseases, maintains routine check-ups"
        },
        "Disease Information": {
            "Disease": "Breast ductal carcinoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Bloody nipple discharge, palpable breast lump with firm texture, smooth surface and clear boundaries",
            "Duration": "Symptoms have been noticeable for approximately 3 weeks",
            "Curability": "Yes",
            "Severity Score": 32
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.6 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.7 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "200 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "90 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "80 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A"
            },
            "Breast Ultrasound": "Identified dilated ducts with papillary solid echoes within the retro-areola region",
            "Ductography": "Round intraductal filling defects noted with duct dilation",
            "Breast MRI": "Shows a 1 cm intraductal lesion with smooth edges in the retro-areola area alongside duct dilation",
            "Cytology": "Fine needle aspiration cytology reveals benign ductal epithelial cells",
            "Exfoliative Cytology": "Presence of epithelial cells, no tumor cells identified",
            "Fiberoptic Ductoscopy": "Smooth duct walls observed with minor intraductal lesions"
        },
        "Treatment Plan": "Linda Taylor's condition of moderate severity intraductal papilloma demands a precise approach to ensure complete lesion removal while maintaining breast aesthetics. Surgical excision will be performed, focusing on segmental excision under direct ductoscopic visualization, allowing for accurate localization of the affected ducts and limiting the extent of surgical intervention. This approach also reduces scarring. Prior to surgery, preoperative imaging and fine-needle aspiration cytology will guide precise surgical planning. Post-surgery, regular follow-ups with imaging and physical examinations will be scheduled to monitor recovery and check for recurrence. Considering the potential for hormonal influence on papilloma formation, hormone level assessments will be conducted and managed accordingly. Linda is advised to maintain a nutritious diet rich in vitamins and proteins to support recovery while avoiding smoking and alcohol. She will engage in light physical exercises including yoga to aid in maintaining physical and mental wellness. Awareness and regular self-examinations are encouraged to support early detection and treatment of any new changes.",
        "User Profile": {
            "id": 138,
            "trust_in_healthcare": 0.493,
            "health_literacy": 0.784,
            "openness": 0.409,
            "conscientiousness": 1,
            "extraversion": 0.118,
            "agreeableness": 0.779,
            "neuroticism": 0.162,
            "region": "Washington"
        },
        "Relations": {
            "strong": [
                40,
                42
            ],
            "moderate": [
                60,
                20,
                17,
                62,
                4,
                61,
                26,
                0,
                36,
                41,
                5,
                34,
                66,
                50,
                1,
                29,
                16,
                21,
                2
            ],
            "weak": [
                49,
                22,
                11,
                65,
                64,
                7,
                45,
                47,
                63,
                58,
                33,
                6,
                57,
                48,
                25,
                14,
                39,
                59,
                28,
                55,
                32,
                54,
                52,
                38,
                13,
                10,
                35,
                12,
                56,
                53,
                3,
                30,
                31,
                69,
                18,
                27,
                15,
                51,
                19,
                37,
                23,
                43,
                8,
                24,
                9,
                68,
                46,
                67
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "John Zhang",
            "Age": "67",
            "Gender": "Male",
            "Medical History": "Chronic gastroesophageal reflux disease, Barrett's esophagus, and a long history of smoking and alcohol consumption."
        },
        "Disease Information": {
            "Disease": "Esophageal cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Progressive dysphagia, persistent pain behind the sternum, significant weight loss, intermittent hematemesis, and back pain",
            "Duration": "Symptoms have been progressively worsening over the past 6 months",
            "Curability": "No",
            "Severity Score": 71
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "29 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "79 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mild esophageal dilation with no visible pulmonary metastasis",
            "Chest Computerized Tomography": "Circumferential thickening of the esophagus with no distant metastasis",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "No viral or bacterial pathogens detected",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "John Zhang has been diagnosed with advanced esophageal cancer characterized by progressive dysphagia, significant weight loss, and persistent sternum pain. Given the major severity of the condition and the involvement of surrounding tissues, a comprehensive treatment plan including chemoradiotherapy is essential. Immediate initiation of neoadjuvant chemotherapy is recommended to shrink the tumor and address potential micrometastases, using a combination of cisplatin and 5-fluorouracil, which are standard for squamous cell carcinoma. Concurrent radiotherapy should be planned to maximize tumor response. Surgical resection may be considered based on the response to initial treatment and re-evaluation of the tumor staging. Nutritional support is critical due to significant weight loss, with a focus on enteral nutrition via gastrostomy feeding to maintain calorie intake and nutritional status. Regular monitoring of blood chemistry and imaging to assess the treatment response is vital, with potential adjustments to the chemotherapy regimen depending on tolerance and efficacy. John and his family should be counseled on the importance of adherence to the treatment regimen and recognizing symptoms of potential complications. Psychological support and palliative care options should be discussed to manage pain and improve quality of life during treatment. Post-treatment follow-ups will be essential to monitor his condition and make timely modifications to his treatment plan as necessary.",
        "User Profile": {
            "id": 141,
            "trust_in_healthcare": 0.319,
            "health_literacy": 0.129,
            "openness": 0.359,
            "conscientiousness": 0.694,
            "extraversion": 0.268,
            "agreeableness": 0.129,
            "neuroticism": 0.14,
            "region": "Tennessee"
        },
        "Relations": {
            "strong": [
                48
            ],
            "moderate": [
                10,
                65,
                68,
                15,
                60,
                56,
                17,
                22,
                21,
                5,
                57,
                36,
                34,
                11,
                14,
                66,
                35
            ],
            "weak": [
                67,
                38,
                55,
                25,
                37,
                30,
                58,
                2,
                62,
                12,
                8,
                42,
                52,
                49,
                50,
                64,
                39,
                4,
                53,
                6,
                23,
                54,
                3,
                59,
                43,
                44,
                40,
                7,
                0,
                41,
                20,
                13,
                1,
                29,
                69,
                28,
                46,
                47,
                63,
                32,
                18,
                16,
                26,
                9,
                61,
                24,
                33,
                27,
                19,
                31,
                51
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Sophia Thompson",
            "Age": "3",
            "Gender": "Female",
            "Medical History": "Family history of neuroblastoma, recurrent abdominal pain"
        },
        "Disease Information": {
            "Disease": "Neuroblastoma",
            "Severity Level": "Minor Severity",
            "Symptoms": "Abdominal distension, constipation, unexplained weight loss, fatigue, bone pain",
            "Duration": "Symptoms have been persisting for several months",
            "Curability": "No",
            "Severity Score": 23
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "60 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "300 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.35 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "350 ng/mL (20 − 500 for males)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Neuroblastoma",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "Normal",
            "Serological Diagnosis": "Elevated catecholamine metabolites",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Normal",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Normal",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative for SARS-CoV-2",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal",
            "Abdominal Ultrasound": "Presence of mass in the abdomen",
            "Bone Marrow Aspiration": "Presence of neuroblastoma cells",
            "MRI": "Abdominal mass with potential spread"
        },
        "Treatment Plan": "Sophia Thompson has been diagnosed with high-risk neuroblastoma, necessitating an aggressive and comprehensive treatment approach due to the persistence and severity of symptoms such as abdominal distension, weight loss, and fatigue over several months. Immediate initiation of treatment involving multi-drug chemotherapy in conjunction with surgical interventions is recommended to address the tumor and potential metastasis. Given the high-risk classification, high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation will be considered to enhance treatment efficacy. Continuous monitoring of catecholamine metabolite levels and imaging assessments is essential to evaluate the progression and response to treatment. Radiotherapy targeting the primary abdominal site may be conducted post-chemotherapy to eradicate residual tumor cells. Additional supportive care, including nutritional management and symptom alleviation, such as pain relief, will be provided to ensure optimal comfort and recovery. Family education regarding the importance of treatment adherence, recognizing symptom changes, and the need for regular follow-ups will be crucial. Long-term follow-up and health surveillance are necessary to assess the impact on growth and development and to prevent recurrence. Sophia and her family will be guided through the treatment process, ensuring understanding and cooperation for optimal outcomes.",
        "User Profile": {
            "id": 144,
            "trust_in_healthcare": 0.185,
            "health_literacy": 0.049,
            "openness": 0.516,
            "conscientiousness": 0.364,
            "extraversion": 0.8,
            "agreeableness": 0.101,
            "neuroticism": 0.469,
            "region": "California"
        },
        "Relations": {
            "strong": [
                9,
                24,
                43,
                51
            ],
            "moderate": [
                28,
                69,
                68,
                33,
                41,
                19,
                35,
                27,
                38,
                10,
                16,
                13,
                21,
                63,
                18,
                55,
                1
            ],
            "weak": [
                31,
                23,
                22,
                53,
                57,
                8,
                66,
                36,
                11,
                45,
                6,
                15,
                40,
                34,
                52,
                3,
                67,
                49,
                25,
                32,
                29,
                4,
                58,
                20,
                7,
                0,
                37,
                48,
                17,
                47,
                50,
                61,
                14,
                39,
                54,
                56,
                59,
                26,
                42,
                12,
                65,
                64,
                60,
                30,
                2,
                5,
                62,
                44
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Laura Thompson",
            "Age": "65",
            "Gender": "Female",
            "Medical History": "Hypertension, Hypokalemia, Diabetes Mellitus"
        },
        "Disease Information": {
            "Disease": "Adrenal tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Hypertension, Electrolyte imbalance, Abdominal pain, Metabolic abnormalities, Muscle weakness",
            "Duration": "Symptoms have been gradually worsening over the last 6 months",
            "Curability": "Yes",
            "Severity Score": 32
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "35 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU /L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.3 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "240 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "28% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "90 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "250 ng/mL (15 − 150 for females)",
                "CRP": "4 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.4 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Not applicable",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal findings",
            "Chest Computerized Tomography": "Presence of an adrenal mass on the left side",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Within normal limits",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Normal",
            "Pulmonary Function Test": "Normal",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Laura Thompson has been diagnosed with a moderate-severity functional adrenal tumor, presenting with symptoms such as hypertension, metabolic abnormalities, and muscle weakness. Given the nature of the tumor, surgical intervention is recommended as the primary treatment to prevent further complications. A transabdominal laparoscopic adrenal tumor resection will be performed, considering the size and characteristics of the tumor. Preoperative management includes controlling blood pressure and correcting electrolyte imbalances. Post-operative care involves monitoring adrenal cortical function and potentially providing hormone replacement therapy to manage any adrenal insufficiency resulting from surgery. Laura will also be advised on lifestyle modifications, including maintaining a balanced diet and regular physical activity, to support postoperative recovery and prevent recurrence. Regular follow-up appointments will be scheduled to monitor her recovery progress, assess adrenal function, and ensure that there are no signs of tumor recurrence. Laura and her family will be educated on recognizing symptoms that require immediate medical attention and the importance of adhering to the follow-up regimen to optimize health outcomes.",
        "User Profile": {
            "id": 147,
            "trust_in_healthcare": 0.608,
            "health_literacy": 0.823,
            "openness": 1,
            "conscientiousness": 0.765,
            "extraversion": 0.645,
            "agreeableness": 0.759,
            "neuroticism": 0.737,
            "region": "California"
        },
        "Relations": {
            "strong": [
                5,
                25,
                7,
                3
            ],
            "moderate": [
                55,
                6,
                49,
                4,
                60,
                10,
                65,
                52,
                2,
                15,
                66,
                23,
                34,
                39,
                57,
                64
            ],
            "weak": [
                37,
                40,
                11,
                1,
                29,
                12,
                53,
                8,
                36,
                38,
                54,
                30,
                26,
                17,
                27,
                44,
                21,
                13,
                16,
                19,
                51,
                56,
                31,
                62,
                14,
                48,
                59,
                68,
                0,
                42,
                61,
                22,
                45,
                24,
                32,
                63,
                28,
                67,
                58,
                20,
                41,
                43,
                33,
                46,
                69,
                35,
                50,
                18,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "David Anderson",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Hypertension, Obesity, History of smoking"
        },
        "Disease Information": {
            "Disease": "Kidney cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Hematuria, flank pain, abdominal mass, unexplained weight loss, decreased appetite",
            "Duration": "Symptoms have persisted for over 3 months with worsening hematuria and pain",
            "Curability": "No",
            "Severity Score": 87
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "38 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "40 IU/L (13 − 35)",
                "Urea": "9.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "120 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "34% (35 − 50)",
                "Hemoglobin (Hb)": "105 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "190 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.0 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "6.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "6% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.05 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "650 ng/mL (20 − 500 for males)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "50 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "2.0 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "68 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Clear lung fields; no evidence of metastasis",
            "Abdominal Ultrasound": "Presence of a solid mass in the left kidney measuring 8 cm",
            "Abdominal CT Scan": "Large solid mass in left kidney with signs of invasion into perirenal fat",
            "MRI": "Mass compatible with renal cell carcinoma; no distant metastases",
            "PET-CT": "No distant metastases detected, local invasion confined to left kidney area",
            "Bone Imaging": "No signs of bone metastasis",
            "Renal Dynamic Imaging": "Reduced function in left kidney",
            "Urinalysis": "Presence of blood in urine",
            "Coagulation Function Test": "Normal",
            "Renal Biopsy": "Clear cell carcinoma confirmed",
            "Radionuclide Renography": "Normal right kidney function"
        },
        "Treatment Plan": "David Anderson has been diagnosed with advanced kidney cancer, likely exacerbated by his pre-existing conditions of hypertension and obesity, necessitating a rigorous and tailored treatment strategy. Given the extreme severity of his renal cell carcinoma, immediate surgical intervention through radical nephrectomy is considered a priority to remove the cancerous mass and prevent further local invasion. The surgery will also include assessment for possible removal of enlarged lymph nodes if detected. Post-surgery, David's treatment will focus on close monitoring of renal function, regular imaging to assess any residual disease, and medical management for systemic control of his hypertension and obesity to optimize recovery. Additionally, interventional therapy like renal artery embolization may be applied to enhance post-operative outcomes and alleviate symptoms. If necessary, ablation therapy could serve as a secondary method to target residual tumor tissues. David will be advised on dietary adjustments to reduce strain on the remaining kidney, including limiting salt and protein intake while encouraging hydration to support renal health, and daily physical activities to improve cardiovascular health. Psychological support will be provided to mitigate anxiety and enhance patient confidence throughout the treatment journey. Follow-up appointments will be crucial to monitor his progress and adjust treatment plans as required, and David will be educated on recognizing symptoms indicating complications, focusing on a positive outlook, and the necessity of adhering to prescribed medications and lifestyle modifications.",
        "User Profile": {
            "id": 150,
            "trust_in_healthcare": 0.381,
            "health_literacy": 0.04,
            "openness": 0.047,
            "conscientiousness": 0.752,
            "extraversion": 0.199,
            "agreeableness": 0.174,
            "neuroticism": 0.217,
            "region": "Kentucky"
        },
        "Relations": {
            "strong": [
                45,
                10
            ],
            "moderate": [
                68,
                56,
                15,
                21,
                60,
                22,
                14,
                17,
                34,
                36,
                65,
                57,
                42,
                67,
                11,
                37,
                35,
                66,
                50,
                8
            ],
            "weak": [
                38,
                30,
                62,
                64,
                55,
                59,
                2,
                12,
                58,
                39,
                3,
                49,
                5,
                4,
                53,
                20,
                44,
                23,
                25,
                40,
                6,
                52,
                47,
                41,
                54,
                18,
                7,
                43,
                0,
                9,
                29,
                26,
                13,
                16,
                32,
                28,
                1,
                46,
                69,
                61,
                63,
                24,
                31,
                33,
                27,
                51,
                19
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Emily Zhang",
            "Age": "55",
            "Gender": "Female",
            "Medical History": "Hypertension, Type 2 Diabetes"
        },
        "Disease Information": {
            "Disease": "Neuroendocrine tumor",
            "Severity Level": "Major Severity",
            "Symptoms": "Abdominal pain, nausea, weight loss, visual field defects, hypercalcemia, hypertension",
            "Duration": "Symptoms have been persisting and worsening over the past six months",
            "Curability": "No",
            "Severity Score": 56
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "38 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "5.6 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "128 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "190 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "71% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.6% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for females)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Chromogranin A (CgA)": "Elevated",
                "Neuron-Specific Enolase (NSE)": "Elevated",
                "5-Hydroxyindoleacetic Acid (5-HIAA)": "Elevated",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "CT Scan": "Presence of a large pancreatic mass with liver metastasis",
            "MRI": "Pancreatic mass invading surrounding structures",
            "Somatostatin Receptor Scintigraphy": "Positive uptake in pancreatic region",
            "Octreotide Scan": "Multiple positive areas indicating metastatic spread",
            "Endoscopy": "Large gastric ulcer and multiple polyps",
            "Pathology Examination": "Poorly differentiated neuroendocrine carcinoma",
            "Bone Scan": "Signs of metastatic bone lesions",
            "Thyroid Function Test": "Normal",
            "Liver Function Test": "Mild dysfunction"
        },
        "Treatment Plan": "Emily Zhang's diagnosis of a major neuroendocrine tumor necessitates a multidisciplinary approach for management, considering the complexity and severity of her condition. Surgical intervention to excise the primary tumor is imperative to alleviate compression symptoms and potentially reduce metastatic spread, given the tumor's current impact on surrounding structures. Preoperative preparation with octreotide may be critical to prevent carcinoid crisis, with postoperative monitoring of hormone levels essential to manage metabolic complications. Adjunctive targeted therapy using somatostatin analogs like octreotide or lanreotide can help control tumor growth and hormonal imbalances, with close monitoring for potential side effects such as gallstones and gastrointestinal disturbances. Radiotherapy may be employed for symptom control and to manage residual tumor mass post-surgery. Due to the metastatic nature of her tumor, chemotherapy using platinum-based regimens could be advised, bearing in mind the potential for bone marrow suppression and other common side effects. Nutritional and lifestyle modifications, including a balanced diet, regular exercise tailored to her capacity, and psychological support, will be vital for her recovery and overall well-being, along with regular follow-up to monitor for recurrence and manage any new symptoms. Family involvement in her care plan is crucial for emotional support, adherence to lifestyle changes, and recognizing signs of deterioration. As her condition is severe, ongoing multidisciplinary evaluations will be necessary to adapt her treatment plan based on disease progression and therapeutic response, with consideration for potential future research and trials as appropriate.",
        "User Profile": {
            "id": 153,
            "trust_in_healthcare": 0.526,
            "health_literacy": 0.664,
            "openness": 1,
            "conscientiousness": 0.677,
            "extraversion": 0.351,
            "agreeableness": 0.172,
            "neuroticism": 0.775,
            "region": "Massachusetts"
        },
        "Relations": {
            "strong": [
                66
            ],
            "moderate": [
                36,
                65,
                34,
                47,
                4,
                55,
                29,
                38,
                22,
                14,
                11,
                17,
                58,
                39,
                25,
                7,
                69,
                64
            ],
            "weak": [
                60,
                6,
                43,
                21,
                15,
                45,
                13,
                23,
                1,
                2,
                5,
                57,
                0,
                52,
                44,
                32,
                37,
                3,
                53,
                40,
                19,
                48,
                68,
                56,
                10,
                35,
                42,
                27,
                12,
                30,
                50,
                59,
                62,
                61,
                8,
                31,
                54,
                46,
                24,
                28,
                41,
                18,
                26,
                67,
                51,
                20,
                33,
                63,
                16,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Emily Thompson",
            "Age": "45",
            "Gender": "Female",
            "Medical History": "Smoker, history of chronic sinus infections"
        },
        "Disease Information": {
            "Disease": "Parotid gland tumor.",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Newly developed mass in the parotid region, slow growth, smooth and nodular mass, moderately firm, with clear boundaries",
            "Duration": "Symptoms have been present for approximately 6 months with gradual growth",
            "Curability": "Yes",
            "Severity Score": 45
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.95 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.02 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198 for males)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "5 ng/L (< 14 ng/L)",
                "Ferritin": "130 ng/mL (20 − 500 for females)",
                "CRP": "2 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.05 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound": "Presence of a well-defined mass in the superficial lobe of the right parotid gland",
            "CT Scan": "3 cm solitary mass located in the superficial lobe, no evidence of local tissue invasion",
            "MRI": "The mass is hyperintense on T2-weighted images, consistent with a benign parotid tumor",
            "Fine Needle Aspiration Cytology": "Consistent with pleomorphic adenoma",
            "Facial Nerve Function Test": "Normal function with no signs of facial paralysis",
            "Chest X-ray": "No metastasis observed, lungs clear",
            "PET-CT": "No distant metastasis detected, localized tumor activity"
        },
        "Treatment Plan": "Emily Thompson has been diagnosed with a pleomorphic adenoma, a benign tumor of the parotid gland, which requires surgical intervention to prevent potential malignant transformation or complications. A superficial parotidectomy is recommended to remove the tumor entirely, ensuring clear margins to minimize the risk of recurrence. Preoperatively, the surgical area will be prepared to ensure optimal access, with facial nerve monitoring during the procedure to ensure nerve preservation and reduce the risk of facial paralysis. Postoperative care will involve regular monitoring for complications such as salivary fistula or facial nerve dysfunction. Emily will be advised to abstain from smoking, as it may affect recovery and increase the risk of recurrence. Nutritional support and adequate hydration will be emphasized to promote healing. Regular follow-up appointments will be scheduled to monitor for signs of recurrence or new lesion development, with imaging studies and clinical examinations as part of the postoperative care plan. Education on recognizing signs of infection or complications will be provided to Emily and her family to ensure prompt medical attention if necessary. A lifestyle modification plan, including cessation of smoking and moderate exercise, will be recommended to reduce future risk factors.",
        "User Profile": {
            "id": 156,
            "trust_in_healthcare": 0.909,
            "health_literacy": 0.207,
            "openness": 0.102,
            "conscientiousness": 0.513,
            "extraversion": 0.197,
            "agreeableness": 0.262,
            "neuroticism": 0.088,
            "region": "Alabama"
        },
        "Relations": {
            "strong": [
                42
            ],
            "moderate": [
                62,
                36,
                11,
                58,
                61,
                22,
                21,
                40,
                48,
                35,
                34,
                66,
                57,
                44,
                45
            ],
            "weak": [
                1,
                41,
                56,
                63,
                18,
                14,
                38,
                32,
                8,
                39,
                29,
                26,
                17,
                55,
                6,
                43,
                9,
                7,
                60,
                49,
                31,
                64,
                0,
                28,
                12,
                20,
                52,
                54,
                15,
                13,
                59,
                68,
                10,
                67,
                30,
                53,
                69,
                46,
                65,
                27,
                25,
                4,
                24,
                16,
                33,
                5,
                2,
                23,
                19,
                47,
                3,
                37,
                51
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Ethan Lee",
            "Age": "3",
            "Gender": "Male",
            "Medical History": "No significant past medical history; normal development until presenting with abdominal mass"
        },
        "Disease Information": {
            "Disease": "Wilms tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Asymptomatic abdominal mass, occasional abdominal pain, mild abdominal distention, no hematuria, no hypertension",
            "Duration": "Symptoms noted by parents for approximately 1 week, with mass identified during routine pediatric examination",
            "Curability": "Yes",
            "Severity Score": 50
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "25 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "3.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "40 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lactate Dehydrogenase": "160 U/L (135 − 225)",
                "Alpha-Fetoprotein (AFP)": "Normal",
                "Neuron-Specific Enolase (NSE)": "Normal"
            },
            "Abdominal Ultrasound": "Solid mass detected in right kidney; no invasion of surrounding tissues",
            "Abdominal CT Scan": "Confirms 5 cm unilateral Wilms tumor in right kidney; no evidence of metastatic spread",
            "Chest CT": "No lung metastasis detected",
            "Urine Analysis": "No hematuria observed",
            "Kidney Function Test": "Normal function maintained"
        },
        "Treatment Plan": "Ethan Lee has been diagnosed with a moderate severity unilateral Wilms tumor located in the right kidney. Given the early stage and localized nature of the tumor, a treatment plan involving initial surgical intervention is recommended. This will include a radical nephrectomy of the affected kidney to ensure complete removal of the tumor, followed by a tailored chemotherapy regimen post-surgery to reduce the risk of recurrence. The chemotherapy plan will likely follow the AV regimen, involving Vincristine and Dactinomycin, to be administered over several weeks as required by postoperative pathology results. Regular monitoring of Ethan's kidney function is crucial due to the removal of one kidney, alongside supportive care including adequate nutrition and hydration to support recovery. Postoperative follow-up will be essential at regular intervals to monitor his recovery and assess any late effects or signs of tumor recurrence. Long-term, Ethan will require lifestyle adjustments to maintain optimal health with a single kidney, and his family will receive guidance on dietary and activity considerations to support his growth and development. The prognosis is favorable with anticipated curability due to early detection and comprehensive treatment.",
        "User Profile": {
            "id": 159,
            "trust_in_healthcare": 0.449,
            "health_literacy": 0.771,
            "openness": 0.999,
            "conscientiousness": 0.235,
            "extraversion": 0.642,
            "agreeableness": 0.706,
            "neuroticism": 0.185,
            "region": "Florida"
        },
        "Relations": {
            "strong": [
                27,
                24
            ],
            "moderate": [
                19,
                28,
                46,
                20,
                16,
                0,
                63,
                53,
                4,
                52,
                2,
                47,
                66,
                61,
                13,
                69
            ],
            "weak": [
                7,
                40,
                1,
                5,
                41,
                54,
                31,
                29,
                33,
                9,
                22,
                32,
                36,
                64,
                49,
                8,
                21,
                6,
                44,
                26,
                42,
                60,
                57,
                25,
                11,
                38,
                3,
                17,
                12,
                37,
                43,
                39,
                62,
                10,
                35,
                56,
                48,
                58,
                55,
                50,
                45,
                65,
                18,
                59,
                30,
                67,
                23,
                68,
                34,
                15,
                14
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "James Lee",
            "Age": "65",
            "Gender": "Male",
            "Medical History": "Chronic atrophic gastritis, Helicobacter pylori infection"
        },
        "Disease Information": {
            "Disease": "Stomach cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Upper abdominal pain, weight loss, anorexia, anemia",
            "Duration": "Symptoms have been persistent and worsening over several months",
            "Curability": "No",
            "Severity Score": 70
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "34% (35 − 50)",
                "Hemoglobin (Hb)": "100 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.14 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.4 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "160 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "9 ng/L (< 14 ng/L)",
                "Ferritin": "700 ng/mL (20 − 500 for males)",
                "CRP": "7 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "CEA - 5.0 ng/mL (0 − 3)",
                "Blood Silver Level": "65 μg/L (50 − 150)"
            },
            "Gastroscopy": "Irregular, ulcerated masses in the antrum of the stomach",
            "Biopsy": "Adenocarcinoma cells identified",
            "CT Scan": "Thickening of the gastric wall with local lymph node involvement",
            "Abdominal Ultrasound": "No evidence of distant metastasis",
            "Endoscopic Ultrasound": "Tumor invasion into the muscularis propria",
            "X-ray Barium Meal": "Ulcer-like lesions with filling defects",
            "MRI": "No liver metastasis detected",
            "PET-CT": "Increased metabolic activity indicative of malignancy"
        },
        "Treatment Plan": "James Lee's diagnosis of major severity stomach cancer, characterized by progressive symptoms such as upper abdominal pain and significant weight loss, necessitates an integrated treatment approach. Given the tumor's location and depth of invasion, surgical intervention in the form of a gastrectomy is proposed, followed by adjuvant chemotherapy to address regional lymph node involvement and enhance overall survival prospects. Perioperative nutritional support will be crucial, ensuring maintenance of his nutritional status, which can enhance both recovery and quality of life post-surgery. Additionally, symptomatic pharmacotherapy will be employed, including proton pump inhibitors to reduce gastric acid secretion and manage gastritis-related discomfort, along with analgesics for pain control. Regular imaging and endoscopic assessments will be scheduled post-operatively to monitor for recurrence or metastasis. His current Helicobacter pylori infection, noted in his medical history, may be addressed concurrently with antibiotics to diminish potential tumor progression risks. A multidisciplinary team approach involving gastroenterology, oncology, and nutritional specialists will support James through this treatment journey. Maintaining open communication with him and his family will be vital to ensure adherence to the plan and to provide psychological support throughout the treatment process.",
        "User Profile": {
            "id": 162,
            "trust_in_healthcare": 0.811,
            "health_literacy": 0.598,
            "openness": 0.66,
            "conscientiousness": 0.253,
            "extraversion": 0.768,
            "agreeableness": 0.659,
            "neuroticism": 0.019,
            "region": "Pennsylvania"
        },
        "Relations": {
            "strong": [
                57,
                4
            ],
            "moderate": [
                5,
                6,
                7,
                66,
                8,
                39,
                36,
                54,
                53,
                47,
                11,
                12,
                55,
                40,
                22,
                60,
                1,
                25,
                64,
                56,
                13,
                2,
                38,
                62,
                61
            ],
            "weak": [
                21,
                37,
                45,
                67,
                49,
                10,
                65,
                0,
                3,
                30,
                17,
                68,
                51,
                19,
                29,
                48,
                58,
                42,
                23,
                15,
                44,
                28,
                50,
                63,
                46,
                34,
                20,
                59,
                31,
                16,
                32,
                26,
                35,
                14,
                24,
                69,
                41,
                43,
                27,
                33,
                18,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Sophia Anderson",
            "Age": "60",
            "Gender": "Female",
            "Medical History": "Previous episodes of abdominal pain and bloating; family history of Carney-Stratakis syndrome"
        },
        "Disease Information": {
            "Disease": "Gastrointestinal stromal tumor",
            "Severity Level": "Minor Severity",
            "Symptoms": "Abdominal bloating, early satiety, occasional melena",
            "Duration": "Symptoms have been present intermittently over the past 6 months",
            "Curability": "Yes",
            "Severity Score": 22
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "220 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "32% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.44 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.7 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "11% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.3 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "120 U/L (22 − 198 for females)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "200 ng/mL (20 − 300 for females)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.4 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Negative",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Abdominal Ultrasound": "Presence of a mass in the stomach with unclear margins",
            "CT Scan": "GIST identified in the stomach, measuring approximately 4cm",
            "MRI": "Soft tissue mass in the gastric region with potential liver metastasis",
            "Endoscopic Ultrasound": "Hypo-echoic lesion detected with potential bleeding sites",
            "Stool Test": "Positive for occult blood",
            "Genetic Testing": "Positive mutation in c-kit gene",
            "Respiratory Function Test": "Normal",
            "Urinalysis": "No abnormal findings",
            "Electrolyte Test": "Normal",
            "Serum Antibody Test": "Negative for PDGFRA mutation"
        },
        "Treatment Plan": "Sophia Anderson is diagnosed with an intermediate severity gastrointestinal stromal tumor located in the stomach, necessitating a personalized and comprehensive treatment approach. The primary recommendation is surgical resection to remove the tumor, given its localized nature, followed by targeted therapy to reduce recurrence risk. Preoperative treatment with Imatinib may be initiated to minimize surgical complications and ensure complete removal, especially considering the positive c-kit mutation. Postoperative adjuvant therapy with Imatinib is advised for 3 years to prevent recurrence, given the intermediate risk assessment. Regular follow-ups will include CT scans and MRI evaluations every 3 months for the first 3 years to monitor for potential metastasis or recurrence. Symptomatic management for occasional melena includes iron supplementation for anemia and pain relief as necessary. Nutritional support with a diet of easily digestible foods will be provided to address early satiety and abdominal bloating. Lifestyle modifications will be encouraged, incorporating moderate exercise and stress-relieving practices to improve quality of life. Sophia and her family will receive counseling on adherence to the treatment plan and recognizing signs of worsening symptoms, with additional support to mitigate psychological impacts and boost her recovery chances.",
        "User Profile": {
            "id": 165,
            "trust_in_healthcare": 0.41,
            "health_literacy": 0.237,
            "openness": 0.808,
            "conscientiousness": 0.216,
            "extraversion": 0.896,
            "agreeableness": 0.904,
            "neuroticism": 0.289,
            "region": "Michigan"
        },
        "Relations": {
            "strong": [
                57,
                4,
                64,
                13
            ],
            "moderate": [
                1,
                52,
                66,
                3,
                54,
                21,
                38,
                22,
                12,
                5,
                37,
                6,
                11,
                36,
                47,
                29
            ],
            "weak": [
                68,
                42,
                10,
                2,
                8,
                30,
                60,
                62,
                58,
                7,
                51,
                65,
                45,
                56,
                49,
                61,
                67,
                28,
                48,
                25,
                59,
                63,
                32,
                31,
                40,
                0,
                41,
                19,
                46,
                55,
                34,
                15,
                39,
                44,
                17,
                50,
                23,
                16,
                43,
                14,
                35,
                20,
                24,
                27,
                69,
                18,
                26,
                33,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Eleanor Smith",
            "Age": "77",
            "Gender": "Female",
            "Medical History": "Postmenopausal, history of HPV infection, lichen sclerosus"
        },
        "Disease Information": {
            "Disease": "Vulvar cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent vulvar itching, pain, cauliflower-like mass on the vulva, groin mass due to lymph node metastasis, abnormal pigmentation on the vulva, urinary frequency, dysuria",
            "Duration": "Symptoms have persisted for several months with gradual worsening",
            "Curability": "Yes",
            "Severity Score": 56
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "36 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.4 mmol/L (< 5.18)",
                "White Blood Cell Ct. (WBC)": "8.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.6 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "240 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.7 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "9% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "190 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "100 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "6 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 300 for females)",
                "CRP": "7 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.7 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Human Papillomavirus (HPV)",
                "Blood Silver Level": "55 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Normal",
            "Chest Computerized Tomography": "No lung metastasis",
            "Vulvar Examination": "Cauliflower-like mass with ulceration",
            "Pelvic Magnetic Resonance Imaging (MRI)": "Enlarged lymph nodes in the groin, mass connection to surrounding structures",
            "Colposcopic Biopsy": "Presence of squamous cell carcinoma",
            "PET-CT Scan": "No distant metastasis detected",
            "Fine Needle Aspiration of Groin Lymph node": "Positive for malignancy",
            "Urinary Function Test": "Impaired due to urethral involvement",
            "Rectal Examination": "No rectal involvement"
        },
        "Treatment Plan": "Eleanor Smith has been diagnosed with vulvar cancer, exhibiting major severity due to persistent symptoms and lymph node involvement. The approach to treatment will focus primarily on comprehensive surgery, including wide vulvar excision and groin lymph node dissection, tailored to her condition. Preoperative planning involves radiation therapy to reduce tumor volume, facilitating surgical efficacy, and minimizing invasion of surrounding organs. Post-surgical adjuvant radiation will be considered if the margins are not clean or if lymph node metastasis is observed, aiming to prevent recurrence. Chemotherapy may be applied in combination with radiation for advanced tumor control, particularly considering her sensitivity. Additional supportive measures include quitting smoking, maintaining a balanced diet, and enhancing overall immunity. Regular monitoring and imaging will ensure the detection of any recurrence or metastasis. Post-recovery, encouraging a healthy lifestyle with HPV vaccination will be crucial in preventing future occurrences. Follow-up assessments every 3 months will be vital in ensuring recovery progress and adjusting the treatment plan as needed.",
        "User Profile": {
            "id": 168,
            "trust_in_healthcare": 0.929,
            "health_literacy": 0.31,
            "openness": 0.742,
            "conscientiousness": 0.337,
            "extraversion": 0.428,
            "agreeableness": 0.916,
            "neuroticism": 0.27,
            "region": "New York"
        },
        "Relations": {
            "strong": [
                12,
                2
            ],
            "moderate": [
                52,
                11,
                7,
                6,
                64,
                8,
                53,
                5,
                62,
                13,
                39,
                56,
                1,
                30,
                40,
                42,
                47,
                21,
                4,
                36,
                61,
                22,
                45,
                66
            ],
            "weak": [
                37,
                60,
                55,
                0,
                57,
                63,
                38,
                29,
                10,
                25,
                48,
                44,
                58,
                3,
                19,
                41,
                32,
                15,
                34,
                49,
                50,
                51,
                65,
                43,
                26,
                67,
                59,
                17,
                68,
                28,
                20,
                31,
                35,
                16,
                46,
                27,
                33,
                18,
                69,
                14,
                23,
                9,
                24
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Jessica Thompson",
            "Age": "65",
            "Gender": "Female",
            "Medical History": "Chronic cough, occasional hemoptysis, history of smoking (40 pack-years)"
        },
        "Disease Information": {
            "Disease": "Small cell lung cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent cough, hemoptysis, dyspnea, wheezing, chest pain, weight loss",
            "Duration": "Symptoms have been persistent for several months, with increased severity over the past month",
            "Curability": "No",
            "Severity Score": 51
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "75 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "240 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "20% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.2 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "180 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "15 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for females)",
                "CRP": "35 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative for SARS-CoV-2",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mass in the right upper lung field with possible pleural effusion",
            "Chest Computerized Tomography": "Large mass in right upper lobe with mediastinal lymph node enlargement",
            "Serological Diagnosis": "Positive for small cell lung carcinoma markers",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Presence of malignant cells",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for recent infections",
            "Pulmonary Function Test": "Reduced lung capacity",
            "Nucleic Acid Amplification Test": "Negative for respiratory pathogens",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Unremarkable",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Jessica Thompson has been diagnosed with small cell lung cancer, which has progressed to an advanced stage, necessitating immediate intervention centered on combined radiotherapy and chemotherapy. Due to the rapid progression and moderate symptom severity, a regimen including etoposide and platinum-based chemotherapy will be initiated, tailored to her specific situation and disease stage. Concurrently, chest radiotherapy during the early cycles of chemotherapy will be crucial to manage tumor growth and prevent metastasis. Consideration for immunotherapy with atezolizumab or durvalumab may be taken, given the extensive stage of the disease. Supportive care including nutritional support, pain management, and psychological counseling will be provided to enhance her quality of life, with close monitoring of treatment response and potential side effects such as fatigue, dyspnea, and gastrointestinal disturbances. Regular imaging and blood tests will be conducted to assess progress and adapt the treatment plan accordingly. Jessica and her caregivers will be educated on recognizing signs of adverse reactions, adhering to the treatment protocol, and preparing for potential palliative measures to improve comfort and prolong survival. Follow-up care with a multidisciplinary team will be pivotal to address any complications and adjust therapies to ensure optimal management, with particular attention to mitigating risks of recurrence and managing psychological and social wellbeing.",
        "User Profile": {
            "id": 171,
            "trust_in_healthcare": 0.67,
            "health_literacy": 0.785,
            "openness": 0.43,
            "conscientiousness": 0.491,
            "extraversion": 0.526,
            "agreeableness": 0.142,
            "neuroticism": 0.76,
            "region": "Georgia"
        },
        "Relations": {
            "strong": [
                6,
                25
            ],
            "moderate": [
                47,
                7,
                57,
                39,
                49,
                38,
                11,
                36,
                56,
                34,
                15,
                10,
                65,
                52,
                23,
                60,
                5,
                66,
                8,
                68,
                37
            ],
            "weak": [
                17,
                45,
                67,
                30,
                40,
                14,
                22,
                29,
                12,
                21,
                58,
                43,
                64,
                69,
                4,
                48,
                2,
                3,
                1,
                24,
                54,
                13,
                28,
                35,
                42,
                50,
                46,
                62,
                19,
                0,
                59,
                44,
                18,
                53,
                31,
                61,
                26,
                16,
                32,
                33,
                27,
                63,
                9,
                41,
                20
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Jonathan Park",
            "Age": "67",
            "Gender": "Male",
            "Medical History": "Chronic smoker, hypertension, family history of prostate cancer"
        },
        "Disease Information": {
            "Disease": "Adenocarcinoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Persistent dry cough, hemoptysis, shortness of breath, chest pain",
            "Duration": "Symptoms have been present for over six months, with gradual worsening",
            "Curability": "No",
            "Severity Score": 60
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "27 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "6.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "89 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.7 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.2 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.7 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "145 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "240 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.6 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "230 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (20 − 500 for males)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "SARS-CoV-2 Nucleocapsid",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Mass in the right upper lobe with spiculation",
            "Chest Computerized Tomography": "Irregular nodule with pleural involvement in the right lung",
            "Serological Diagnosis": "Elevated CEA",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Presence of malignant cells",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Reduced volume and capacity",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Jonathan Park has been diagnosed with an advanced case of lung adenocarcinoma, characterized by persistent dry cough, hemoptysis, and chest pain over the past months. Given the major severity of his condition, a multi-disciplinary approach is crucial. Surgical intervention is not feasible due to the advanced stage and pleural involvement. The treatment plan focuses on palliative care aimed at symptom management and prolongation of life. Chemotherapy regimens including cisplatin and paclitaxel are proposed to control tumor growth, potentially combined with targeted therapy, contingent upon molecular profiling results. Radiotherapy will be considered to alleviate symptoms and manage local tumor control. Regular monitoring of tumor markers and imaging is essential to assess the response to treatment. Supportive care involving analgesics for pain management, bronchodilators for respiratory ease, and nutritional support will be provided. Psychological support and smoking cessation programs are recommended to improve quality of life and reduce further risk factors. Jonathan and his family will receive counseling on the prognosis and be encouraged to make informed decisions about his care preferences and goals.",
        "User Profile": {
            "id": 174,
            "trust_in_healthcare": 0.587,
            "health_literacy": 0.378,
            "openness": 0.071,
            "conscientiousness": 0.048,
            "extraversion": 0.275,
            "agreeableness": 0.367,
            "neuroticism": 0.41,
            "region": "Texas"
        },
        "Relations": {
            "strong": [
                39
            ],
            "moderate": [
                22,
                58,
                12,
                45,
                21,
                67,
                10,
                48,
                55,
                15,
                11,
                30,
                36,
                42,
                57,
                8,
                38,
                34,
                37
            ],
            "weak": [
                64,
                68,
                6,
                60,
                66,
                52,
                54,
                7,
                14,
                50,
                40,
                25,
                65,
                13,
                17,
                53,
                9,
                2,
                1,
                18,
                49,
                35,
                5,
                47,
                62,
                0,
                59,
                23,
                28,
                32,
                29,
                4,
                69,
                3,
                26,
                43,
                44,
                61,
                41,
                20,
                31,
                19,
                63,
                46,
                24,
                16,
                33,
                51,
                27
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "James Thompson",
            "Age": "63",
            "Gender": "Male",
            "Medical History": "Type 2 diabetes diagnosed 12 years ago, chronic pancreatitis, smoker with a history of heavy smoking for 30 years"
        },
        "Disease Information": {
            "Disease": "Pancreatic cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Persistent upper abdominal pain, significant weight loss, jaundice, newly developed diabetes, fatigue, mental and emotional disorders",
            "Duration": "Symptoms have been present and worsening over the past 6 months",
            "Curability": "No",
            "Severity Score": 76
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "75 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "90 IU/L (13 − 35)",
                "Urea": "6.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "215 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.9 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.3 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.14 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.04 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "300 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "250 U/L (22 − 198 for males)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "450 ng/mL (30 − 400)",
                "CRP": "20 mg/L (< 3 mg/L)",
                "ESR": "55 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Imaging Exams": {
                "Abdominal CT scan": "Mass in the pancreatic head with bile duct obstruction",
                "MRI": "Liver metastasis, enlarged pancreatic duct",
                "PET-CT": "High metabolic activity in the pancreatic and hepatic regions",
                "Endoscopic Ultrasound": "Large pancreatic mass with malignant features"
            },
            "Pathology Exam": "Biopsy confirmed ductal adenocarcinoma with tissue necrosis",
            "Tumor Marker Analysis": "Elevated CA199 at 500 U/ml, CEA at 15 ng/ml, CA125 at 60 U/ml"
        },
        "Treatment Plan": "The treatment plan for James Thompson encompasses palliative and supportive care aimed at alleviating pain and improving quality of life, given the advanced stage of pancreatic cancer with metastasis. As surgical intervention is not an option due to the extensive spread of the disease, the focus is on managing symptoms through a multidisciplinary approach. A combination of chemotherapy with gemcitabine and pain management using opioid analgesics will be initiated to provide relief from severe abdominal pain, following the WHO's pain relief guidelines. Nutritional support through a high-protein, easily digestible diet, along with pancreatic enzyme supplements, will aid in maintaining nutritional status, while antiemetic drugs are prescribed to address chemotherapy-induced nausea. The oncologist will evaluate potential inclusion in a clinical trial for immunotherapy, with genetic testing for MSI or MMR prior. Regular follow-up every month will include assessments of liver and kidney function, complete blood count, tumor markers, and imaging studies to monitor progression and adjust therapy as needed. Emotional support through counseling will be provided to mitigate mental and emotional disorders; communication with James and his family will be crucial throughout, emphasizing the importance of adherence to the treatment plan and lifestyle adjustments, including cessation of smoking and alcohol consumption to improve prognosis and welfare. For refractory pain not controlled by medication, interventional pain management such as neurolysis may be considered. Community support resources will be explored to assist in managing home care effectively.",
        "User Profile": {
            "id": 177,
            "trust_in_healthcare": 0.661,
            "health_literacy": 0.571,
            "openness": 0.237,
            "conscientiousness": 0.563,
            "extraversion": 0.979,
            "agreeableness": 0.382,
            "neuroticism": 0.136,
            "region": "Michigan"
        },
        "Relations": {
            "strong": [
                6,
                52,
                36
            ],
            "moderate": [
                55,
                21,
                5,
                53,
                60,
                22,
                11,
                7,
                39,
                25,
                4,
                38,
                45,
                56,
                66,
                40,
                10,
                37,
                23,
                48,
                47,
                68,
                17
            ],
            "weak": [
                8,
                1,
                15,
                42,
                65,
                62,
                3,
                14,
                50,
                34,
                67,
                28,
                49,
                29,
                24,
                58,
                30,
                2,
                59,
                13,
                64,
                12,
                54,
                44,
                31,
                61,
                35,
                16,
                46,
                0,
                20,
                26,
                63,
                19,
                43,
                69,
                51,
                41,
                27,
                33,
                18,
                32,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Hannah Smith",
            "Age": "52",
            "Gender": "Female",
            "Medical History": "Recent discomfort swallowing, history of cervicitis, occasional esophageal discomfort"
        },
        "Disease Information": {
            "Disease": "Carcinoma in situ",
            "Severity Level": "Minor Severity",
            "Symptoms": "Discomfort swallowing food, dryness in the throat, local erosion in the esophageal lining",
            "Duration": "Symptoms noticed and gradually worsening over the past three months",
            "Curability": "Yes",
            "Severity Score": 14
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "28 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "4.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "60 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.4 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "5.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "36% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "90 U/L (22 − 198 for females)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Ferritin": "100 ng/mL (20 − 200 for females)",
                "CRP": "8 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Endoscopic Examination": "Localized mucosal congestion with superficial erosion in the esophagus",
            "Esophagogastroduodenoscopy": "Histology confirmed carcinoma in situ in esophageal lining",
            "Ultrasound Examination": "No detectable mass in the breast",
            "Breast Cytology": "Normal",
            "Cervical Cytology Smear": "Normal",
            "Nuclear Imaging": "No invasive cancer signs detected",
            "Histological Biopsy": "Confirms carcinoma in situ with cells not breaching basal membrane",
            "Tumor Marker Tests": "Negative for carcinoma markers"
        },
        "Treatment Plan": "Hannah Smith's diagnosis of carcinoma in situ of the esophagus has been established through endoscopic examination and histological biopsy. Due to the non-invasive nature of the condition, an endoscopic mucosal resection is recommended as a primary treatment method to effectively remove the affected site. This minimally invasive procedure will ensure complete removal of localized cancerous cells while causing minimal discomfort and recovery time. Further evaluation through regular endoscopic surveillance will be necessary to monitor for potential progression or recurrence, and patient education regarding esophageal health and dietary modifications will be provided. Hannah is advised to follow up with her gastroenterologist for monitoring and possible treatment of any precancerous lesions detected in future screenings. Since her condition is highly curable in this early stage, a proactive approach will focus on maintaining regular health checks and adopting lifestyle changes, including dietary adjustments to minimize potential risk factors for esophageal cancer development. Additionally, psychological support and routine examinations will be emphasized to ensure her physical and mental well-being throughout recovery.",
        "User Profile": {
            "id": 180,
            "trust_in_healthcare": 0.561,
            "health_literacy": 0.279,
            "openness": 0.254,
            "conscientiousness": 0.053,
            "extraversion": 0.352,
            "agreeableness": 0.282,
            "neuroticism": 0.665,
            "region": "South Carolina"
        },
        "Relations": {
            "strong": [
                36,
                34,
                22
            ],
            "moderate": [
                38,
                56,
                64,
                21,
                13,
                42,
                1,
                49,
                66,
                50,
                12,
                14,
                39,
                43,
                8,
                45
            ],
            "weak": [
                67,
                11,
                55,
                18,
                32,
                68,
                40,
                59,
                29,
                62,
                10,
                15,
                6,
                57,
                65,
                53,
                48,
                30,
                35,
                69,
                25,
                44,
                23,
                37,
                52,
                28,
                9,
                4,
                17,
                7,
                54,
                60,
                19,
                3,
                0,
                61,
                31,
                46,
                41,
                47,
                26,
                5,
                24,
                33,
                2,
                63,
                20,
                16,
                27,
                51
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "John Doe",
            "Age": "53",
            "Gender": "Male",
            "Medical History": "Phimosis, Smoking, Infrequent Personal Hygiene"
        },
        "Disease Information": {
            "Disease": "Penile cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Presence of papules and ulcerations on the glans, purulent discharge, occasional bleeding during intercourse, and mild pain",
            "Duration": "Symptoms have been present and gradually worsening for the past 6 months",
            "Curability": "Yes",
            "Severity Score": 48
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "27 IU /L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "8.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.4 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.8 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.3% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "160 U/L (22 − 198 for males)",
                "Myoglobin": "50 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500 for males)",
                "CRP": "4 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "SCC Antigen",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Lesion identified at the glans with no evident invasion of the tunica albuginea",
            "MRI": "Localized mass in the glans area with slight invasion noted",
            "Pathological Examination": "Confirms squamous cell carcinoma",
            "Inguinal Lymph Node Biopsy": "Negative for metastasis",
            "Serological Diagnosis": "Normal",
            "Urinalysis": "Normal",
            "Physical Examination": "Presence of indurated mass on the glans with ulceration"
        },
        "Treatment Plan": "John Doe has been diagnosed with penile cancer with moderate severity, as indicated by the localized mass in the glans and absence of lymph node metastasis. The treatment will primarily focus on surgical intervention to excise the tumor while attempting to preserve penile structure and function. A partial penectomy is recommended, given that the cancer is confined to the glans area, which should aid in maintaining both urination and some sexual function. Post-surgery, John will undergo localized radiation therapy to ensure all cancer cells are eradicated and to prevent recurrence. In the presence of any signs of infection such as purulent discharge, appropriate antibiotics will be administered after obtaining culture results to ensure effective treatment. Follow-up appointments will be arranged to closely monitor healing, with regular physical examinations to identify any potential recurrence. John will be advised on personal hygiene improvement and smoking cessation to aid in his recovery and reduce future cancer risk. Nutritional support and possible psychological counseling will be offered to support his mental and physical well-being during and after treatment.",
        "User Profile": {
            "id": 183,
            "trust_in_healthcare": 0.177,
            "health_literacy": 0.232,
            "openness": 0.16,
            "conscientiousness": 0.786,
            "extraversion": 0.812,
            "agreeableness": 0.556,
            "neuroticism": 1,
            "region": "Connecticut"
        },
        "Relations": {
            "strong": [
                68,
                3,
                14,
                21
            ],
            "moderate": [
                10,
                34,
                38,
                13,
                23,
                37,
                67,
                25,
                15,
                30,
                29,
                1,
                35,
                36,
                4,
                58,
                22
            ],
            "weak": [
                32,
                8,
                43,
                62,
                65,
                48,
                31,
                42,
                57,
                64,
                45,
                18,
                53,
                24,
                11,
                17,
                60,
                66,
                16,
                28,
                44,
                49,
                55,
                69,
                47,
                56,
                6,
                39,
                40,
                5,
                19,
                12,
                33,
                50,
                41,
                52,
                26,
                2,
                54,
                20,
                0,
                7,
                46,
                27,
                9,
                51
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Margaret Johnson",
            "Age": "65",
            "Gender": "Female",
            "Medical History": "Chronic pancreatitis, hypertension"
        },
        "Disease Information": {
            "Disease": "Pancreatic tumor",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Abdominal pain, jaundice, weight loss, cachexia",
            "Duration": "Symptoms have been progressively worsening over the past three months",
            "Curability": "No",
            "Severity Score": 77
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "75 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "90 IU /L (13 − 35)",
                "Urea": "9.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "110 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "120 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "35% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "2.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "10% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "400 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "210 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "1000 ng/mL (20 − 500 for females)",
                "CRP": "80 mg/L (< 3 mg/L)",
                "ESR": "55 mm/hr (0 − 20)",
                "Procalcitonin": "0.8 ng/mL (< 0.5)",
                "D-dimer": "1.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Pancreatic cancer marker CA 19-9",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "CT Scan": "Large mass in the head of the pancreas with involvement of surrounding tissues and distant metastasis",
            "MRI": "Advanced stage pancreatic tumor with vascular encasement",
            "Endoscopic Ultrasound": "Significant mass with mixed solid and cystic components in the pancreas",
            "PET-CT": "High uptake indicating malignancy and metastasis to liver and lungs",
            "ERCP": "Ductal compression and obstruction",
            "Liver Function Test": "Impaired liver function with elevated bilirubin",
            "Tumor Marker Test": "Elevated CA 19-9 levels",
            "Biopsy": "Adenocarcinoma of the pancreas"
        },
        "Treatment Plan": "Margaret Johnson has been diagnosed with an advanced pancreatic tumor characterized by extreme severity, with metastasis to the liver and lungs. Her medical history of chronic pancreatitis and current hypertension complicates the treatment plan. Surgery is not viable due to the widespread metastasis and vessel encasement, and the treatment will focus on palliative care to manage symptoms and improve quality of life. Chemotherapy with agents such as Gemcitabine or Nab-Paclitaxel will be initiated to attempt tumor reduction and alleviate symptoms, alongside targeted radiotherapy where feasible, to control local tumor growth and reduce pain. Supportive care will include analgesics for pain management, antiemetics for nausea, and nutritional support to address cachexia and weight loss, along with regular blood glucose monitoring due to potential glucagonoma effects. Follow-ups for liver function and other organ involvement will be essential, with collaborative care from oncology, gastroenterology, and palliative specialists to ensure comprehensive management. Margaret and her family will be counseled on the prognosis and given psychological support, with hospice care options discussed as necessary, ensuring respect for her comfort and dignity throughout the progression of her illness.",
        "User Profile": {
            "id": 186,
            "trust_in_healthcare": 0.28,
            "health_literacy": 0.711,
            "openness": 0.367,
            "conscientiousness": 0.957,
            "extraversion": 0.227,
            "agreeableness": 0.736,
            "neuroticism": 0.245,
            "region": "New Mexico"
        },
        "Relations": {
            "strong": [
                5,
                2
            ],
            "moderate": [
                17,
                45,
                44,
                25,
                65,
                57,
                48,
                36,
                47,
                10,
                4,
                6,
                20,
                22,
                66,
                7,
                55,
                52,
                14,
                15
            ],
            "weak": [
                11,
                39,
                30,
                37,
                56,
                40,
                3,
                62,
                16,
                49,
                23,
                42,
                26,
                0,
                21,
                12,
                34,
                61,
                64,
                53,
                41,
                38,
                54,
                68,
                33,
                29,
                35,
                59,
                1,
                50,
                8,
                28,
                13,
                67,
                63,
                58,
                32,
                31,
                27,
                24,
                69,
                51,
                19,
                43,
                18,
                46,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Emma Thompson",
            "Age": "35",
            "Gender": "Female",
            "Medical History": "No significant family history of tumors, sporadic insulinoma diagnosis"
        },
        "Disease Information": {
            "Disease": "Insulinoma",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Spontaneous hypoglycemic episodes, blood glucose levels below 2.8 mmol/L, hunger, sweating, palpitations, confusion, abnormal behavior",
            "Duration": "Symptoms have been present for several weeks, occurring mainly during fasting periods",
            "Curability": "Yes",
            "Severity Score": 30
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU /L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "80 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "40% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "210 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.0 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.1 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "300 ng/mL (20 − 500 for females)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.1 ng/mL (< 0.5)",
                "D-dimer": "0.3 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Abdominal CT Exam": "Small pancreatic lesion in the tail, suggestive of insulinoma",
            "MRI": "Enhanced signal in pancreatic tail, correlating with CT findings",
            "Endoscopic Ultrasound": "Clear image of small insulinoma in pancreatic tail",
            "Chromogranin A Test": "Elevated",
            "Pancreatic Polypeptide Test": "Normal",
            "Insulin Suppression Test": "Positive",
            "Serum Biomarkers": "Elevated insulin levels consistent with hypoglycemia",
            "CT Angiography": "Not necessary at this stage",
            "68Ga PET Imaging": "Inconclusive",
            "Pathology": "Biopsy pending"
        },
        "Treatment Plan": "Emma Thompson has been diagnosed with a moderate severity insulinoma, located in the pancreatic tail. Initial treatment will focus on controlling symptoms through medical management, including frequent small meals and intravenous glucose infusion to manage hypoglycemic episodes effectively. Diazoxide may be employed to suppress insulin secretion and alleviate hypoglycemia. Ongoing evaluation of her condition will be crucial, with a close watch on her response to medical management. Should Emma's health allow, a surgical approach may be considered to remove the insulinoma after preoperative localization is confirmed through imaging techniques like CT and endoscopic ultrasound. The surgical option being explored is laparoscopic tumor enucleation, emphasizing preservation of pancreatic tissue. Post-operative monitoring will involve regular checks on blood glucose levels and periodic imaging studies to assess any recurrence. Emma and her family will receive guidance on managing hypoglycemia symptoms and lifestyle adjustments necessary for recovery. The treatment strategy will adapt based on Emma's progress, with potential involvement in clinical trials if conventional approaches are not viable, ensuring her comfort and wellbeing are prioritized throughout the treatment phase.",
        "User Profile": {
            "id": 189,
            "trust_in_healthcare": 0.843,
            "health_literacy": 0.624,
            "openness": 0.449,
            "conscientiousness": 0.351,
            "extraversion": 0.064,
            "agreeableness": 0.989,
            "neuroticism": 0.185,
            "region": "Pennsylvania"
        },
        "Relations": {
            "strong": [
                20,
                0
            ],
            "moderate": [
                40,
                26,
                63,
                42,
                44,
                50,
                66,
                41,
                52,
                62,
                12,
                19,
                60,
                36,
                29,
                4,
                39,
                54,
                32
            ],
            "weak": [
                31,
                22,
                6,
                28,
                53,
                64,
                17,
                11,
                7,
                1,
                57,
                51,
                69,
                16,
                2,
                5,
                33,
                49,
                21,
                47,
                55,
                8,
                58,
                35,
                56,
                38,
                43,
                18,
                27,
                14,
                48,
                46,
                45,
                30,
                13,
                24,
                25,
                9,
                34,
                65,
                67,
                3,
                10,
                37,
                15,
                59,
                23,
                68
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Margaret Thompson",
            "Age": "53",
            "Gender": "Female",
            "Medical History": "Postmenopausal, history of breast lumps, hypertension"
        },
        "Disease Information": {
            "Disease": "Inflammatory breast cancer",
            "Severity Level": "Extreme Severity",
            "Symptoms": "Diffuse erythema, edema, peau d'orange over one-third of the breast, rapid progression, breast enlargement, skin redness and hardening, tenderness",
            "Duration": "Symptoms have progressed over the past two weeks",
            "Curability": "No",
            "Severity Score": 78
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU/L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "65 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.0 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.2 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "122 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "180 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "70% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.9 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "5.25 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "5% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.1% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "220 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "170 U/L (22 − 198 for females)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "210 ng/mL (20 − 500 for females)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "55 mm/hr (0 − 20)",
                "Procalcitonin": "0.25 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "HER2 overexpression",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Breast Ultrasound": "Diffuse thickening of the skin with underlying edematous changes and indistinct mass margins",
            "Mammography": "Large area of asymmetric density with skin thickening",
            "Breast MRI": "Extensive skin thickening and edema, large, ill-defined mass in the breast",
            "PET-CT": "Multiple lymph node involvement, no distant metastasis detected",
            "Biopsy": "Inflammatory breast cancer with HER2 overexpression and negative ER/PR receptors",
            "Liver Function Test": "Normal",
            "Kidney Function Test": "Normal"
        },
        "Treatment Plan": "Margaret Thompson's diagnosis of inflammatory breast cancer presents with extreme severity, necessitating immediate and aggressive multidisciplinary treatment. Initial neoadjuvant chemotherapy is imperative to reduce the primary tumor size and lymph node involvement, enabling her to meet surgical criteria for a modified radical mastectomy. Given the HER2-positive status, targeted therapy with trastuzumab and pertuzumab will be administered concurrently with chemotherapy to maximize treatment efficacy. Post-surgery, adjuvant chemotherapy will continue, using a regimen consistent with the pre-operative treatment, followed by radiation therapy to the chest wall and regional lymph nodes to prevent recurrence. Endocrine therapy is not applicable due to the absence of ER/PR receptor expression. Throughout this treatment process, it is crucial for Margaret to maintain her overall health through a balanced diet, regular light exercise, and psychological support to cope with the stress associated with her diagnosis and treatment. Regular follow-ups and imaging studies will be necessary to monitor her response to therapy and make any needed adjustments to her treatment plan. Her family should be actively involved in her care, helping her adhere to medical advice and supporting her emotional well-being.",
        "User Profile": {
            "id": 192,
            "trust_in_healthcare": 0.947,
            "health_literacy": 0.223,
            "openness": 0.342,
            "conscientiousness": 0.846,
            "extraversion": 0.396,
            "agreeableness": 0.891,
            "neuroticism": 0.067,
            "region": "Ohio"
        },
        "Relations": {
            "strong": [
                42,
                11
            ],
            "moderate": [
                21,
                40,
                34,
                50,
                38,
                44,
                54,
                36,
                8,
                5,
                45,
                60,
                52,
                12,
                1
            ],
            "weak": [
                63,
                57,
                61,
                6,
                4,
                22,
                26,
                58,
                64,
                48,
                59,
                20,
                10,
                53,
                41,
                30,
                7,
                16,
                17,
                14,
                66,
                35,
                33,
                39,
                56,
                55,
                29,
                47,
                3,
                49,
                0,
                15,
                31,
                2,
                13,
                65,
                37,
                25,
                43,
                28,
                68,
                32,
                27,
                67,
                19,
                51,
                46
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Ella Thompson",
            "Age": "15",
            "Gender": "Female",
            "Medical History": "Previous pneumonia, recent respiratory infection, history of cough and chest pains"
        },
        "Disease Information": {
            "Disease": "Inflammatory Myofibroblastic Tumor",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Cough, chest pain, difficulty breathing, mild fever, weight loss",
            "Duration": "Symptoms have persisted for approximately 2 weeks",
            "Curability": "Yes",
            "Severity Score": 43
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "25 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "20 IU /L (13 − 35)",
                "Urea": "4.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "60 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.0 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "41% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "300 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.1 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "180 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "140 U/L (22 − 198 for males)",
                "Myoglobin": "70 ng/mL (< 90 ng/mL)",
                "Troponin I": "12 ng/L (< 14 ng/L)",
                "Ferritin": "250 ng/mL (20 − 500 for males)",
                "CRP": "15 mg/L (< 3 mg/L)",
                "ESR": "30 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.6 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Localized soft tissue mass in the lung causing compression",
            "Chest Computerized Tomography": "Soft tissue mass identified in the lung region, causing mild compression",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Mildly impaired",
            "Sputum Examination": "Normal",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative for specific antibodies",
            "Pulmonary Function Test": "Moderate impairment observed",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Ella Thompson has been diagnosed with an inflammatory myofibroblastic tumor located in the lung region, leading to moderate compression and associated respiratory symptoms. The preferred treatment approach is surgical removal of the tumor to alleviate compression and associated symptoms. The identified tumor appears suitable for surgical excision, and preparations for thoracic surgery are underway to ensure complete removal, prioritizing Ella's lung function preservation. Given the tumor's moderate severity, postoperative chemotherapy or ALK inhibitor therapy may be considered based on Ella's response and any molecular characteristics identified during the pathology. Regular follow-up and imaging studies, including CT scans, will be conducted every three to six months to monitor for potential recurrence, given the higher likelihood associated with inflammatory myofibroblastic tumors. Ella's parents will be advised on recognizing signs of recurrence, maintaining scheduled follow-ups, and Ella will receive postoperative care instructions to ensure optimal recovery. Nutritional support, pain management, and respiratory exercises will be integrated into her recovery plan to enhance lung function and overall health outcomes.",
        "User Profile": {
            "id": 195,
            "trust_in_healthcare": 0.699,
            "health_literacy": 0.121,
            "openness": 0.758,
            "conscientiousness": 0.585,
            "extraversion": 0.097,
            "agreeableness": 0.866,
            "neuroticism": 0.119,
            "region": "Missouri"
        },
        "Relations": {
            "strong": [
                41
            ],
            "moderate": [
                20,
                61,
                0,
                42,
                62,
                19,
                33,
                31,
                32,
                51,
                50,
                11,
                44,
                64,
                1,
                46,
                53,
                54,
                26,
                40
            ],
            "weak": [
                27,
                29,
                66,
                2,
                21,
                16,
                9,
                7,
                43,
                12,
                5,
                60,
                52,
                45,
                4,
                28,
                47,
                17,
                35,
                57,
                48,
                24,
                69,
                36,
                55,
                56,
                49,
                22,
                37,
                13,
                39,
                6,
                10,
                25,
                18,
                8,
                58,
                3,
                30,
                14,
                38,
                34,
                65,
                15,
                59,
                67,
                68,
                23
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Margaret Poe",
            "Age": "61",
            "Gender": "Female",
            "Medical History": "Hypertension, Diabetes, Obesity, Post-menopausal bleeding"
        },
        "Disease Information": {
            "Disease": "Endometrial cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Irregular vaginal bleeding, abdominal discomfort, abnormal vaginal discharge",
            "Duration": "Symptoms have been present for two months with increasing frequency",
            "Curability": "Yes",
            "Severity Score": 46
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "30 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.0 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "70 μmol/L (41 − 81)",
                "Triglycerides (TG)": "2.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "130 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "230 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.9 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.4% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase": "150 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "60 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "400 ng/mL (20 − 500 for females)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "20 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Blood Silver Level": "80 μg/L (50 − 150)"
            },
            "Pelvic Ultrasound": "Increased endometrial thickness",
            "Pelvic MRI": "Endometrial and myometrial structures suggestive of tumor invasion",
            "Endometrial Biopsy": "Positive for carcinoma cells",
            "CT Scan": "No evidence of distant metastasis",
            "Serum Tumor Marker": "CA125 slightly elevated",
            "Cervical Cytology Test": "Negative for cervical cancer",
            "PET-CT": "No recurrence or metastasis detected",
            "Pathological Examination": "Confirms diagnosis of endometrial cancer"
        },
        "Treatment Plan": "Margaret Poe has been diagnosed with moderate severity endometrial cancer. Considering her age, post-menopausal status, and underlying conditions of hypertension, diabetes, and obesity, a personalized treatment plan is necessary. The primary approach includes total hysterectomy with bilateral salpingo-oophorectomy, ensuring complete removal of the uterus and ovaries to minimize the spread of cancer. Pelvic MRI and ultrasound have shown localized endometrial thickening without distant metastasis, allowing for potential conservation of lymph nodes initially, with monitoring post-surgery for any changes. Following surgery, adjuvant therapy will be considered, including both hormone and chemotherapy, tailored to her histological profile and receptor status. Margaret's progress will be closely monitored through regular follow-up appointments every 3 to 6 months post-surgery, including imaging studies and serum CA125 evaluation. Nutritional support and lifestyle modifications are advised, with emphasis on weight management and controlling her hypertension and diabetes. Margaret will be educated on the importance of adhering to her treatment plan, recognizing signs of potential recurrence, and maintaining a positive lifestyle. The medical team will support Margaret throughout her treatment, ensuring comprehensive care and monitoring to optimize recovery and quality of life.",
        "User Profile": {
            "id": 198,
            "trust_in_healthcare": 0.646,
            "health_literacy": 0.131,
            "openness": 0.76,
            "conscientiousness": 0.248,
            "extraversion": 0.118,
            "agreeableness": 0.789,
            "neuroticism": 0.746,
            "region": "South Carolina"
        },
        "Relations": {
            "strong": [
                12,
                58,
                53
            ],
            "moderate": [
                8,
                39,
                36,
                54,
                32,
                1,
                38,
                13,
                56,
                47,
                65,
                21,
                43,
                52,
                11,
                6,
                30,
                49,
                66,
                55
            ],
            "weak": [
                3,
                34,
                37,
                62,
                4,
                7,
                42,
                29,
                45,
                48,
                10,
                60,
                68,
                22,
                2,
                25,
                40,
                67,
                5,
                41,
                14,
                59,
                61,
                44,
                19,
                15,
                0,
                57,
                63,
                18,
                50,
                69,
                31,
                17,
                33,
                26,
                51,
                20,
                23,
                46,
                9,
                16,
                35,
                28,
                24,
                27
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "John Anderson",
            "Age": "62",
            "Gender": "Male",
            "Medical History": "History of adenomatous polyps, family history of colorectal cancer"
        },
        "Disease Information": {
            "Disease": "Rectal cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Change in bowel habits, blood and mucus in stool, abdominal pain, weight loss, tenesmus",
            "Duration": "Symptoms have been present for the past six months and have progressively worsened",
            "Curability": "Yes",
            "Severity Score": 65
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "29 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.8 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.2 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "7.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "135 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "2.3 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.5 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.6 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "8% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.05 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 fL (9 − 13)",
                "Lactate Dehydrogenase": "175 U/L (135 − 225)",
                "Ferritin": "110 ng/mL (30 − 400 for males)",
                "CRP": "5 mg/L (< 3 mg/L)",
                "ESR": "25 mm/hr (0 − 20)",
                "Carcinoembryonic Antigen (CEA)": "12 ng/mL (0 − 5)",
                "Blood Silver Level": "75 μg/L (50 − 150)"
            },
            "Colonoscopy": "Presence of ulcerative tumor in the lower rectum",
            "CT Scan": "Thickening of the rectal wall, possible local lymph node involvement",
            "MRI": "Confirms rectal wall invasion, no distant metastasis",
            "Endoscopic Ultrasound": "Tumor infiltration into the muscularis propria",
            "Fecal Occult Blood Test": "Positive",
            "Serum Tumor Marker Test": "Increased CEA level",
            "Liver Function Test": "Normal",
            "Kidney Function Test": "Normal",
            "Chest X-ray": "Clear, no metastasis observed"
        },
        "Treatment Plan": "John Anderson has been diagnosed with rectal cancer with a major severity, characterized by bowel habit changes, blood in stool, and significant weight loss over the past six months. An individualized comprehensive treatment plan focusing on surgical intervention is advised, given the tumor's location and characteristics seen in imaging and endoscopic evaluations. Considering the potential lymph node involvement, neoadjuvant chemoradiotherapy will be administered to shrink the tumor and enhance operability. This will be followed by surgical resection, utilizing a sphincter-sparing surgery approach if feasible, given the tumor's proximity to the anal verge. Postoperative adjuvant chemotherapy will be considered to mitigate the risk of recurrence. Nutritional support is vital due to John's weight loss and potential malnutrition, with a high-protein, low-residue diet recommended to sustain strength and support recovery. Pain management and regular monitoring of CEA levels and imaging tests will guide ongoing care, and John will be educated on recognizing symptoms of recurrence. Family involvement in care strategies and creating a supportive environment is crucial for his recovery and quality of life. Given the favorable curability prognosis, adherence to follow-up visits, lifestyle modifications, and regular physical activity, John's prognosis is optimistic with the potential for long-term survival.",
        "User Profile": {
            "id": 201,
            "trust_in_healthcare": 0.384,
            "health_literacy": 0.587,
            "openness": 0.892,
            "conscientiousness": 0.939,
            "extraversion": 0.237,
            "agreeableness": 0.25,
            "neuroticism": 0.885,
            "region": "Tennessee"
        },
        "Relations": {
            "strong": [
                45,
                66
            ],
            "moderate": [
                49,
                5,
                4,
                14,
                60,
                25,
                3,
                47,
                55,
                34,
                10,
                11,
                17,
                48,
                15,
                38
            ],
            "weak": [
                2,
                23,
                37,
                64,
                7,
                36,
                29,
                39,
                22,
                57,
                6,
                68,
                59,
                21,
                56,
                58,
                13,
                52,
                30,
                53,
                43,
                69,
                44,
                12,
                0,
                32,
                19,
                67,
                1,
                8,
                26,
                54,
                62,
                27,
                33,
                20,
                35,
                18,
                40,
                42,
                50,
                24,
                16,
                28,
                41,
                46,
                61,
                63,
                31,
                51,
                9
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "James Peterson",
            "Age": "55",
            "Gender": "Male",
            "Medical History": "Occasional abdominal discomfort, history of a slow-growing, painless soft tissue mass"
        },
        "Disease Information": {
            "Disease": "Liposarcoma",
            "Severity Level": "Major Severity",
            "Symptoms": "Slowly enlarging, painless soft tissue mass, abdominal discomfort, bloating, loss of appetite",
            "Duration": "Symptoms have been present and progressively noticeable over the past few months",
            "Curability": "Yes",
            "Severity Score": 63
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU /L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "28 IU /L (13 − 35)",
                "Urea": "5.6 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.3 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.9 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "25% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "65% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.5 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "4.2 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.5 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.08 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)"
            },
            "Chest X-ray Exam": "Normal findings",
            "Abdominal Ultrasound": "Dense echogenic mass with uneven echoes in the retroperitoneum",
            "Computerized Tomography (CT)": "Large mass with fat density and clear boundaries, slightly lobulated shape in the retroperitoneum",
            "Magnetic Resonance Imaging (MRI)": "Shows mixed echoes with clear boundaries and minimal fatty infiltration",
            "Biopsy": "Well-differentiated liposarcoma with primitive mesenchymal cells and lipoblasts",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture": "Normal",
            "Respiratory Function Test": "Normal",
            "Gastrointestinal Function Test": "Gastrointestinal compression symptoms present",
            "PET-CT": "Some metabolic activity present, suggesting a mixed tissue composition"
        },
        "Treatment Plan": "James Peterson has been diagnosed with well-differentiated liposarcoma, requiring meticulous surgical intervention due to the tumor's retroperitoneal location and accompanying symptoms like abdominal discomfort and loss of appetite. The primary treatment strategy focuses on wide excision surgery, aimed at removing the tumor while minimizing the risk of local recurrence. Preoperative imaging, including CT and MRI, has been conducted to precisely assess the tumor's boundaries and plan the surgical approach. Post-surgery adjuvant radiotherapy may be considered to enhance local control and reduce the recurrence risk, although chemotherapy is unlikely to be effective due to the tumor's insensitivity. James will be advised to maintain a nutritious and easily digestible diet post-surgery to support recovery, engage in moderate exercise as per medical advice, and manage stress to foster a positive emotional state. Regular follow-up checks will be scheduled to monitor for any signs of recurrence, adhering to a protocol of every 3 months for the first 3 years post-surgery, and subsequently every 6 months. Should he experience symptoms indicative of recurrence, further imaging and potential surgical intervention will be evaluated based on tumor size and location. Family support remains crucial, emphasizing adherence to medical guidance and lifestyle modifications to optimize his recovery and long-term health outcomes.",
        "User Profile": {
            "id": 204,
            "trust_in_healthcare": 0.436,
            "health_literacy": 0.613,
            "openness": 0.956,
            "conscientiousness": 0.532,
            "extraversion": 0.276,
            "agreeableness": 0.288,
            "neuroticism": 0.365,
            "region": "Pennsylvania"
        },
        "Relations": {
            "strong": [
                4,
                49,
                36
            ],
            "moderate": [
                65,
                22,
                52,
                2,
                38,
                17,
                11,
                7,
                21,
                34,
                60,
                47,
                53,
                57,
                55,
                45,
                14
            ],
            "weak": [
                29,
                0,
                58,
                13,
                48,
                25,
                61,
                56,
                1,
                19,
                5,
                44,
                64,
                40,
                50,
                6,
                10,
                39,
                28,
                42,
                37,
                32,
                15,
                27,
                20,
                3,
                12,
                69,
                35,
                54,
                23,
                41,
                43,
                67,
                62,
                51,
                8,
                63,
                59,
                68,
                30,
                46,
                16,
                26,
                18,
                24
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Henry Thompson",
            "Age": "70",
            "Gender": "Male",
            "Medical History": "Chronic bronchitis, history of smoking (40 pack-years)"
        },
        "Disease Information": {
            "Disease": "Peripheral lung cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Irritating cough, hemoptysis, dyspnea, chest pain, unintentional weight loss",
            "Duration": "Symptoms have been progressively worsening over the past 3 months",
            "Curability": "No",
            "Severity Score": 69
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "36 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "44 IU/L (13 − 35)",
                "Urea": "8.2 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "89 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.9 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "5.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "10.5 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.5 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "42% (35 − 50)",
                "Hemoglobin (Hb)": "145 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "340 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "18% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "77% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.89 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "8.1 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.45 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "4.3% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.15 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "1.4% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.02 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10.5 f l (9 − 13)",
                "Lactate Dehydrogenase": "280 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "190 U/L (22 − 198 for males)",
                "Myoglobin": "82 ng/mL (< 90 ng/mL)",
                "Troponin I": "9 ng/L (< 14 ng/L)",
                "Ferritin": "420 ng/mL (20 − 500 for males)",
                "CRP": "25 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.8 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "B",
                "Specific Antigen": "None detected",
                "Blood Silver Level": "58 μg/L (50 − 150)"
            },
            "Chest X-ray Exam": "Irregular mass in the peripheral right lung field",
            "Chest Computerized Tomography": "Solitary round mass with spiculated margins in the right lower lobe",
            "Serological Diagnosis": "Normal",
            "Viral Antigen Detection": "Negative",
            "Allergen Test": "Normal",
            "Bacterial Culture of Nasal Secretions": "Normal",
            "Respiratory Function Test": "Moderately impaired",
            "Sputum Examination": "Presence of malignant cells",
            "Nasopharyngeal Examination": "Normal",
            "Serum Antibody Test": "Negative",
            "Pulmonary Function Test": "Reduced lung volumes and capacities",
            "Nucleic Acid Amplification Test": "Negative",
            "Eosinophil Count in Sputum": "Normal",
            "Oral Pharyngeal Examination": "Normal",
            "Nasal Endoscopy": "Normal"
        },
        "Treatment Plan": "Henry Thompson has been diagnosed with advanced-stage peripheral lung cancer, characterized by a significant solitary mass in the right lower lobe of the lung and associated symptoms of persistent cough, hemoptysis, and unintended weight loss. Considering the patient's age, medical history of chronic bronchitis, and extensive smoking history, an aggressive treatment approach with a focus on palliative care is recommended. Due to the major severity and the advancement of the disease stage, surgical intervention is not viable. The primary treatment modalities will include a combination of chemotherapy and targeted therapy to manage tumor growth and alleviate symptoms. Chemotherapy with platinum-based agents such as carboplatin in combination with pemetrexed will be initiated, with cycles planned every three weeks, and the response and side effects closely monitored. Concurrently, targeted therapy with an EGFR inhibitor, such as erlotinib, will be considered if genetic markers suggest sensitivity, aiming to delay disease progression and improve quality of life. Supportive care measures, including pain management, nutritional support, and respiratory therapy, will be provided to improve overall well-being and maintain functionality. Regular follow-ups will assess treatment efficacy and side effects, with adjustments made as necessary. Psychological support and counseling will be offered to help Henry and his family cope with the emotional and psychological impacts of the diagnosis. Smoking cessation support will be provided to prevent further lung damage and reduce the progression of the disease. Hospice care options will be discussed as part of an advance care planning strategy, ensuring alignment with Henry's preferences and promoting quality of life throughout the treatment journey.",
        "User Profile": {
            "id": 207,
            "trust_in_healthcare": 0.235,
            "health_literacy": 0.106,
            "openness": 0.034,
            "conscientiousness": 0.096,
            "extraversion": 0.845,
            "agreeableness": 0.305,
            "neuroticism": 0.897,
            "region": "Pennsylvania"
        },
        "Relations": {
            "strong": [
                68,
                10
            ],
            "moderate": [
                56,
                30,
                37,
                8,
                38,
                15,
                3,
                59,
                45,
                48,
                22,
                55,
                25,
                14,
                23,
                58,
                39,
                21,
                13,
                52,
                57
            ],
            "weak": [
                12,
                34,
                6,
                43,
                64,
                36,
                53,
                66,
                11,
                24,
                65,
                4,
                69,
                18,
                35,
                1,
                60,
                31,
                42,
                29,
                19,
                46,
                32,
                28,
                50,
                47,
                54,
                49,
                17,
                9,
                2,
                7,
                40,
                62,
                16,
                5,
                61,
                33,
                0,
                41,
                20,
                51,
                63,
                26,
                44,
                27
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Elaine Zhang",
            "Age": "65",
            "Gender": "Female",
            "Medical History": "Gastroesophageal reflux disease, hiatal hernia, obesity, smoking history"
        },
        "Disease Information": {
            "Disease": "Cardia cancer",
            "Severity Level": "Major Severity",
            "Symptoms": "Difficulty swallowing, weight loss, upper abdominal pain, hematemesis, fatigue, palpable lumps in the upper abdomen",
            "Duration": "Symptoms have progressively worsened over the past 3 months",
            "Curability": "No",
            "Severity Score": 70
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "38 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "42 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "85 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.8 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "6.5 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "4.8 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "3.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "38% (35 − 50)",
                "Hemoglobin (Hb)": "100 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "22% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "68% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.05 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.26 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.35 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.03 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "0.5% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.01 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.2% (0 − 1)",
                "Mean Platelet Volume (MPV)": "11 fL (9 − 13)",
                "Lactate Dehydrogenase": "210 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for females)",
                "Myoglobin": "75 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "500 ng/mL (30 − 400 for females)",
                "CRP": "30 mg/L (< 3 mg/L)",
                "ESR": "35 mm/hr (0 − 20)",
                "Procalcitonin": "0.2 ng/mL (< 0.5)",
                "D-dimer": "0.9 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "None",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Endoscopic Examination": "Nodular and cauliflower-like growths at the esophagogastric junction, ulcerative lesions with mucosal congestion",
            "Ultrasound Endoscopy": "Infiltration into the gastric wall with suspected local lymph node metastases",
            "Barium Meal X-ray": "Visible lesions at the esophagogastric junction with irregular mucosal patterns",
            "CT Scan": "Invasive tumor at the esophagogastric junction with potential involvement of surrounding tissues",
            "PET-CT Scan": "Suspected metastases in mediastinal and abdominal lymph nodes",
            "Tumor Marker Examination": "Elevated CEA, CA19-9, suggesting advanced disease",
            "Biopsy Results": "Poorly differentiated adenocarcinoma consistent with advanced cardia cancer"
        },
        "Treatment Plan": "Elaine Zhang’s advanced cardia cancer diagnosis necessitates an integrated treatment approach focused on symptom management and potential life extension. Given the significant severity of her condition, comprehensive systemic therapy involving chemotherapy paired with targeted therapy like trastuzumab is recommended due to HER-2 positive indications. Initial efforts will focus on maintaining nutritional support through parenteral nutrition, addressing malnutrition and dehydration resulting from her condition. Radical radiotherapy may be considered to manage non-metastatic local lesions and support chemotherapy efforts. Palliative care measures including analgesics for pain management, antiemetics for reducing nausea, and medications to manage gastroesophageal reflux symptoms will aid in improving comfort and quality of life. As surgery is not viable given the metastatic spread, ongoing assessments using imaging studies will guide adjustments in treatment, with regular evaluations every few months to monitor progression and response to therapy. Detailed family and psychosocial support are critical to managing emotional stress. Elaine’s adherence to nutritional support and hydration protocols will be pivotal in ensuring tolerance to systemic therapies. Regular monitoring for changes in symptoms and maintaining a supportive environment will contribute substantially to her care, complemented by post-discharge daily management practices encouraging moderate physical activity and dietary adjustments tailored to her preferences while avoiding potential irritants.",
        "User Profile": {
            "id": 210,
            "trust_in_healthcare": 0.21,
            "health_literacy": 0.138,
            "openness": 0.115,
            "conscientiousness": 0.401,
            "extraversion": 0.889,
            "agreeableness": 0.079,
            "neuroticism": 0.94,
            "region": "Connecticut"
        },
        "Relations": {
            "strong": [
                67
            ],
            "moderate": [
                59,
                10,
                23,
                45,
                15,
                38,
                48,
                37,
                14,
                3,
                30,
                34,
                25,
                55,
                8,
                36,
                22,
                57,
                56,
                21,
                43,
                13
            ],
            "weak": [
                58,
                53,
                35,
                65,
                64,
                6,
                46,
                49,
                18,
                52,
                1,
                60,
                31,
                29,
                12,
                24,
                11,
                66,
                69,
                39,
                32,
                17,
                47,
                42,
                4,
                28,
                40,
                50,
                2,
                5,
                54,
                7,
                62,
                19,
                9,
                16,
                0,
                41,
                33,
                44,
                26,
                20,
                61,
                51,
                27,
                63
            ]
        }
    },
    {
        "Patient Information": {
            "Name": "Ryan Thompson",
            "Age": "27",
            "Gender": "Male",
            "Medical History": "Cryptorchidism history, no previous major illnesses"
        },
        "Disease Information": {
            "Disease": "Testicular cancer",
            "Severity Level": "Moderate Severity",
            "Symptoms": "Single painless mass in the affected testicle, slight swelling and heaviness, mild dull pain",
            "Duration": "Symptoms have been present for about 3 weeks",
            "Curability": "Yes",
            "Severity Score": 49
        },
        "Examination Results": {
            "Blood Tests": {
                "ALT (Alanine Aminotransferase)": "32 IU/L (7 − 40)",
                "AST (Aspartate Aminotransferase)": "30 IU/L (13 − 35)",
                "Urea": "5.5 mmol/L (2.6 − 8.8)",
                "Creatinine (Cr)": "78 μmol/L (41 − 81)",
                "Triglycerides (TG)": "1.1 mmol/L (< 1.7)",
                "Total Cholesterol (TC)": "4.8 mmol/L (< 5.18)",
                "Hepatitis B Surface Antigen (HBsAG)": "Negative",
                "HIV Antibody Test (anti-HIV)": "Negative",
                "Syphilis Test (RPR)": "Negative",
                "White Blood Cell Ct. (WBC)": "6.0 × 10^9/L (3.5 − 9.5)",
                "Red Blood Cell Ct. (RBC)": "4.9 × 10^12/L (3.5 − 5.5)",
                "Hematocrit (Hct)": "44% (35 − 50)",
                "Hemoglobin (Hb)": "140 g/L (115 − 150)",
                "Platelet Ct. (PLT)": "250 × 10^9/L (125 − 350)",
                "Lymphocyte Percentage (LYMPH%)": "30% (20 − 50)",
                "Neutrophil Percentage (NEUT%)": "60% (40 − 75)",
                "Lymphocyte Abs. Ct. (LYMPH#)": "1.8 × 10^9/L (1.3−3.2)",
                "Neutrophil Abs. Ct. (NEUT#)": "3.6 × 10^9/L (1.8 − 6.3)",
                "Monocyte Abs. Ct. (MONO#)": "0.4 × 10^9/L (0.2 − 1.0)",
                "Monocyte Percentage (MONO%)": "7% (3 − 10)",
                "Eosinophil Abs. Ct. (EO#)": "0.04 × 10^9/L (0.02 − 0.52)",
                "Eosinophil Percentage (EO%)": "2.0% (0.4 − 8.0)",
                "Basophil Abs. Ct. (BASO#)": "0.03 × 10^9/L (0 − 0.06)",
                "Basophil Percentage (BASO%)": "0.5% (0 − 1)",
                "Mean Platelet Volume (MPV)": "10 f l (9 − 13)",
                "Lactate Dehydrogenase (LDH)": "185 U/L (135 − 225)",
                "Muscle Enzymes (CK)": "150 U/L (22 − 198 for males)",
                "Myoglobin": "55 ng/mL (< 90 ng/mL)",
                "Troponin I": "10 ng/L (< 14 ng/L)",
                "Ferritin": "250 ng/mL (20 − 500 for males)",
                "CRP": "10 mg/L (< 3 mg/L)",
                "ESR": "15 mm/hr (0 − 20)",
                "Procalcitonin": "0.3 ng/mL (< 0.5)",
                "D-dimer": "0.5 mg/L FEU (0 − 0.5)",
                "Rh Type": "Positive",
                "ABO Group": "A",
                "Specific Antigen": "Negative",
                "Blood Silver Level": "70 μg/L (50 − 150)"
            },
            "Ultrasound Exam": "Presence of a large mass in the left testicle, heterogeneous texture, no retroperitoneal metastasis",
            "CT Scan": "No signs of lymph node metastasis",
            "Tumor Marker Analysis": {
                "AFP": "40 ng/mL (0 − 10)",
                "β-HCG": "15 IU/L (0 − 5)",
                "LDH": "200 U/L (135 − 225)"
            },
            "Chest X-ray Exam": "No lung metastasis detected",
            "Abdominal Examination": "No signs of visceral metastasis",
            "Physical Examination": "Enlarged left testicle with hard mass, negative transillumination"
        },
        "Treatment Plan": "Ryan Thompson has been diagnosed with testicular cancer, with a moderate severity level indicated by the presence of a single painless mass in the affected testicle and elevated AFP and β-HCG levels. The recommended treatment approach involves a radical orchiectomy through an inguinal approach, followed by surveillance and consideration of retroperitoneal lymph node dissection and chemotherapy if metastatic risk is assessed or histological findings indicate non-seminomatous tumors. Chemotherapy options may include cisplatin, vinblastine, and bleomycin, tailored according to the tumor's specific histological type and patient's response. Post-surgery radiotherapy may be considered if seminomas are detected, given their sensitivity to radiation therapy. Ryan is advised to undergo preoperative cryopreservation of semen due to potential impacts on fertility from treatment, alongside professional psychological support to manage the stress and potential sexual dysfunction following treatment. Follow-up care is crucial, involving regular physical exams, tumor marker detection, and imaging studies for at least five years to monitor recurrence. Ryan and his family will receive education on self-examination and signs of deterioration, with the importance of adhering to the treatment plan emphasized. Additionally, supporting psychological wellbeing and social support can enhance recovery outcomes, ensuring Ryan adapts to changes post-treatment and maintains a quality life.",
        "User Profile": {
            "id": 213,
            "trust_in_healthcare": 0.285,
            "health_literacy": 0.729,
            "openness": 0.515,
            "conscientiousness": 0.224,
            "extraversion": 0.274,
            "agreeableness": 0,
            "neuroticism": 0.926,
            "region": "Massachusetts"
        },
        "Relations": {
            "strong": [
                43,
                28
            ],
            "moderate": [
                18,
                19,
                0,
                29,
                32,
                49,
                55,
                39,
                24,
                38,
                16,
                14,
                41,
                46,
                66,
                35,
                65,
                23
            ],
            "weak": [
                58,
                20,
                9,
                17,
                31,
                33,
                6,
                13,
                34,
                25,
                26,
                22,
                61,
                36,
                68,
                51,
                67,
                59,
                15,
                45,
                8,
                64,
                56,
                12,
                40,
                3,
                7,
                27,
                21,
                11,
                50,
                10,
                44,
                48,
                1,
                2,
                42,
                37,
                63,
                47,
                60,
                30,
                4,
                52,
                57,
                54,
                53,
                5,
                62
            ]
        }
    }
]